Turning a scientific idea into a therapy takes time.
Years of testing. Validation. Refinement.
Our latest data, alongside @10NewsAU coverage, shows the progress we are making step by step.
youtu.be/aasEY17FQIw
#imugene #biotech #clinicaltrials $IMU
Imugene
Imugene Ltd is a biotechnology company working in cancer immunotherapy. The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer, where the cancer is HER-2-positive. Imugene was planning a Phase Ib/II clinical study of HER-Vaxx in gastric cancer which it intended to initiate in 2016. Imugene stock is publicly traded on the Australian Securities Exchange (ASX). More on Wikipedia
-
Imugene | Cancer Immunotherapies
@TeamImugene
-
Imugene | Cancer Immunotherapies
@TeamImugene
“We know this is working in a late-stage patient population… with complete clearance of cancer in some patients.”
Encouraging signals continue from our azer-cel program, even in heavily pre-treated cases.
Our CEO Leslie Chong on Fear & Greed discussing the path forward.
Watch:
youtu.be/e9FsZ-nyG4c
$IMU #cancerresearch #immunotherapy #celltherapy #cart #biotech #clinicaltrials #oncology #drugdevelopment -
Imugene | Cancer Immunotherapies
@TeamImugene
Progress in biotech is built on collaboration between researchers, clinicians and industry.
No one works in isolation.
#collaboration #biotech #research -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO Leslie Chong speaking at the Bell Potter Healthcare Horizons Summit, alongside 15+ biotech companies presenting across the program.
A great opportunity to share updates on our progress as we continue to advance our clinical pipeline and immunotherapy technologies.
#biotech #healthcare #immunotherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
New Phase 1b Azer-cel trial data reports responses in additional blood cancers
Results from the CAR-T naïve cohort show:
• 100% ORR — CLL/SLL
• 80% ORR — marginal zone lymphoma
$IMU ASX announcement: imugene.com/investors/asx-announcements/
#imugene #bloodcancer #clinicaltrials -
Imugene | Cancer Immunotherapies
@TeamImugene
Thank you to @10NewsAU and @EmmaOlsenNZ for sharing this powerful patient story highlighting azer-cel, Imugene’s allogeneic CAR-T therapy.
“It’s given me another chance at life.”
Stories like these remind us why this work matters.
youtu.be/aasEY17FQIw
#biotechnology #immunotherapy #cartcelltherapy #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
This International Women’s Day we recognise the women across science, clinical research and operations who contribute to advancing medical research every day.
#internationalwomensday #womeninscience -
Imugene | Cancer Immunotherapies
@TeamImugene
A powerful story of a clinical trial participant given another chance at life thanks to azer-cel, Imugene’s investigational allogeneic CAR-T therapy, will air on @10NewsFirst tonight at 6pm. Report by @EmmaOlsenTV.
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Clinical trials are carefully designed, independently monitored, and essential to improving future treatments.
#clinicaltrials #medicalresearch #healthcare -
Imugene | Cancer Immunotherapies
@TeamImugene
A powerful story of a clinical trial participant given another chance at life thanks to azer-cel, Imugene’s investigational allogeneic CAR-T therapy, will air on @10NewsAU around Australia this weekend.
Report by Emma Olsen
#imugene #10newsfirst #azercel -
Imugene | Cancer Immunotherapies
@TeamImugene
Drug development is a team effort.
Scientists, clinicians, trial coordinators and patients all play a role in moving research forward.
#biotechcareers #science #stem -
Imugene | Cancer Immunotherapies
@TeamImugene
Immuno-oncology in simple terms: helping the immune system recognise and respond to cancer.
That’s the focus of our work at Imugene.
#immunooncology #cancerresearch #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Our first patient remains cancer free, more than 22+ months on.
While individual outcomes don’t predict broader results, moments like this reinforce why the work matters. As outlined in our half-year results, we continue to progress our clinical programs with a disciplined, step-by-step approach.
#patientimpact #clinicalresearch #biotech #immunooncology -
Imugene | Cancer Immunotherapies
@TeamImugene
Today, Leslie Chong joined the Fear & Greed Podcast @PodcastFear to talk about the realities of running a biotech company and progressing life-changing therapies.
“We know this is working in a late-stage patient population, with some patients seeing a complete clearance of their cancer.”
Listen: omny.fm/shows/fear-and-greed/q-a-how-this-biotech-ceo-kee…
#biotech #immunooncology #cancerresearch #asx #healthcare -
Imugene | Cancer Immunotherapies
@TeamImugene
Good results start with good trial design.
Clear endpoints and disciplined methodology are essential for generating credible clinical data.
#clinicaltrials #biotech #clinicalresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Progress in biotech isn’t about speed.
It’s about evidence, discipline and clarity.
#biotech #lifesciences #clinicalresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Clinical progress matters because patients matter.
Azer-cel has shown an 82% response rate in trials, including a patient cancer-free after 21+ months.
#cancerresearch #clinicaldata #imu -
Imugene | Cancer Immunotherapies
@TeamImugene
For many blood cancer patients, waiting weeks for treatment isn’t an option.
Imugene’s azer-cel is an off-the-shelf CAR-T therapy designed to be delivered in days, not weeks, and is already showing strong responses in heavily pre-treated patients.
Faster access could change everything.
More in Biotech Daily: www.biotechdaily.com.au/wp/wp-content/uploads/2026/02/IMU…
#hematology #celltherapy #cartcelltherapy #biotechnews #immunotherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
Yesterday marked International Day of Women and Girls in Science, a moment to recognise the critical role women play in driving progress across research, innovation and leadership.
We’re proud to support and celebrate the women shaping the future of science and setting the standard for the next generation.
#womeninscience #stem #biotechnology -
Imugene | Cancer Immunotherapies
@TeamImugene
Regulatory clarity changes everything.
Our FDA meeting confirms a clear pathway for azer-cel, backed by 82% response rates and strong clinical data.
Watch the full investor webinar:
youtu.be/O9oPUdDDpCA
#fda #biotechnology #imu -
Imugene | Cancer Immunotherapies
@TeamImugene
World Cancer Day is a reminder of why progress matters.
Every step forward in research brings hope closer to reality for patients and families. We remain committed to advancing innovation that can make a real difference.
#worldcancerday #cancerresearch #patientimpact -
Imugene | Cancer Immunotherapies
@TeamImugene
Next-gen cancer therapies require precision, scale and regulatory alignment.
Our CEO, Leslie Chong, recently discussed our azer-cel platform strategy and development pathways at the ASX Gem Conference.
Watch: youtu.be/JpAogVUGIhE
#immunooncology #biotech #cancertherapy #imugene -
Imugene | Cancer Immunotherapies
@TeamImugene
January momentum building for $IMU.
Every milestone brings us closer to advancing cancer treatment.
First patient cancer-free 21+ months.
Lives improved through developing science.
#patientimpact #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU azer-cel: next-gen allogeneic CAR-T therapy. Off-the-shelf treatment reaching more patients efficiently.
FDA-endorsed dual endpoint strategy = multiple routes to market. Innovation with purpose.
#carttherapy #personalisedmedicine -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU 2025 achievements:
✅ 82-83% response rates
✅ FDA endorsement
✅ Strategic partnerships
✅ 50% cost reduction.
Focused execution delivering results.
#biotech #clinicaldata -
Imugene | Cancer Immunotherapies
@TeamImugene
Optimistic updates from Imugene's January 2026 newsletter highlight the progress of our off-the-shelf CAR T therapy, azer-cel, in treating blood cancers like relapsed/refractory DLBCL, as well as our FDA alignment for advancing to a pivotal trial.
imugene.com/wp-content/uploads/2026/01/Imugene_Newsletter… -
Imugene | Cancer Immunotherapies
@TeamImugene
Strategic partnership with JW Therapeutics reduces $IMU operating costs ~50% while advancing onCARlytics.
More focus on azer-cel = better outcomes for patients & shareholders.
Disciplined capital allocation.
wcsecure.weblink.com.au/pdf/IMU/03029106.pdf
#biotech #partnership $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Seeing our CAR‑T therapy on @7NewsAustralia last year was a meaningful moment for Imugene, sharing our work advancing innovative therapies that bring hope to patients and families.
Grateful to the patients, clinicians, teams, and @amberlaidler7 for making it possible.
Watch: youtu.be/bHLzTvw86dQ
#personalisedmedicine #carttherapy #futureofmedicine #imugene -
Imugene | Cancer Immunotherapies
@TeamImugene
Novel “mark-and-kill” approach:
$IMU onCARlytics + JW Therapeutics’ CAR-T targeting solid tumours.
A combination therapy leveraging existing commercial infrastructure.
Strategic science meets focused execution.
#innovation #partnership -
Imugene | Cancer Immunotherapies
@TeamImugene
At the @jpmorgan Healthcare Conference this week.
Energising discussions shaping the future of healthcare and biotech.
Sharing a quick moment from the conference floor.
#jpm2026 #healthcareinnovation #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
#azercel
🔬 First patient cancer-free for 20 + months and counting.
These results represent lives improved by advancing science.
#clinicaltrials #cancerresearch #biotechnology $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU Phase 1b delivering solid results: 82% response in R/R DLBCL, 83% in CAR-T naïve.
Durable responses.
Lives improved through advancing science.
#clinicaltrials #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU targeting rare lymphomas with 83% response rate in CAR-T naïve patients.
Bringing hope to underserved populations with limited treatment options. Patient-focused innovation.
#raredisease #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU 2026 priorities:
✅ Build on FDA success
✅ Refine pivotal study
✅ Advance partnerships
✅ Maintain cost discipline.
Foundation established. Pathway defined. Execution is key.
#biotech #strategy -
Imugene | Cancer Immunotherapies
@TeamImugene
2026 outlook for $IMU:
FDA-aligned pathway ✅
Strong clinical data✅
Strategic partnerships ✅
Disciplined capital management ✅
First patient cancer-free 19+ months.
Encouraging progress ahead.
#biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
As we look to the new year, we're optimistic about the outlook for azer-cel and the progress that's happening across our programmes.
Behind every data point is a person, a family, a life transformed. This is what drives us forward each day, the knowledge that our work has the potential to offer hope where treatment options have been limited.
Here is to a new year filled with hope.
$IMU #asx #azercel -
Imugene | Cancer Immunotherapies
@TeamImugene
Rare FDA endorsement for $IMU azer-cel program ✅ Dosing regimen validated ✅ Manufacturing ready ✅ Clear commercial pathway ahead. Strong regulatory alignment in biotech. #fda #biotech www.youtube.com/watch?v=O9oPUdDDpCA
-
Imugene | Cancer Immunotherapies
@TeamImugene
Impressive presentation by @SupriyaGuptaMD at #ash25 - the world's largest hematology conference - on azer-cel safety & efficacy in LBCL post-CAR-T relapse setting .
✅ 81% response rate in CAR-T relapsed DLBCL
✅ 83% response rate in CAR-T naïve patients
✅ Off-the-shelf allogeneic therapy
$IMU advancing important clinical research.
#biotech #carttherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO & Chair's shareholder update is out this morning. Here CEO Leslie Chong speaks about a key highlight. #cartt success in naïve patients with azer-cel achieving 83% overall response rate - bringing hope to those with limited treatment options.
Full update covers FDA alignment, clinical progress & strategic priorities for 2026, link in our thread.
$IMU #shareholderupdate #clinicaldata #carttherapy
Imugene | Cancer Immunotherapies
@TeamImugene
To access our full shareholder update, click here imugene.com/investors/asx-announcements/
-
Imugene | Cancer Immunotherapies
@TeamImugene
This morning we conducted an investor webinar for shareholders following our historic FDA milestone. Hosted by Leslie Chong and Brad Glover. Our key takeaways centred on the risk reduction around regulatory uncertainty, our the clear pathway and process to market that the FDA has now provided
and our demonstrated commercial readiness with validated manufacturing and compelling clinical data. $IMU
For those who missed it, you can watch the full webinar here: www.youtube.com/watch?v=O9oPUdDDpCA
#asx #oncology -
Imugene | Cancer Immunotherapies
@TeamImugene
Tomorrow at 11am AESDT we will host an update on our #fda meeting for shareholders. $IMU
wcsecure.weblink.com.au/pdf/IMU/03034340.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
On $IMU and our #fda meeting minutes. Positive news and movement ahead.
Proactive
@proactive_x
Imugene gets FDA backing for azer-cel treatment @TeamImugene www.proactiveinvestors.com/companies/news/1083930/imugene… #imugene #azercel #fdaapproval #celltherapy #biotechnews #cancertreatment #dlbcl #ash2025 #immunotherapy
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU
FDA supports strategy toward registration for Azer-cel.
See our #asx announcement here announcements.asx.com.au/asxpdf/20251208/pdf/06t1v891tmmv… -
Imugene | Cancer Immunotherapies
@TeamImugene
At #ash25 @SupriyaGuptaMD on Azer-cel.
Amisha Gupta
@amishagupta2012
Great presentation by my colleague @SupriyaGuptaMD at #ash25 👏
Allo CD19 CAR T azer-cel + low-dose SC IL-2 for LBCL relapsing after auto CAR T (n=12)
• ORR 75%, CR 50%
• CRS 67% (Gr 1–2), ICANS 17% (Gr 2–3), infections 33% (all Gr 2)
@ASHClinicalNews @ASH_hematology -
Imugene | Cancer Immunotherapies reposted
Christopher Graham
@ChrisGrahamMD
High early responses following Azer-cel in heavily pretreated, prior CD19 CAR-T relapse with ORR 81%, CR 44%. Can allo CAR-Ts with IL2 be an answer to T cell exhaustion and post CAR relapse? #ash25 @SupriyaGuptaMD @TeamImugene
-
Imugene | Cancer Immunotherapies reposted
Proactive
@proactive_x
Imugene's CAR-T therapy hits 82% response rate @TeamImugene www.proactiveinvestors.com/companies/news/1083539/imugene… #imugene #azercel #cartherapybloodcancer #biotechnews #cancerresearch #immunotherapy #fda
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Exceptional response - Azer-cel achieves 82% response rate in aggressive blood cancer trial
• 7 complete + 7 partial responses
• 19+ months cancer-free (first patient)
• Durable responses ongoing
• Treating heavily pre-treated patients
Off-the-shelf CAR T changing the game
$IMU #carttherapy #cancerresearch
announcements.asx.com.au/asxpdf/20251201/pdf/06srm7b843d5… -
Imugene | Cancer Immunotherapies reposted
Proactive
@proactive_x
Imugene, JW partner on CF33-CD19 for solid tumors @TeamImugene www.proactiveinvestors.com/companies/news/1083307/imugene… #imugene #oncolyticvirus #biotechnews #cancerresearch #solidtumors #immunooncology #jwtherapeutics
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies reposted
Proactive
@proactive_x
$IMU Imugene and JW Therapeutics launch collaborative program to bring CD19 CAR-T innovation to solid tumours www.proactiveinvestors.com.au/companies/news/1083293/imug… @TeamImugene $ILA $IUGNF #imu #ila #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve entered into a strategic collaboration with JW Therapeutics 药明巨诺 to evaluate a first-in-class combination therapy for refractory solid tumours. The initiative will combine our onCARlytics (CF33-CD19) platform with JW’s CD19 CAR-T therapy, Carteyva®, in preclinical studies and a Phase 1 investigator-initiated trial in China. This “mark and kill” approach could redefine how we target difficult-to-treat cancers.
Read the full $IMU ASX Announcement here: wcsecure.weblink.com.au/pdf/IMU/03029101.pdf
#asx #immunooncology #celltherapy #car_t #oncarlytics -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene was recently featured in @Forbes Australia alongside other Australian biotechs advancing next-generation cancer therapies.
The article highlights the potential of azer-cel, our allogeneic CAR T therapy, which is currently in a multi-site Phase 1b trial across Australia and the U.S. for patients with large B-cell lymphoma who have relapsed after autologous CAR T and chemotherapy.
Read more via Forbes Australia: www.forbes.com.au/covers/innovation/the-australian-biotec…
$IMU #biotech #cart -
Imugene | Cancer Immunotherapies
@TeamImugene
Annual General Meeting Presentation: November 2025
View the full presentation here: wcsecure.weblink.com.au/pdf/IMU/03022370.pdf
$IMU #asx #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
In case you missed it: This morning we hosted a live webinar discussing the early efficacy seen in CAR T naïve lymphomas as part of our azer-cel Phase 1b trial, and the upcoming oral presentation at ASH 2025.
Presented by CEO & Managing Director Leslie Chong and CMO Dr John Byon.
▶️ Watch the replay here:
youtu.be/LvFyUs1Wrio
$IMU #asx #immunooncology #car_t #lymphoma #ash2025 #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
REMINDER | We’re hosting a live webinar today (Wednesday, 5 November) at 10 am AEDT to update shareholders, investors and interested parties on encouraging early efficacy seen in CAR T naïve lymphomas in our azer-cel Phase 1b trial and the oral presentation at the ASH Annual Meeting.
Featuring $IMU CEO & MD Leslie Chong and CMO Dr John Byon.
Register now: us02web.zoom.us/webinar/register/WN_e2i4cf4zR3Cdr95C6_PBoA
Questions in advance can be sent to matt@nwrcommunications.com.au.
A replay will be available after the session. -
Imugene | Cancer Immunotherapies
@TeamImugene
We’re hosting a live webinar on Wednesday, 5 November at 10 am AEDT to update shareholders, investors and interested parties on encouraging early efficacy seen in CAR T naïve lymphomas in our azer-cel Phase 1b trial and the oral presentation at the ASH Annual Meeting.
Featuring CEO & MD Leslie Chong and CMO Dr John Byon.
Register now: us02web.zoom.us/webinar/register/WN_e2i4cf4zR3Cdr95C6_PBoA
Questions in advance can be sent to matt@nwrcommunications.com.au.
A replay will be available after the session.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/03018664.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
We’re honoured that our abstract on azer-cel has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the world’s premier event in malignant and non-malignant haematology.
The abstract, titled “Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T”, will be presented on Saturday 6 December 2025 in the session “Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next Generation CAR-T Clinical Trials in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Multiple Myeloma.”
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/03018662.pdf
#asx #asxnews#ASH2025 #immunooncology #car_t #lbcl #hematology -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene presented at @ausbiztv Investor Connect this week, providing an update on the Company's clinical pipeline followed by a Q&A.
Click here to view the replay: youtu.be/0dum7HRiDoE -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Quarterly Activities Report for the period ending 30 September 2025 has been released.
View the full report: mcusercontent.com/e38c43331936a9627acb6427c/files/7ce28d9… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've received the first efficacy results from the CAR T‑naïve indication portion of our ongoing Phase 1b azer‑cel trial, evaluating our off‑the‑shelf allogeneic CD19 CAR T therapy across multiple B‑cell lymphomas.
Of six evaluable CAR T‑naïve patients, five (83%) achieved an overall response, including three (50%) complete responses, with results from the sixth patient pending. A total of ten patients have been treated to date, with follow‑up scans pending for four additional patients.
These early findings include several rare lymphoma subtypes: Waldenström macroglobulinemia, marginal zone lymphoma, and primary CNS lymphoma, areas of significant unmet need where no CAR T products are currently approved.
Enrolment in the CAR T‑naïve cohort is progressing significantly faster than the CAR T‑relapsed DLBCL cohort, supporting a potential expedited clinical path for azer‑cel.
Chief Executive Officer Leslie Chong said, “We are encouraged by these early signals of efficacy in the CAR T-naïve population, with at least five of the first six evaluable patients responding to treatment. As best responses can be seen up to 90 days or more after treatment, we look forward to further data on the depth and durability of these outcomes. Enrolment in this portion of the trial is proceeding at a remarkable pace, positioning us to explore an expedited development pathway for azer-cel.”
Read the full ASX Announcement here: wcsecure.weblink.com.au/pdf/IMU/03015604.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Neo‑POLEM Phase II trial has been accepted for e‑poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (17–21 October 2025).
The abstract, titled “Phase II trial of neoadjuvant PD‑1 vaccine PD1‑Vaxx in operable MSI‑high colorectal cancer”, will be presented by Dr Tony Dhillon, Consultant Medical Oncologist at the Royal Surrey NHS Foundation Trust, UK.
We’re delighted to see PD1‑Vaxx recognised with presentation at ESMO, highlighting its growing international clinical footprint. The Neo‑POLEM study marks an important expansion of our PD1‑Vaxx program into early‑stage colorectal cancer an area where improved treatment options remain urgently needed.
The poster can viewed below and at: imugene.com/investors/conference-presentations
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/03010422.pdf
#imu #immunooncology #pd1vaxx #esmo2025 #colorectalcancer #cancerresearch #clinicaltrials #oncology -
Imugene | Cancer Immunotherapies
@TeamImugene
Bioshares has issued a “Speculative Buy” rating on Imugene and notably added the company to its Model Portfolio in its latest issue which highlights the encouraging results from our Phase 1b clinical trial of azer-cel in relapsed/refractory DLBCL patients, most of whom had failed multiple prior therapies, including autologous CAR-T.
We thank the Bioshares team for recognising the potential of our allogeneic CAR-T program, and for clarity note the following:
🧬 Patient data to date (as of the latest update):
- 16 patients treated
- 7 complete responses (CR) with the CR rate percentage subject to change as the trial progresses and time to best response evolves
- 6 partial responses (PR) delivering an overall response rate (ORR) of 81%
- Multiple CRs have shown durability beyond 12 months, with others ongoing
- The first patient in the study was treated with azer-cel monotherapy in November 2023
- The first patient treated with azer-cel + IL-2 treated in April 2024 and still ongoing
- Partial responses continue to convert to complete responses adding to the CR rate
Our Phase 1b trial continues to progress, with enrolment expanding to include earlier lines of therapy and additional CAR T naïve patients.
$IMU #imugene #imu #biotech #car_t #bloodcancer #lymphoma #dlbcl #clinicaltrials #immunooncology #azercel #bioshares -
Imugene | Cancer Immunotherapies
@TeamImugene
Our 2025 Annual General Meeting will be held on Thursday, 13 November 2025 at 9:00am AEDT, both in person and online.
📍 Automic Pty Ltd, Level 5, 126 Phillip Street, Sydney
💻 Virtual attendance via investor.automic.com.au
Shareholders can access the full Notice of Meeting and proxy voting details at: www.imugene.com or via the ASX (ASX:IMU).
View the full $IMU ASX Announcement here: wcsecure.weblink.com.au/pdf/IMU/03006922.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
Blood cancer is projected to become Australia’s leading cause of cancer-related death within the next decade.
World Lymphoma Awareness Day, which took place earlier this month on 15 September, serves as an important reminder of the need for new and effective treatment options to include patients with relapsed or refractory lymphoma, where standard therapies have failed.
At Imugene, we’re advancing azer-cel, a next-generation allogeneic CAR-T therapy designed for hard-to-treat blood cancers. This novel approach offers renewed hope for patients who have exhausted conventional treatments, including autologous CAR-T and for patients who have limited therapy options.
📺 Watch the full story below.
www.instagram.com/reel/DPC6MKKEQzv/
$IMU #biotech #bloodcancer #lymphoma -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve increased the Overall Response Rate to 81% in our Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma, an aggressive type of blood cancer.
This includes 7 Complete Responses and 6 Partial Responses, with two new patients achieving Partial Response.
The trial is now open to enrol into CAR T naïve niche indications in other lymphomas, with additional updates expected in the coming months.
Read the full $IMU #asx Announcement here: mcusercontent.com/e38c43331936a9627acb6427c/files/eb0aad5…
#cart #dlbcl #bloodcancer #immunooncology #cancerresearch #clinicaltrials #biotech #asxnews #biotechnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Today on World Lymphoma Awareness Day, we join the global community in raising awareness for the most common form of blood cancer- lymphoma.
At Imugene, we’re focused on advancing azer-cel, our off-the-shelf CAR-T cell therapy, as a potential new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other forms of rare lymphomas.
With support from patients, clinicians, and global trial partners, our goal is to bring fast, effective immunotherapy to those who need it most.
Learn more about lymphoma, the signs and symptoms, and how to support the cause:
www.leukaemia.org.au/get-involved/world-lymphoma-awarenes…
#wlad2025 #lymphomaawareness #bloodcancer #immunotherapy #car_t #azercel #imugene #imu #asx #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Our COO, Dr Brad Glover, is representing Imugene today at the Asia Bio Partnering Forum in Singapore, where he's sharing Imugene’s progress in advancing next-generation immunotherapies.
Asia Bio brings together global leaders and innovators to build strategic partnerships and drive life science innovation across the Asia-Pacific region.
$IMU #imugene #asiabio2025 #biotech #immunooncology #car_t #azercel #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
We’re incredibly grateful to patient Brendan Roberts for bravely sharing his journey with lymphoma on 7NEWS Australia last night, as well as to journalist Amber Laidler and Associate Professor Matthew Ku from Royal Prince Alfred Hospital for highlighting the potential of our off-the-shelf CAR-T therapy, azer-cel.
The segment featured our CEO & MD, Leslie Chong and explored how azer-cel is delivering life-changing responses for patients who have exhausted conventional treatments. As Brendan said, “It would have been wonderful to have different options to consider.” This is exactly why we’re doing what we do.
📺 Watch the full story here: youtu.be/bHLzTvw86dQ
$IMU #immunotherapy #car_t #lymphoma #celltherapy #biotech #azercel #cancerresearch #7news #clinicaltrials #asx #cancertreatment #breakthroughtherapy @7NewsAustraliaThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene raises A$2.42M in SPP to go towards azer-cel program | $IMU Media coverage by @proactive_au
www.proactiveinvestors.com.au/companies/news/1077427/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve completed the Share Purchase Plan, raising $2.42 million from the issue of 7,335,608 fully paid ordinary shares at $0.33 per share, following the successful $22.5 million institutional placement.
New Shares will be issued on 1 September 2025.
CEO and Managing Director Leslie Chong said, “We thank those investors who participated in the share purchase plan for their continued support of the Company.”
Read the full $IMU ASX Announcement here: wcsecure.weblink.com.au/pdf/IMU/02985727.pdf
#asx #imu #imugene #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
View our 2025 Annual Report and Appendix 4E here:
wcsecure.weblink.com.au/pdf/IMU/02983606.pdf
$IMU #imugene #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Today is Daffodil Day, a national day of hope and progress for everyone impacted by cancer.
At Imugene, we walk with patients, families, researchers, and advocates towards a future where innovation in therapy means better outcomes, renewed hope, and longer, healthier lives.
Learn more or donate at www.daffodilday.com.au
IMU #daffodilday #cancerresearch #hopeforacure #imugene #oncology #cancerawareness #car_t #celltherapy #biotech #clinicaltrials #immunotherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
Extraordinary General Meeting Presentation: August 2025
View the full $IMU Presentation here: wcsecure.weblink.com.au/pdf/IMU/02980628.pdf
#imu #imugene #egm #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
“CAR-T has transformed the treatment landscape for relapsed or refractory lymphoid malignancies. For some patients, it offers the potential for long-term remission and even cure.”
In our latest newsletter, we sat down with Dr Supriya Gupta, Principal Investigator for Imugene’s azer-cel clinical trial, to discuss the future of CAR T therapy in lymphoma.
Dr Gupta shared her insights on how allogeneic CAR T therapy is expanding access, reducing manufacturing delays, and improving outcomes for patients who have progressed after autologous CAR T.
Read the full $IMU Q&A in our August newsletter: imugene.com/wp-content/uploads/2025/08/Imugene_Newsletter…
#imugene #imu #azercel #celltherapy #car_t #oncology #clinicaltrials #cancerresearch #biotech #dlbcl #hematology #immunotherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
📣 We're excited to share our August newsletter.
In this edition, we highlight continued progress in our azer-cel clinical program, share insights from our latest Q&A with Dr Supriya Gupta, Principal Investigator for Imugene’s azer-cel trial, and introduce our newly appointed Chief Medical Officer, Dr John Byon.
📩 Read the latest here: imugene.com/wp-content/uploads/2025/08/Imugene_Newsletter…
$IMU #imugene #immunooncology #cdh17 #cf33 #azer_cel #cancerresearch #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene’s onCARlytics, a clever 'mark and kill' platform uses a virus to force cancer cells to express CD19, making them vulnerable to approved CD19-targeted therapies, such as blinatumomab. This game-changing therapy has the potential to revolutionise treatment of solid tumours.
jitc.bmj.com/content/13/8/e011051 $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Non-Executive Director, Jakob Dupont, took the stage as a keynote speaker at the 2025 Bioshares Biotech Summit, delivering a presentation titled “What are US Investors Looking For?”
Drawing on his experience as a physician scientist, and leader in global biotech and pharmaceutical companies, as well as his role as a managing executive at Sofinnova, Jakob shared his perspectives on investor expectations, market trends, and what it takes to capture attention in the US.
$IMU #imugene #biotech #bioshares2025 #investorinsights #globalbiotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO & MD Leslie Chong, presented today at the 2025 Bioshares Biotech Summit in Hobart as part of Session 4: The Drug Development Journey.
Thank you to the Bioshares team for hosting another valuable event.
$IMU #biotech #immunotherapy #cart #bioshares2025 #cancerresearch #drugdevelopment -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene posts 79% overall response rate in azer-cel Phase 1b trial | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1075972/imug…
#imugene #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
“You could visibly see the tumours shrink through the days of her treatment.” – Dr Joseph Maakaron
In our latest Science Series video, Principal Investigator Dr Joseph Maakaron shares the story of a patient whose visible lymph node tumours dramatically responded during the trial, a powerful reminder of the potential impact of Azer-cel in relapsed DLBCL.
Watch the full clip to hear more: youtu.be/pqvEg3jFLrA
$IMU #imugene #azercel #dlbcl #cart #immunotherapy #bloodcancer #clinicaltrials #cancerresearch #scienceseries #asx #imu -
Imugene | Cancer Immunotherapies
@TeamImugene
📰 Imugene’s Leslie Chong talks Azer-cel breakthrough | Media coverage by @proactive_au
View the full interview here; youtu.be/6xqeLSjgpOE
$IMU #asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve increased the Overall Response Rate to 79% in our Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma, an aggressive type of blood cancer.
This includes 6 Complete Responses and 5 Partial Responses, with two new patients achieving Partial Response, reinforcing the potential of azer-cel in this high unmet need population.
The trial is now open to enrol into CAR T naïve niche indications in other lymphomas, with additional updates expected in the coming months.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02974580.pdf
#cart #dlbcl #bloodcancer #immunooncology #cancerresearch #clinicaltrials #biotech #asxnews #biotechnews -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene reports progress across clinical pipeline and bolsters capital position | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1075870/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
"Azer-cel has given most of my patients the opportunity to reach those life milestones; it’s been pretty magical." Dr Joseph Maakaron
In our latest Science Series episode, Principal Investigator Dr Joseph Maakaron reflects on how far treatment options for aggressive lymphoma have come, and the impact Azer-cel is making for patients who have exhausted other therapies.
🎥 Watch the full discussion with Dr Maakaron, Chief Medical Officer, Dr John Byon, and CEO & MD Leslie Chong: www.youtube.com/watch?v=pqvEg3jFLrA
$IMU #car_t #azercel #immunotherapy #lymphoma #oncology #scienceseries #clinicaltrials #biotech #cancerresearchThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Quarterly Activities Report for the period ending 30 June 2025 has been released.
View the full $IMU report: wcsecure.weblink.com.au/pdf/IMU/02973273.pdf
#imugene #asx #immunotherapy #biotech #drugdevelopment #clinicaltrials #oncology #car_t #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ll be attending the 2025 Bioshares Biotech Summit in Hobart next week.
Our CEO & MD, Leslie Chong will be presenting in Session 4: The Drug Development Journey at 3:00 - 3:20pm on Friday, 8 August, sharing Imugene’s progress across our immuno-oncology pipeline, including updates on our azer-cel program in blood cancers.
📍 Hotel Grand Chancellor, Hobart
📅 August 7–8, 2025
$IMU #bioshares2025 #immunotherapy #biotech #drugdevelopment #clinicaltrials #oncology #car_t #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve released a new episode in our Science Series to dive into some of the groundbreaking work happening at Imugene in the world of immunotherapy, focusing on our recent progress and data in azer-cel, our allogeneic CAR T cell therapy platform for blood cancers.
Featuring CEO & MD Leslie Chong, Chief Medical Officer Dr. John Byon, and Principal Investigator Dr. Joseph Maakaron, the discussion explores new Phase 1b data, including multiple complete responses and one patient who remains cancer-free 15 months after treatment.
📺 Watch the full $IMU discussion here: ⬇️
youtu.be/pqvEg3jFLrA
#asx #cancerresearch #oncology #car_t #celltherapy #cancertreatment #scienceseries #oncolyticvirus #immunotherapy #stockmarketnews -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | $IMU Media coverage by Applied Clinical Trials.
www.appliedclinicaltrialsonline.com/view/imugene-azer-cel… -
Imugene | Cancer Immunotherapies
@TeamImugene
“We’re extremely encouraged by the data emerging from the Phase Ib study,” Bradley Glover, PhD, COO of Imugene $IMU, told Inside Precision Medicine.
www.insideprecisionmedicine.com/topics/oncology/take-2-of… @Inside_PM -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses | Media coverage by @TargetedOncology.
www.targetedonc.com/view/optimizing-r-r-dlbcl-treatment-a…
$IMU #imugene #biotech #biotechnews -
Imugene | Cancer Immunotherapies
@TeamImugene
The replay of our July 2025 Investor Webinar, featuring our Azer-cel data is now available.
Executive Chairman Paul Hopper, Managing Director & CEO Leslie Chong and Chief Medical Officer Dr John Byon discuss the latest data from the azer-cel Phase 1b clinical trial in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This update follows the announcement made on 14 July 2025, highlighting our trial results.
📺Watch the full $IMU session here:
youtu.be/FzdA_8VOprc
#imugene #investorupdate #biotech #clinicaltrials #immunotherapy #cancerresearch #faqwebinar -
Imugene | Cancer Immunotherapies
@TeamImugene
📰 Media coverage by @Inside_PM
Take II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma Patients
Read the full article here: www.insideprecisionmedicine.com/topics/oncology/take-2-of…
#imu #asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
📰Imugene secures $22.5 million placement and launches $15 million SPP to fund azer-cel trial | Media coverage by @proactive_au
Read the full article here; www.proactiveinvestors.com.au/companies/news/1074805/imug…
$IMU #asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We’re hosting a live webinar to present the latest data from our Phase 1b trial of azer-cel.
The webinar will be hosted by Executive Chairman Paul Hopper, CEO & Managing Director Leslie Chong, and Chief Medical Officer Dr John Byon.
The webinar will be held at 11am AEST on Thursday 17 July 2025.
Register here: us02web.zoom.us/webinar/register/WN_zHtM-QGKRwOlbfkL8tf0EQ
Shareholders are encouraged to submit questions for the webinar in advance via email at: matt@nwrcommunications.com.au
A replay will be available after the session via our website and social channels.
$IMU #biotech #cancerresearch #immunooncology #clinicaltrials -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve successfully completed a strongly supported $22.5 million Placement and launched a $15 million Share Purchase Plan at $0.33 per share.
Participants in the Placement and SPP will receive 3 free attaching listed options for every 4 shares subscribed, with an exercise price of $0.43 and expiry 30 March 2026. Upon exercise, participants will also receive 1 additional listed option with an exercise price of $0.86 and expiry 30 June 2028.
The proceeds of the capital raising will primarily be used to fund the azer-cel program through to initiating a pivotal clinical trial in CY26
MD and CEO Leslie Chong said, “Following the strong support received in the recent oversubscribed placement, Imugene is pleased to extend this opportunity to existing retail shareholders through a Share Purchase Plan, enabling participation on the same terms. The placement, together with the SPP and existing cash reserves, places the company in a strong financial position to progress the azer-cel program towards a potential pivotal Phase 2 clinical trial, based on the promising efficacy data reported earlier this week".
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02968003.pdf
#asxnews #clinicaltrials #biotech #cancerresearch #car_t -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene Capital Raising Presentation: wcsecure.weblink.com.au/pdf/IMU/02968007.pdf
$IMU #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We've been featured on Money News.
Imugene CEO & MD Leslie Chong joined the show to discuss our latest azer-cel trial results, the growing potential of allogeneic CAR T therapies, and what’s next for Imugene in the fight against blood cancer.
🎧 Listen to the full interview: omny.fm/shows/money-news/leslie-chong-imugene-ceo
#imugene #azercel #biotech #immunooncology #car_t #cancerresearch #dlbcl #celltherapy #oncology #clinicaltrials #moneynews #asx $IMU #bloodcancer #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial | $IMU Media coverage by @AusBiotech
biotechdispatch.com.au/news/imugene-reports-two-additiona…
#azercel #biotech #immunooncology #car_t #cancerresearch #dlbcl #celltherapy #oncology #bloodcancer #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
“Two more patients are now cancer-free after failing up to six prior lines of therapy – including autologous CAR T. That’s the power of azer-cel,” – CEO & MD Leslie Chong.
We’ve reported a 75% overall response rate and 55% complete response rate in our Phase 1b trial of azer-cel in relapsed/refractory DLBCL, an aggressive form of blood cancer. The first patient remains cancer-free at 15 months and counting.
Leslie joined @proactive_au to discuss what this means for patients, the durability of responses, and next steps as we prepare to meet with the FDA in Q4 to discuss a pivotal/registrational trial.
🎥 Watch the full $IMU interview: youtu.be/WL7HUiAizaA
#car_t #allogeneictherapy #cancerresearch #biotech #immunooncology #clinicaltrials #bloodcancer #celltherapy #fda #oncology #cancertreatmentThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene's azer-cel shows strong results in Phase 1b trial for DLBCL, set for FDA meeting | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1074631/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve reported two additional Complete Responses and three Partial Responses in the Phase 1b trial of azer-cel, our allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell #lymphoma (DLBCL).
This brings the overall response rate to 75% and the Complete Response rate to 55%, with durability data continuing to mature.
Patients in the trial had previously failed multiple lines of therapy, including autologous CAR-T, reinforcing the potential of azer-cel in this high unmet need population.
Based on these positive results, we expect to meet with the US #fda in Q4 2025 regarding a pivotal / registrational study for azer-cel.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02967117.pdf
#immunooncology #cancerresearch #biotech #clinicaltrials #bloodcancer #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
“We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T,” CEO and managing director Leslie Chong told @StockheadAU. $IMU
stockhead.com.au/health/asx-biotechs-join-global-race-for…
#imu #imugene #biotech #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene receives A$5.87M R&D tax refund to support clinical programs | IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1074116/imug…
#biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We've received our R&D tax refund for the 2024 financial year, totalling A$5,872,248, including $84,990 interest.
The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 48.5%. The refund received will enable further clinical development of our immuno-oncology pipeline.
Read more: wcsecure.weblink.com.au/pdf/IMU/02964287.pdf $IMU #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
📰Imugene doses first patient in Australia for PD1-Vaxx Neo-POLEM Phase II trial | Media coverage by @proactive_au
Read the full article here; www.proactiveinvestors.com.au/companies/news/1073728/imug…
$IMU #asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve dosed the first patient in Australia in our Phase II Neo-POLEM clinical trial of PD1-Vaxx at the Queen Elizabeth Hospital in Adelaide.
The trial is investigating the potential of PD1-Vaxx to improve treatment outcomes for a specific subtype of colorectal (bowel) cancer.
CEO and MD Leslie Chong said: “Dosing the first patient in the Neo-POLEM study represents hopeful treatment options for those suffering from these subtypes of colorectal cancer. We are encouraged by the potential of PD1-Vaxx to activate the body’s own immune system to fight cancer in this earliest stage of disease. Our focus remains firmly on improving outcomes for people living with this disease, and we’re grateful to the patients and clinical teams in Australia and the UK who are making this progress possible.”
Read the full $IMU #asx Announcement: wcsecure.weblink.com.au/pdf/IMU/02961064.pdf
#immunotherapy #colorectalcancer #bowelcancer #cancerresearch #biotech #clinicaltrials -
Imugene | Cancer Immunotherapies
@TeamImugene
EGM Presentation: June 2025
View the full $IMU Presentation here: wcsecure.weblink.com.au/pdf/IMU/02960614.pdf
#imugene #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene announces US patent allowance for onCARlytics | Media coverge by @AusBiotech.
$IMU #imugene #oncarlytics #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene secures core US patent for onCARlytics virotherapy platform | Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1073156/imug…
$IMU #imugene #asx #asxnews #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve received a Notice of Allowance from the US Patent and Trademark Office for our onCARlytics technology, protecting the method of composition and use of CF33-CD19 and its combination with CD19-targeting CAR T therapies through to August 2038.
Managing Director and CEO Leslie Chong said, “Imugene receiving this US patent allowance for the CF33-CD19 onCARlytics platform is a crucial step forward for our IP position, with the US being the largest healthcare market in the world. This follows patent allowance in China, an equally large cell therapy market, earlier in 2025.”
View the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02957808.pdf
#imu #imugene #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
In case you missed it, the Neo-POLEM clinical trial opened this week in Australia. The study will recruit patients with a specific type of bowel cancer across hospitals in both Australia and the UK, with the first site now open at the Queen Elizabeth Hospital in South Australia.
$IMU #cancerresearch #bowelcancer #colorectalcancer #immunotherapy #pd1vaxx #neopolem
Southampton CTU
@SouthamptonCTU
Our international trial of a new #cancervaccine for #bowelcancer has opened its 1st site in Australia!
Neo-POLEM explores if a vaccine that stimulates the immune system to attack #cancer cells can improve quality of life & survival outcomes.
Read more - www.southampton.ac.uk/ctu/news/2025/06/international-tria… -
Imugene | Cancer Immunotherapies
@TeamImugene
Following last week’s appointment of Dr John Byon as Chief Medical Officer and this week’s first Australian site activation for the Neo-POLEM colorectal cancer trial, our CEO, Leslie Chong, and CMO Dr Byon sat down with @proactive_au to discuss progress across our pipeline.
Dr Byon: “We’re starting to see not just responses, but durable responses, and that’s what matters most to patients, physicians and regulators alike.”
📺Watch the full $IMU interview here: youtu.be/i0Il1gUDTCs
#imu #imugene #immunotherapy #cancerresearch #clinicaltrials #asxThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
June is Bowel Cancer Awareness Month, a time to recognise the impact of Australia’s second deadliest #cancer and support efforts to improve outcomes through early detection, research, and treatment.
Bowel cancer affects more than 14,500 Australians each year and claims over 5,000 lives, yet it remains one of the most treatable cancers when caught early.
At Imugene, we’re proud to be advancing clinical research into new treatment options for bowel cancer, including the PD1-Vaxx immunotherapy being evaluated in the Phase II Neo-POLEM trial.
Learn more: www.bowelcanceraustralia.org/get-involved/campaigns/bowel…
@BowelCancerAust $IMU #bowelcancerawarenessmonth #pd1vaxx #imugene #cancerresearch #immunotherapy #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
📰 Imugene activates Australian site for Phase II bowel cancer vaccine trial | Media coverage by Proactive
👉 Read more: www.proactiveinvestors.com.au/companies/news/1072195/imug…
$IMU #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve activated the first Australian site for the Phase II Neo-POLEM trial, evaluating PD1-Vaxx in patients with dMMR/MSI-high colorectal cancer.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02952555.pdf
#pd1vaxx #colorectalcancer #cancerresearch #immunotherapy #asx #imu -
Imugene | Cancer Immunotherapies
@TeamImugene
“As Chief Medical Officer, I’m focused on building on the momentum we’ve created, especially with Azer-cel. The early results show real potential for patients with limited options, and I’m committed to progressing our pipeline with that purpose in mind.” – Dr. John Byon, MD, PhD., Chief Medical Officer.
Dr. Byon brings deep expertise in CAR-T, regulatory strategy and translational medicine. His leadership continues to shape the direction of our clinical programs, with a clear focus on advancing meaningful therapeutic options for patients with difficult-to-treat cancers.
$IMU #leadership #immunotherapy #car_t #cancerresearch #clinicaltrials #biotech #oncology #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
We've appointed Dr John Byon as Chief Medical Officer at Imugene. Dr Byon has extensive experience leading the clinical development of innovative CAR-T and CAR-NK therapies for multiple hematologic malignancies at Fate Therapeutics, Lyell Immunopharma, Juno Therapeutics as well as development of atezolizumab at Genentech.
Dr Byon was instrumental in developing Imugene’s strategy to combine azer-cel with IL-2, significantly improving efficacy and durability in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
We thank Dr Paul Woodard for his contributions and welcome Dr Byon to his new role as we continue advancing cancer immunotherapy.
Read the full $IMU ASX Announcement here: wcsecure.weblink.com.au/pdf/IMU/02952005.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
We've released a letter to shareholders from CEO & MD Leslie Chong outlining the proposed 34:1 share consolidation and upcoming EGM on 26 June 2025.
Read the full $IMU letter here: wcsecure.weblink.com.au/pdf/IMU/02951067.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
This Clinical Trials Day, we recognise the patients, investigators, and clinical trial teams and especially the patients who make our work possible.
At Imugene, our mission to develop innovative cancer therapies relies on the strength of the data from our clinical trials from first-in-human studies to multi-site mid to late phase programs across the U.S. and Australia.
Thank you to everyone contributing to the future of cancer treatment and together, let’s find a cure.
To learn more, visit: www.clinicaltrialsday.org
#clinicaltrialsday #ctd2025 $IMU #immunooncology #cancerresearch #clinicaltrials #car_t #oncolyticvirus #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
📰Imugene advances clinical programs with strong trial results and Fast Track status for azer-cel in quarter | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1070490/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Quarterly Activities Report for the period ending 31 March 2025 has been released.
View the full $IMU report here: wcsecure.weblink.com.au/pdf/IMU/02940981.pdf
#imu #imugene #biotech #asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
The replay of our April 2025 Investor Update & FAQ Webinar is now available.
Executive Chairman Paul Hopper, Managing Director & CEO Leslie Chong and Chief Operating Officer Bradley Glover responded to shareholder questions and provided updates across Imugene’s programs.
Watch the full $IMU session here: us02web.zoom.us/webinar/register/WN_EH_SAZ5HRhSqakP_yDKHeA
#imugene #investorupdate #biotech #clinicaltrials #immunotherapy #cancerresearch #faqwebinar -
Imugene | Cancer Immunotherapies
@TeamImugene
REMINDER | Tomorrow, we're hosting a webinar for shareholders, investors, and anyone interested to share the latest company updates and answer some of the most frequently asked questions.
The webinar will be hosted by Executive Chairman Paul Hopper, and he will be joined by CEO & Managing Director Leslie Chong and Chief Operating Officer Brad Glover.
The webinar will be held at 11:00am AEST (Wednesday, 16 April 2025).
Shareholders, investors and interested parties can register to attend the webinar at the following link: us02web.zoom.us/webinar/register/WN_EH_SAZ5HRhSqakP_yDKHeA
$IMU Shareholders are encouraged to submit questions for the webinar in advance via email at:
shareholderenquiries@imugene.com
A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via our website and social media channels.
#imu #imugene #biotech #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene’s Senior Director, Translational Research, Grey Wilkinson, presented our poster 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑜𝑓 𝐶ℎ𝑜𝑙𝑎𝑛𝑔𝑖𝑜𝑐𝑎𝑟𝑐𝑖𝑛𝑜𝑚𝑎 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑂𝑛𝑐𝑜𝑙𝑦𝑡𝑖𝑐 𝑉𝑖𝑟𝑢𝑠 𝐶𝐹33-ℎ𝑁𝐼𝑆 yesterday at the 2025 Cholangiocarcinoma Foundation Annual Conference (CFAC) in Salt Lake City, Utah.
$IMU #imu #imugene #cfac2025 #cholangiocarcinoma #cf33 #oncolyticvirus #immunotherapy #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
We're hosting a webinar for shareholders, investors, and anyone interested to share the latest company updates and answer some of the most frequently asked questions.
The webinar will be hosted by Executive Chairman Paul Hopper, and he will be joined by CEO & MD Leslie Chong and COO Bradley Glover.
The webinar will be held at 11:00 am AEST on Wednesday, 16 April 2025.
$IMU Shareholders, investors and interested parties can register to attend the webinar at the following link: us02web.zoom.us/webinar/register/WN_EH_SAZ5HRhSqakP_yDKHeA
Shareholders are encouraged to submit questions for the webinar in advance via email at:
shareholderenquiries@imugene.com.
A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via our website and social media channels. -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene clears first IV dose level in Phase 1 onCARlytics trial for solid tumours | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1069033/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've cleared the first dose level in the intravenous (IV) combination arm of our Phase 1 onCARlytics trial.
The study, known as OASIS, is targeting adult patients with advanced or metastatic solid tumours and is evaluating the safety and efficacy of intravenous and intratumoural administration of either onCARlytics (a CD19-expressing oncolytic virus) alone or in combination with CD19 targeting bispecific monoclonal antibody blinatumomab (Blincyto®), which is a cancer immunotherapy.
Dose escalation will continue as we advance towards full recruitment of 40-50 patients across U.S. trial sites.
MD and CEO Leslie Chong, said: “CD19 is a very significant target for blood cancers, but solid cancers like breast, lung or gastric do not have a common target on their cell surface, and therefore the aim with onCARlytics is to make available a target for CD19 therapies to treat these solid cancers. As the trial continues to progress and dose escalation is executed, we are eager to learn of the potential impact our treatment is having for patients in need.”
Read the full $IMU #asx Announcement: wcsecure.weblink.com.au/pdf/IMU/02932184.pdf
#imugene #oncarlytics #cd19 #immunotherapy #asx #cancerresearch #dlbcl #solidtumours #biotech #oasistrial #imu -
Imugene | Cancer Immunotherapies
@TeamImugene
𝗠𝗲𝗲𝘁 𝗦𝗵𝗮𝗿𝗼𝗻 𝗬𝗮𝘃𝗿𝗼𝗺– 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝘁 𝗜𝗺𝘂𝗴𝗲𝗻𝗲
Sharon brings extensive experience in oncology drug development, having contributed to therapies like Yervoy, Nivolumab, Nerlynx, and XGEVA. She has worked across academia and industry, earning a Ph.D. in pathology and focusing on treatments for lung cancer, glioblastoma, breast cancer, Ewing’s sarcoma, and lymphomas.
Since joining Imugene nearly three years ago, Sharon has played a key role across all clinical programs, shaping study designs, supporting publications, and driving trial execution. She now focuses on azer-cel, where she has developed expertise in cell therapy. Sharon is particularly excited about azer-cel’s IL-2 cohort data, which shows promise in improving CAR-T expansion and persistence, potentially redefining allogeneic CAR-T treatment.
As Executive Director of Clinical Science, Sharon helps guide Imugene’s clinical programs from design through to execution, ensuring trials progress.
$IMU #meettheteam #clinicalresearch #car_t #immunotherapy #imugene #imu #leadership #oncology #clinicaldevelopment -
Imugene | Cancer Immunotherapies
@TeamImugene
📣 We're excited to share our March newsletter.
This edition includes updates on our key clinical milestones for azer-cel, recent intellectual property milestones, and highlights from our latest Q&A sessions. We also welcome our new CFO, Darren Keamy, and highlight recent media coverage and presentations.
$IMU Read more: imugene.com/wp-content/uploads/2025/03/Imugene_Newsletter…
#biotech #cancerresearch #immunotherapy #newsletter -
Imugene | Cancer Immunotherapies
@TeamImugene
In case you missed it – CEO & Managing Director Leslie Chong's presentation at the NWR Communications Healthcare Conference is now available to watch.
🎥 Watch the $IMU replay here: youtu.be/WBMJCie3WME
#imugene #biotech #asx #healthcare @NWRcomms -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO & MD Leslie Chong joins @proactive_au to discuss the FDA’s Fast Track Designation for azer-cel, our allogeneic CAR T-cell therapy for relapsed/refractory DLBCL. With promising response rates and a growing clinical program, this designation supports expedited development for patients with high unmet need.
📺 Watch the full $IMU interview here: youtu.be/CFtMmAG7SXI
#imugene #imu #biotech #cancerresearch #car_t #fda #fasttrack #dlbcl #immunotherapy #bloodcancer #medicalinnovation #oncology -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene secures FDA fast track designation for CAR T-cell therapy azer-cel to combat blood #cancer | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1068106/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've been granted Fast Track Designation by the U.S. FDA for our allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
This designation is designed to facilitate the development and expedite the review process for therapies addressing serious conditions. It supports our efforts to advance azer-cel as a potential off-the-shelf CAR T treatment for patients with limited options.
Managing Director and CEO Leslie Chong said, “Receiving FDA Fast Track Designation is a testament to the transformative potential of azer-cel for patients battling relapsed or refractory DLBCL. We are committed to working closely with the FDA to bring this important therapy to patients as efficiently as possible.”
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02926523.pdf
#imugene #imu #car_t #biotech #fda #cancerresearch #immunooncology -
Imugene | Cancer Immunotherapies
@TeamImugene
REMINDER | Imugene CEO & Managing Director Leslie Chong will present tomorrow (19 March 2025), at 9:00 AM AEDT as part of the @NWRcomms Virtual Healthcare Conference.
Date: Wednesday, 19 March 2025
Time: 9:00 AM AEDT
Register here: us02web.zoom.us/webinar/register/WN__t8AkG1KSrWQRHn57DLzNw
A recording will be available after the live session. Questions can be submitted on the day or emailed in advance to matt@nwrcommunications.com.au.
For more details: nwrcommunications.com/healthconf
$IMU #healthcareconference #biotech #investorupdate #webinar -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene CEO & Managing Director Leslie Chong will present on Wednesday, 19 March 2025, at 9:00 AM AEDT as part of the @NWRcomms Virtual Healthcare Conference.
Date: Wednesday, 19 March 2025
Time: 9:00 AM AEDT
Register here: us02web.zoom.us/webinar/register/WN__t8AkG1KSrWQRHn57DLzNw
A recording will be available after the live session. Questions can be submitted on the day or emailed in advance to matt@nwrcommunications.com.au.
For more details: nwrcommunications.com/healthconf
#imugene #imu #healthcareconference #biotech #investorupdate #webinar -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene has been featured in Bioshares, highlighting the latest results from our Phase 1b trial of azer-cel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). With two additional complete responses (CRs) reported, the CR rate in Cohort B has now reached 57%.
Read more ⬇️
#imugene $IMU #azercel #car_t #immunooncology #cancerresearch #bioshares -
Imugene | Cancer Immunotherapies
@TeamImugene
Our latest Science Series dives into autologous and allogeneic CAR T-cell therapy and the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL). Dr. Paul Woodard, Chief Medical Officer, and Dr. John Byon, Senior VP Clinical Development, discuss the differences between autologous and allogeneic CAR T-cell therapies, how azer-cel is designed to overcome limitations in current treatments, and the latest promising trial results showing a 57% complete response rate.
📺 Watch the full discussion here: ⬇️
youtu.be/o8Ni14lVQMI
#imugene $IMU #asx #cancerresearch #oncology #car_t #celltherapy #cancertreatment #scienceseries #oncolyticvirus #immunotherapy #cancersurvivorship #drugdevelopment #cancerinnovation #biotechnology #stockmarketnews -
Imugene | Cancer Immunotherapies
@TeamImugene
At Imugene, we recognise the contributions of women in science, medicine, and innovation. On International Women's Day, we celebrate the women driving progress in immuno-oncology, breaking barriers, and shaping the future of cancer treatment and patient care.
MD & CEO, Leslie Chong:
"As a female executive in biotech, I’m proud to stand alongside the incredible women driving innovation in science and medicine. Their dedication and expertise are shaping the future of cancer treatment and inspiring the next generation of pioneers."
#iwd2025 #accelerateaction #womeninstem #imugene #imu #diversityinscience -
Imugene | Cancer Immunotherapies
@TeamImugene
Missed Managing Director & CEO Leslie Chong’s presentation at the Emergence Investment Conference? The replay is now available.
🎥 Watch it here: ⬇️
youtu.be/t5T7qXR5mjs
$IMU #imugene #biotech #leadership #immunooncology @wholesaleinvest -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene appoints Darren Keamy as CFO and company secretary | $IMU Media coverage by @proactive_au
www.proactiveinvestors.com.au/companies/news/1067271/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've appointed Darren Keamy as Chief Financial Officer and Company Secretary. Darren brings 25+ years of financial experience, including 19 years at Clinuvel Pharmaceuticals, where he played a key role in capital raising, corporate governance, and international expansion.
We thank Mike Tonroe for his contributions and wish him all the best in his future endeavours.
MD and Chief Executive Officer, Leslie Chong, said: “Darren’s outstanding experience in financial management, capital markets, and corporate governance within the life sciences sector makes him a valuable addition to Imugene. His proven ability to drive financial performance and strategic growth will support the company as we continue advancing our immuno-oncology pipeline. We are delighted to have him on board.”
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02920606.pdf
#imugene #imu #biotech #leadership #immunooncology -
Imugene | Cancer Immunotherapies
@TeamImugene
CAR T cell #lymphoma trial opens for Aussie patients | $IMU Media coverage by @bloodrepublicAU
www.bloodrepublic.com.au/car-t-cell-lymphoma-trial-opens-… -
Imugene | Cancer Immunotherapies
@TeamImugene
We're pleased to provide our half-year report and accounts for the half year ended 31 December 2024.
View the full $IMU report here: wcsecure.weblink.com.au/pdf/IMU/02919445.pdf
#imu #imugene #biotech #immunooncology #cancerresearch #asx #investorupdates #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene secures patent protection in India for CF33 oncolytic virotherapy technology | $IMU Media covered by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1066995/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Managing Director & CEO, Leslie Chong, presented yesterday at the Emergence Investment Conference in Sydney. A copy of her presentation will be shared once it’s made available.
$IMU #imugene #emergence2025 @wholesaleinvest #lesliechong #biotech #immunooncology #cancerresearch #asx #investorupdates -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve been granted a patent in #india for our #cf33 oncolytic virotherapy technology, protecting the method of composition and method of use until 2037. This strengthens our global intellectual property, adding to existing patents in the United States and Japan.
Managing Director and CEO Leslie Chong said: “The grant of this India patent is another significant step in expanding global protection for CF33, building on our strong foundation in key markets such as the US and Japan. We remain committed to advancing our oncolytic virotherapy pipeline and delivering next-generation immunotherapies to patients worldwide.”
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02918433.pdf
#imugene #imu #asx #asxnews #biotech #oncolyticvirus #cancerresearch #immunooncology #patent -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene secures CD19 oncolytic virus patent in China | $IMU Media coverage by @proactive_au
www.proactiveinvestors.com.au/companies/news/1066912/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve received a Notice of Allowance from the Chinese Patent Office, for City of Hope’s patent application number 201880064280.9 which protects the CD19-expressing oncolytic virus, onCARlytics. This patent provides method of composition and method of use protection through to 2038 in China, Asia’s largest market.
OnCARlytics forces solid tumour cells to express CD19 on their surface, making them targets for CD19-targeting therapies. This strengthens our intellectual property and supports our ongoing OASIS dose escalation trial in the US, with up to 40 patients participating.
MD & CEO Leslie Chong said: "Intellectual property has remained a priority for our innovative range of immuno-oncology assets, and to have onCARlytics protected in a major market like China is an integral part of this strategy."
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02917622.pdf
#imugene #oncarlytics #cd19 #cancerresearch #oncolyticvirus #immunooncology #intellectualproperty #clinicaltrials #china -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO & Managing Director, Leslie Chong, will be presenting at the Emergence Investment Conference in Sydney next week.
📅 Date: Wednesday, 26 February 2025
🕒 Time: 4:45 pm AEDT
📍 Venue: Four Seasons Hotel, Sydney
Access your complimentary ticket here: www.eventbrite.com.au/e/emergence-investment-conference-s…
#emergence2025 #imugene #imu #biotech #investmentconference @wholesaleinvest -
Imugene | Cancer Immunotherapies
@TeamImugene
“We could be a big ‘allo’ CAR-T game, but we could also change the paradigm of how we treat solid tumours with onCARlytics.” – CEO Leslie Chong.
🔗 Read the $IMU full article: stockhead.com.au/health/biocurious-cashed-up-and-pursuing…
#imugene #biotech #immunooncology #azercel #car_t #oncolyticvirus #cancerresearch #clinicaltrials -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene presented new azer-cel data at the 2025 #astct Tandem Meetings, with Chief Medical Officer, Dr. Paul Woodard, showcasing our latest research.
The poster, “Administration of low-dose IL-2 markedly enhances the PK profile of azer-cel” (Abstract ID: 25472), highlights how IL-2 improves pharmacokinetics without compromising safety in patients with relapsed/refractory diffuse large B-cell #lymphoma (DLBCL).
📷 Dr. Woodard and Dr. Sharon Yavrom PhD, Executive Director, Clinical Science, engaged with researchers to discuss the trial’s progress and its potential role in advancing CAR T therapy.
$IMU #azercel #astct2025 #car_t #dlbcl #cancerresearch #immunooncology #clinicaltrials -
Imugene | Cancer Immunotherapies
@TeamImugene
Chief Medical Officer Dr. Paul Woodard and Managing Director and CEO Leslie Chong spoke with @proactive_au about the latest results from the Phase 1b clinical trial of Azer-cel, our CD19 CAR-T therapy.
The latest data reveals a 57% complete response rate, meaning no detectable lymphoma in these patients.
Watch the full $IMU interview below ⬇️
youtu.be/UJ8yjqytfLg -
Imugene | Cancer Immunotherapies
@TeamImugene
We've reported further positive results from our Phase 1b clinical trial of azer-cel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Two more patients in Cohort B have achieved a Complete Response, bringing the total to four out of seven evaluable patients. This represents a 57% CR rate in a population that had previously failed multiple treatments, including autologous CAR-T therapy.
The trial continues to enrol patients across 13 US sites and up to 5 Australian sites, with an ongoing focus on evaluating long-term durability of response.
These findings will be featured at a Poster presentation at the 2025 ASTCT Tandem Meetings.
“All four Complete Responses in Cohort B were achieved in patients who had failed at least 4 lines of therapy in this hard-to-treat population, including autologous CAR T therapy," said Dr Paul Woodard, Chief Medical Officer of Imugene. "This suggests that azer-cel, in combination with IL-2, may offer a meaningful therapeutic option where other treatments have not succeeded. We are continuing to monitor these patients for persistence of response, with the longest durability ongoing at 10 months. We look forward to providing further updates as data matures.”
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02912851.pdf
#imugene #imu #azercel #car_t #dlbcl #clinicaltrials #immunooncology #cancerresearch #astct2025 #biotech #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
𝗠𝗲𝗲𝘁 𝗨𝗿𝘀𝘂𝗹𝗮 𝗠𝗰𝗖𝘂𝗿𝗿𝘆- 𝗖𝗵𝗶𝗲𝗳 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿 𝗮𝘁 𝗜𝗺𝘂𝗴𝗲𝗻𝗲
Ursula has dedicated her career to #oncology, beginning at QLT Therapeutics in Vancouver before relocating to the US to work at Exelixis. Her experience includes both small & large biotech companies, such as Astex, Genentech, and Amunix, focusing primarily on early development of small and large molecules.
Since joining Imugene nearly three years ago, Ursula has played a critical role in advancing Imugene’s clinical development strategy. She began by overseeing studies like HERIZON, nextHERIZON, and IMPRINTER, along with supporting the IND submission for VAXINIA and the start-up of the FIH MAST study. Over time, her role has evolved to include the onCARlytics program, the OASIS trial, and the in-licensing of the azer-cel asset, which brought over 84 treated patients into the Imugene portfolio.
As COO, Ursula oversees clinical trials, ensures they meet regulatory standards, and leads Imugene’s clinical operations team. She also works closely with the executive team to improve processes, manage budgets and timelines, and address challenges in trial execution.
In her free time, Ursula enjoys walking her dog, cooking, and reading.
#teamimugene $IMU #leadership #oncology #clinicaldevelopment #meettheteam -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene’s Managing Director & CEO, Leslie Chong, and COO, Brad Glover, spoke with @proactive_au about the latest quarterly update, covering clinical progress and financial outlook.
Watch the full $IMU interview here: youtu.be/jMSI6VcHPZI
#imugene #proactive #clinicaltrials #immunooncology #cancerresearch #oncolyticvirus #azercel #biotech #cancerresearch #imuThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Today is World Cancer Day. This year’s theme, “United by Unique,” emphasises putting people at the centre of cancer care and their stories at the forefront of the conversation.
At Imugene, we are committed to developing innovative immuno-oncology treatments that address the unmet needs of patients with challenging cancers. From our allogeneic azer-cel CAR T-cell therapy to onCARlytics and CF33 oncolytic virus programs, our work aims to bring new hope to those facing this disease.
Learn more about World Cancer Day and how to take action at www.worldcancerday.org
#worldcancerday #unitedbyunique #imugene #cancerresearch #oncology #patientcare $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
We're pleased to announce our Quarterly Cash Flow report (Appendix 4C) for the quarter ended 31 December 2024.
View the full $IMU report here: wcsecure.weblink.com.au/pdf/IMU/02907723.pdf
#imugene #imu #biotech #immunooncology #oncarlytics #cancerresearch #asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene secures A$20 million in convertible notes issue to CVI Investments | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1065219/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've received A$20M from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, Inc., as the first tranche of a A$46M capital raise announced in December 2024.
The proceeds from this initial tranche will be directed toward advancing our immuno-oncology clinical trial pipeline, including azer-cel, onCARlytics, and VAXINIA programs.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02906534.pdf
#asxnews #biotech #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
EGM Presentation - January 2025
View the full $IMU Presentation here: ⬇️
wcsecure.weblink.com.au/pdf/IMU/02904977.pdf
#asx #asxnews -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene receives A$11.7 million R&D tax refund www.proactiveinvestors.com.au/companies/news/1064095/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We've received our research and development tax refund for the 2023 financial year, totalling A$11,689,963, including interest of A$514,093.
The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%. The refund received will enable further clinical development of our immuno-oncology pipeline.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02902208.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
Diamond Equity Research: Price Target $0.49
$IMU: Announces Up to A$46 Million Financing, Achieves First Intratumoural onCARlytics Dosing Milestone, and Opens First Australian Azer-cel Trial Site for Relapsed or Refractory DLBCL
Read the full report here: imugene.com/wp-content/uploads/2025/01/Imugene-January-20…
#cancerresearch #immunooncology #biotech #clinicaltrials #cancertreatment #oncology #medicalresearch #equityresearch #equityrelease -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene’s abstract has been accepted for a poster presentation at the @AACR Immune-Oncology Conference, taking place from 23-25 February 2025, at the JW Marriott in Los Angeles, California.
Abstract Title: Induction of an anti-tumor immune response following intratumoral injection of oncolytic virus CF33-hNIS-antiPD-L1 in patients with metastatic triple-negative breast cancer (mTNBC).
Session Date: Monday, 24 February, 2025.
Learn more about the conference and session details here: www.aacr.org/meeting/aacr-io-discovery-and-innovation-in-…
#aacrio25 $IMU #cf33 #oncolyticvirus #cancerresearch #immunooncology #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
“Achieving first patient dosed for azer-cel in Australia represents a significant milestone for Imugene and for Australian patients battling this devastating disease,” Imugene managing director and CEO Leslie Chong said.
$IMU Media mention by @proactive_au -
Imugene | Cancer Immunotherapies
@TeamImugene
We've dosed the first Australian patient in our Phase 1b azer-cel clinical trial (azercabtagene zapreleucel) at the Royal Prince Alfred Hospital in Sydney. The trial focuses on patients with relapsed or refractory diffuse large B-cell #lymphoma (#dlbcl), one of the most challenging and aggressive forms of non-Hodgkin’s lymphoma.
Azer-cel is one of the few allogeneic CAR T-cell therapies currently being evaluated in Australia, offering an off-the-shelf alternative to traditional autologous CAR Tcell therapies. Recent data from US trial sites showed promising results, including multiple complete responses in patients who had failed multiple prior treatments.
MD and CEO Leslie Chong said, “Achieving first patient dosed for azer-cel in Australia represents a significant milestone for Imugene and for Australian patients battling this devastating disease. The trial’s opening at RPAH in Sydney reflects our commitment to accelerating the development of innovative, offthe-shelf immunotherapies that have the potential to improve outcomes for patients with relapsed or refractory DLBCL. We are proud to bring this trial to Australia and look forward to expanding recruitment across multiple sites.”
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02900229.pdf
#imugene #azercel #car_t #cancerresearch #clinicaltrials #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
We've entered into a subscription agreement and warrant deed poll, to issue Convertible Notes and Warrants to CVI Investments, Inc.
The funds raised will be put toward the ongoing trials for our azer-cel, onCARlytics and VAXINIA programs, as we anticipate key clinical data readouts in the coming 12 months.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02898504.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
📢 We're excited to share our December $IMU newsletter.
Read the newsletter here for updates on our clinical progress and more: imugene.com/wp-content/uploads/2024/12/Imugene_Newsletter… -
Imugene | Cancer Immunotherapies
@TeamImugene
As we close 2024, we reflect on a year of significant achievements at Imugene, including the opening of our first Australian site for the azer-cel Phase 1b trial, promising results in onCARlytics and VAXINIA trials, a two-year complete response milestone in bile tract cancer, and securing FDA Fast Track and Orphan Drug Designations. We also extended US patent protection for CF33 technologies to 2040.
We’re grateful for your ongoing support and dedication to our mission of developing innovative treatments for patients with cancer. Wishing you a safe and restful holiday season, and we look forward to advancing our work in 2025.
#imugene $IMU #cancerresearch #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene to receive A$11 million R&D tax refund for FY23 | Media coverage by @proactive_au. $IMU
www.proactiveinvestors.com.au/companies/news/1063134/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've received confirmation from the Australian Taxation Office that we will receive a research and development (R&D) tax refund for the 2023 financial year, totalling approximately $11 million (plus interest). These funds, expected around January 2025, will enable further clinical development of our immunooncology pipeline.
Read the full $IMU #asx Announcement here: wcsecure.weblink.com.au/pdf/IMU/02896767.pdf -
Imugene | Cancer Immunotherapies
@TeamImugene
Over the weekend at the 66th ASH Annual Meeting and Exposition in San Diego, Imugene’s key clinical team met with doctors and investigators involved in the azer-cel clinical trial.
📸 Photo 1: Dr. Paul Woodard (Imugene Chief Medical Officer), Dr. Joseph Maakaron (University of Minnesota), and Dr. John Byon (Imugene Senior VP Clinical Development).
📸 Photo 2: Leslie Chong (Imugene MD & CEO) with principal investigators from our Australian trial sites—Dr. Vinay Vanguru (Royal Prince Alfred Hospital), Dr. Ann-Marie Watson (Liverpool Hospital), and Dr. Matthew Ku (St Vincent's Hospital Melbourne).
These connections reinforce the collaborative efforts driving the progress of azer-cel.
#ash2024 #azercel #clinicaltrials #hematology #cancerresearch #oncology #biotech $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene’s key Clinical Development team, will be attending the 66th ASH Annual Meeting and Exposition in San Diego, California, from 7-10 December 2024. This event brings together over 30,000 hematology professionals to discuss the latest advancements in research, treatment, and education.
For more information about the conference, visit: www.hematology.org/hematology-conference?sc_trk=CCFC1FC7-…
#imugene $IMU #ash2024 #hematology #cancerresearch #oncology #biotech @ASH_hematology -
Imugene | Cancer Immunotherapies
@TeamImugene
Managing Director and CEO, Leslie Chong, will be presenting at the CapitalHQ Online Investment Showcase on Thursday, 5 December 2024, at 12:25 PM AEDT.
🔗 Register for the event here: capitalhq.app/events/details/caphq-showcase-dec24
#imugene $IMU #capitalhqshowcase #biotech #immunooncology #clinicaltrials -
Imugene | Cancer Immunotherapies
@TeamImugene
📷 A quick snap from the Future Disrupted Investment Conference 2024, where $IMU CEO & Managing Director, Leslie Chong, joined the panel discussion on the "Future of Healthcare and Medicine".
#futuredisrupted2024 #imugene #healthcareinnovation #biotech #oncology @wholesaleinvest -
Imugene | Cancer Immunotherapies
@TeamImugene
We're proud to be part of the @Bell_Potter Securities Healthcare Conference 2024, a three-day virtual event showcasing leading small and mid-cap healthcare companies.
Our Managing Director and CEO, Leslie Chong, will be presenting on Tuesday, 19 November, at 3:30 PM AEDT.
#imugene $IMU #bellpotterhealthcare2024 #healthcareinnovation #biotech #cancerresearch #oncology #smallcap #midcap -
Imugene | Cancer Immunotherapies
@TeamImugene
Join us at the Future Disrupted Investment Conference 2024 to hear CEO & Managing Director, Leslie Chong, on the "Future of #healthcare and #medicine" panel. Leslie’s session begins on Monday, 18 November, at 11:20 AM (AEDT) at the Hilton Sydney.
Access your complimentary ticket here: capitalhq.app/user/events/details/future-disrupted-24?dis…
$IMU #futuredisrupted2024 #healthcareinnovation #biotech #oncology #investmentconference #sydneyevents @wholesaleinvest -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch our latest interview with Proactive, where CEO and Managing Director, Leslie Chong, and Dr. Yuman Fong, Chair of the Department of Surgery at City of Hope and inventor of the CF33 oncolytic virus, discuss developments in our onCARlytics (CF33-CD19) clinical trial. Hear about the recent dosing of the first patient in the intratumoural (IT) combination arm and the potential of CD19 oncolytic virotherapy for advanced solid tumours.
🎥 Watch the full $IMU interview here: youtu.be/RZ337FfbCR4
#imugene #imu #oncarlytics #cancerresearch #oncolyticvirus #cd19 #clinicaltrials #yumanfong #cityofhope #biotech #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
AGM Presentation - November 2024
View the full $IMU Presentation here: app.sharelinktechnologies.com/announcement/asx/afd6832735…
View the AGM Results here: app.sharelinktechnologies.com/announcement/asx/5c6ca82c8d… -
Imugene | Cancer Immunotherapies
@TeamImugene
Managing Director and CEO, Leslie Chong, recently spoke with @proactive_au's Tylah Tully about the progress in our onCARlytics (CF33-CD19) Phase 1 clinical trial, where the first patient has been dosed in the intratumoural combination arm. She also provided an overview of our first Australian site for the azer-cel Phase 1b clinical trial.
Read the full $IMU article here: www.proactiveinvestors.com.au/companies/news/1060249/imug…
#imugene #imu #oncarlytics #oasistrial #cancerresearch #oncolyticvirus #cd19 #solidtumours #clinicaltrials #virotherapyThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene Phase 1 onCARlytics trial doses first patient in intratumoural combination arm www.proactiveinvestors.com.au/companies/news/1060236/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We've dosed the first patient in the intratumoural (IT) combination arm of our Phase 1 onCARlytics (CF33-CD19) clinical trial. This development is part of the OASIS trial, which is designed to assess the safety and
efficacy of our CD19 oncolytic virotherapy in patients with advanced or metastatic solid tumours.
The OASIS trial is a Phase 1 dose escalation study that explores two routes of administration, intratumoural (IT) injection and intravenous (IV) infusion. onCARlytics, a CD19-expressing oncolytic virus, is being investigated both as a monotherapy and in combination with the CD19-targeting bispecific antibody blinatumomab, an established cancer immunotherapy.
Managing Director & CEO Leslie Chong said: “We are pleased to have dosed the first patient in the intratumoural arm of our OASIS trial. With CD19 being a well-established target in blood cancers, we are optimistic about the effectiveness it could show in solid tumours. onCARlytics has the potential to induce expression of CD19 on the surface of solid tumours and allowing existing CD19 therapies to recognise and attack the cancer. We’re pleased to continue advancing this prospective new treatment option for those in need."
Read the full $IMU #asx Announcement - app.sharelinktechnologies.com/announcement/asx/a7c9a6b7f0…
#imugene #oncarlytics #oasistrial #cancerresearch #oncolyticvirus #cd19 #colorectalcancer #solidtumors #immunooncology #clinicaltrials #biotech #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
Diamond Equity Research: Price Target $0.49
IMU: Sustained Momentum with Key Clinical Advancements and Robust Financial Profile, With Numerous Upcoming Potential Catalysts
Read the $IMU full report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#imu #imugene #imugene #azercel #cancerresearch #dlbcl #car_t #immunooncology #biotech #clinicaltrials #cancertreatment #oncology #medicalresearch #equityresearch #equityrelease -
Imugene | Cancer Immunotherapies
@TeamImugene
We’ve opened our first Australian site for the azer-cel Phase 1b clinical trial at Sydney’s Royal Prince Alfred Hospital, with patient recruitment starting this month. As Australia’s only actively enrolling allogeneic CAR T-cell trial, it targets relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Promising results from U.S. sites include complete responses in patients who had previously failed multiple treatments. Azer-cel, an off-the-shelf CAR T therapy using pre-manufactured donor T-cells, provides quicker and more accessible treatment options compared to traditional autologous CAR T therapies.
“We’re proud to be able to bring this trial to Imugene’s home country and provide an opportunity for Australian patients to benefit from this unique technology,” said Imugene’s Managing Director and CEO Leslie Chong. “ This is the first of up to five sites we plan to open in Australia, as we seek to speed up enrolment and deliver improved outcomes in this form of blood cancer.”
Read the full $IMU #asx Announcement here: app.sharelinktechnologies.com/announcement/asx/d01946a1e6…
#imugene #asx #azercel #car_t #clinicaltrial #immunooncology #dlbcl #cancerresearch #bloodcancer #allogeneiccar_t #cancertreatment #oncology #australianhealthcare #bcelllymphoma #innovativetherapies -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch our latest interview with @ausbiztv, where CEO & Managing Director Leslie Chong discusses the progress in our clinical trials, including a bile tract #cancer patient in our MAST study who has remained cancer-free for over two years.
🎥 Watch the full $IMU interview here:
ausbiz.com.au/media/cancer-free-imugenes-exciting-trial-p… -
Imugene | Cancer Immunotherapies
@TeamImugene
Join our CEO and Managing Director Leslie Chong and Professor Yuman Fong as they discuss their shared commitment to advancing cancer treatment and how CF33 oncolytic virus is bringing new hope to patients and their families.
Watch the full $IMU video here: youtu.be/783wSc5Hfv8
#imugene #scienceseries #cf33 #oncolyticvirus #cancerresearch #immunooncology #healthcareinnovation #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Managing Director and CEO, Leslie Chong, sits down with @proactive_au to discuss our latest milestone. In our Phase 1 MAST trial, a bile tract cancer patient has maintained a complete response, now surpassing two years in remission. With the Bile Tract Cancer Expansion part of the trial clearing its first cohort—showing no dose-limiting toxicities in the initial three patients—enrollment is now open for up to 10 patients. Watch the full $IMU interview for more insights.
🎥 Watch here: youtu.be/U0fv64Xih08
#imugene #asx #cancerresearch #oncology #biletractcancer #masttrial #vaxinia #cf33virus #clinicaltrial #fdafasttrack #orphandrugdesignation #patentextension #cancertreatment #oncolyticvirus #immunotherapy #medicalbreakthrough #cancersurvivorship #ushealthcare #drugdevelopment #cancerinnovation #biotechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #proactiveinvetstorsThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce a major milestone in our CF33 MAST VAXINIA study, with a bile tract cancer patient maintaining a complete response for over two years. The Cohort review committee has cleared the first cohort of three patients in Bile Tract Cancer Expansion of the VAXINIA trial, with patients continuing to be enrolled. VAXINIA has received both FDA Fast Track and Orphan Drug Designation status, and a recent US patent extension now protects CF33 VAXINIA until 2040.
CEO, Leslie Chong, stated: “Imugene receiving this patent extension to 2040 from the US patent office is a significant milestone for the CF33 family of oncolytic viruses. The US is the core healthcare market, and we are delighted to strengthen the patent life.”
“We’re also very pleased to see the two-year milestone reached for the Bile Tract Cancer patient who has maintained a complete response in our MAST study. Most importantly this is an outstanding result for the patient given the limited treatment options available, but also demonstrates the excellent potential of the CF33 oncolytic virus for this and other cancer types. We continue to enroll into the bile tract cancer expansion of the MAST trial.”
Read the full $IMU #asx Announcement here: app.sharelinktechnologies.com/announcement/asx/62cfca27c4…
#vaxinia #maststudy #biletractcancer #cancerresearch #oncolyticvirus #clinicaltrials #biotech #oncology -
Imugene | Cancer Immunotherapies
@TeamImugene
📢 Join us for an upcoming webinar with @sharewiseau on Thursday, 7 November, at 1:00pm AEDT. Our CEO and MD, Leslie Chong, will provide a company presentation followed by a live Q&A session.
🔗 Register here: zoom.us/webinar/register/8517307019437/WN_K0Engn-kS-6IJt3…
$IMU #webinar #biotech #cancerresearch #investorrelations #immunooncology #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
We're pleased to announce our Quarterly Activities and Cash Flow Report for the quarter ended 30 September 2024.
View the full $IMU Report here: 👇
app.sharelinktechnologies.com/announcement/asx/d4d1415e05… -
Imugene | Cancer Immunotherapies
@TeamImugene
Thank you, @AusBiotech, for the opportunity to present at this year’s AusBioInvest conference. Our Managing Director and CEO, Leslie Chong, appreciated the chance to share $IMU's latest advancements in immuno-oncology with such an engaged and forward-thinking audience.
#ausbioinvest #biotech #immunooncology #cancerresearch #ausbiotech2024 -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Managing Director and CEO, Leslie Chong, will be presenting at the upcoming #ausbioinvest conference on Tuesday, 29 October, at the Park Hyatt in Melbourne.
Leslie will be speaking during Session 1 at 9:40am AEDT, sharing insights into $IMU's innovative work in immuno-oncology.
For more information, visit: ausbiotechinvestment.com.au
#ausbio #ausbioinv $IMU #biotech #cancerresearch #oncology #investorconference #healthcareinnovation #melbourneevents @AusBiotech -
Imugene | Cancer Immunotherapies
@TeamImugene
📢 Notice of Annual General Meeting: Imugene's AGM will be held on Thursday, 14 November 2024 at 9:00am (Sydney time). Join us in person at McCullough Robertson, Level 32, 25 Martin Place, Sydney, NSW 2000, or virtually via Zoom.
🔗 Register to attend the virtual AGM here:
us02web.zoom.us/webinar/register/WN_nFmIH-lqR6-bZljU5NyOug
Registration opens at 8:30am. If you're unable to attend, you can still participate by submitting your Proxy Form in advance.
View the $IMU Notice of Annual General Meeting 2024 here: app.sharelinktechnologies.com/announcement/asx/1e2da5faa4…
#agm2024 #investorrelations #shareholders #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
📢 We’re thrilled to share our latest $IMU newsletter.
Check out our September newsletter for updates on our clinical progress and more: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… -
Imugene | Cancer Immunotherapies
@TeamImugene
Diamond Equity Research: Price Target $0.49
IMU: Receives Orphan Drug Designation for Bile Tract CancerTherapy and Reports Encouraging Blood Cancer Trial Outcomes
Read the full $IMU Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#imugene #azercel #cancerresearch #dlbcl #car_t #immunooncology #biotech #clinicaltrials #cancertreatment #oncology #medicalresearch #equityresearch #equityrelease -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene has been featured in BioShares, highlighting positive early results from our Phase 1b trial with Azer-Cel in patients with diffuse large B-cell lymphoma (DLBCL).
Read the full article to learn more about our advancements in CAR-T therapy.
#azercel #cancerresearch #car_t #dlbcl #oncology #biotech #clinicaltrials $IMU #bioshares -
Imugene | Cancer Immunotherapies
@TeamImugene
Lodge Partners: Price Target $0.17
IMU: Innovative and diverse pipeline of clinical-stage assets with significant commercial potential
Read the full $IMU Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#researchreport -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA www.proactiveinvestors.com.au/companies/news/1056578/just… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene Hits Milestone with Orphan Drug Status for Bile Tract Cancer Therapy | $IMU Media coverage by @techinvestmag.
blog.techinvest.online/news/imugene-hits-milestone-with-o… -
Imugene | Cancer Immunotherapies
@TeamImugene
"Receiving Orphan Drug Designation from the FDA is a major milestone for us. It reflects the potential of #vaxinia to address the urgent need for new treatments for cholangiocarcinoma, a disease with limited therapeutic options. We are excited to continue advancing this program, which has already shown meaningful clinical responses in patients," MD and CEO Leslie Chong said.
$IMU Media coverage by @westaustralian.
Read more: thewest.com.au/business/bulls-n-bears/imugene-gets-crucia…
#biotech #fda #cancerresearch #asxnews -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene secures FDA orphan drug designation for bile tract cancer treatment www.proactiveinvestors.com.au/companies/news/1056427/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We've received Orphan Drug Designation from the United States Food and Drug Administration for our oncolytic virotherapy CF33-hNIS (VAXINIA) for the treatment of #cholangiocarcinoma, a rare and aggressive form of bile tract cancer. This designation provides valuable incentives, including seven years of market exclusivity.
Building on positive results from our MAST trial, we have now initiated a Bile Tract Cancer Expansion Trial, with a total of 10 patients to be enrolled.
MD & CEO, Leslie Chong, commented: "Receiving Orphan Drug Designation from the FDA is a major milestone for us. It reflects the potential of VAXINIA to address the urgent need for new treatments for cholangiocarcinoma, a disease with limited therapeutic options. We are excited to continue advancing this program, which has already shown meaningful clinical responses in patients."
Read the full $IMU #asx Announcement here: app.sharelinktechnologies.com/announcement/asx/32f1954153…
#vaxinia #orphandrugdesignation #biletractcancer #cancerresearch #oncolyticvirus #immunooncology #fdaapproval #biotech #cancertreatment #clinicaltrials #raredisease -
Imugene | Cancer Immunotherapies
@TeamImugene
World Lymphoma Awareness Day is a reminder of the courage and resilience of those affected by this disease. At Imugene, we're committed to developing innovative therapies to improve outcomes for lymphoma patients.
Let's raise awareness, support those affected, and unite to create a future without lymphoma.
#worldlymphomaawarenessday #wlad24 #letstalklymphoma #lymphoma #cancerfighter #immunotherapy #imugene $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
🎥 Meet Garrett Gincley, Vice President of Cell Therapy, External Manufacturing, and Imugene Quality. In this video, Garrett shares his passion for advancing azer-cel, an innovative off-the-shelf CAR T therapy developed from healthy donor T cells. With over five years of experience working on azer-cel, he expresses his excitement about its potential to be a lifesaving treatment for cancer patients worldwide. Join him as he discusses the exciting progress Imugene is making in the fight against cancer.
$IMU #azercel #cancerresearch #celltherapy #car_t #oncology #biotech #innovativemedicine #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
🎥 Meet Tilanthi Jayawardena, Imugene’s Translational Sciences Lead for azer-cel. In this video, Tilanthi shares her journey in cell therapy, from her early work in 2019 to joining Imugene in 2023. She discusses the exciting progress of azer-cel in the clinic and its potential to make a significant impact for patients in need.
$IMU #azercel #cancerresearch #translationalscience #oncology #car_t #patientcare #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
We’re delighted to be part of the H.C. Wainwright & Co., LLC 26th Annual Global Investor Conference.
Join us as COO Dr. Bradley Glover presents on Wednesday, September 11th at 11:00 AM ET (Thursday, September 12th at 1:00 AM AEST).
Don't miss out! Register to watch the presentation here: journey.ct.events/view/d87fa340-ff52-46b2-9142-5d3446893064
@HCWCO #hcwainwrightglobal $IMU #cancerresearch #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch the replay of our investor webinar held yesterday. During the webinar, Imugene's Managing Director and CEO Leslie Chong, along with Chief Medical Officer Dr. Paul Woodard, discuss the latest data from the azer-cel Phase 1b clinical trial in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
🎥Watch the full $IMU replay here: youtu.be/gAca4R3HCTc
#imugene #azercel #cancerresearch #car_t #dlbcl #oncology #clinicaltrials #investorwebinar #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Azer-cel Webinar Presentation - September 2024
View the $IMU full presentation here: app.sharelinktechnologies.com/announcement/asx/2f63d95fb6…
#webinar #biotech #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene goes for a cytokine boost | $IMU Media coverage by Oncology Pipeline
www.oncologypipeline.com/apexonco/imugene-goes-cytokine-b… -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Early trial results leave Imugene patients #cancer-free | Media coverage by @westaustralian. $IMU
thewest.com.au/business/bulls-n-bears/early-trial-results… -
Imugene | Cancer Immunotherapies
@TeamImugene
CEO & Managing Director Leslie Chong and Chief Operating Officer Dr Brad Glover sit down with @proactive_au's Tylah Tully to discuss our positive results from the Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic off-the-shelf CD19 CAR T therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).
🎥 youtu.be/W6YnZzccd6Q
$IMU #azercel #cancerresearch #car_t #immunooncology #biotech #clinicaltrials #cancertreatment #oncology #medicalresearchThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Roth Capital Partners: Price Target $0.42
IMU: Azer-Cel Showing CRs In DLBCL Patients In Phase 1b Trial
Read the full $IMU Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… -
Imugene | Cancer Immunotherapies
@TeamImugene
Join us for an investor #webinar on Wednesday, 4 September 2024, at 10am AEST, where we'll discuss the latest the new data from our azer-cel Phase 1b clinical trial in blood cancer Diffuse Large B-Cell Lymphoma.
Presenting will be our MD and CEO, Leslie Chong, along with Chief Medical Officer, Dr. Paul Woodard.
Shareholders, investors and other interested parties are encouraged to register for the webinar at the following link: us02web.zoom.us/webinar/register/WN_8wAd4wMOS-uGeiz2jJ_yYQ
After registering, you will receive a confirmation email with details on how to join the webinar.
A recording will be available at the same link shortly after the conclusion of the session.
Investors are encouraged to send questions prior to the webinar to matt@nwrcommunications.com.au -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene Limited (ASX:IMU) Three Complete Responses in Azer-Cel Phase 1b Trial | Media coverage by @kalkineau. $IMU #biotech #asnews
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene fields positive results in Phase 1b trial of azer-cel CAR T therapy for blood cancer with three complete responses | Media coverage by @proactive_au. $IMU
www.proactiveinvestors.com.au/companies/news/1055224/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
Following the announcement of promising Phase 1b trial results for azer-cel in relapsed/refractory diffuse large B-cell lymphoma, Imugene was featured as the Stock of the Hour by @Finnewsnetwork. $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene reports promising Azer-cel results for advanced lymphoma patients in Phase 1b trial | Media coverage by @SmallCapsASX. $IMU
smallcaps.com.au/imugene-azer-cel-results-advanced-lympho… -
Imugene | Cancer Immunotherapies
@TeamImugene
CEO Leslie Chong and COO Dr. Brad Glover sat down with @JustStocks_Au to discuss the recent announcement of three complete responses in our Phase 1b trial of Azer-Cel Allogeneic CD19 CAR T therapy for diffuse large B-cell lymphoma.
🎥 Watch the full $IMU interview below.This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We've received promising results from our Phase 1b clinical trial with azer-cel, an allogeneic off-the-shelf CD19 CAR T, in patients with relapsed/refractory diffuse large B cell lymphoma, a type of non-Hodgkin’s lymphoma. All enrolled patients had #cancer that had returned following autologous CAR T therapy, a high unmet need for this patient population.
Among the 10 patients treated, three achieved complete responses, with two from Cohort B showing durable responses of over 90 and 120 days. The trial included heavily pre-treated patients who had failed multiple prior therapies, including autologous CAR T. Azer-cel has been well-tolerated, and the Cohort B regimen is being considered for inclusion in a potential registrational FDA Phase 2/3 trial.
“We are delighted that the first 2 patients in the Cohort B in our azer-cel Phase 1b trial achieved a complete response and continue to maintain their complete responses, one for over 120 days and the other for over 90 days," said Paul Woodard, MD, Imugene’s Chief Medical Officer. “All four patients enrolled in Cohort B have failed 4 to 5 prior treatments, including autologous CAR T therapy. All 4 patients remain on the study and given the robust response rates and durability seen to date, we will continue to enrol patients in the azer-cel plus IL-2 cohort and will closely follow all patients for further responses and durability.”
Read the full $IMU #asx Announcement here: app.sharelinktechnologies.com/announcement/asx/9ec9d95529… #asxnews #biotech #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Annual Report 2024
View the full Imugene Annual Report here: app.sharelinktechnologies.com/announcement/asx/0673791b74… $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
We're proud to present Imugene's third annual sustainability report, aligned with the Stakeholder Capitalism Metrics by the World Economic Forum. This year, we've made significant strides in embracing additional #esg frameworks, including SASB and GRI, to better standardise and measure our impact. As the landscape of reporting requirements evolves in Australia, we're proactively gathering the necessary data to support our stakeholders in meeting future obligations.
Read $IMU's #esg report in conjunction with our Annual Report to learn more: app.sharelinktechnologies.com/announcement/asx/621a921158… -
Imugene | Cancer Immunotherapies
@TeamImugene
September is Blood Cancer Awareness Month. Let’s shine a light on this often overlooked disease. 🩸
At Imugene, we're at the forefront of innovative cancer drug development, specifically targeting blood cancers like leukaemia, lymphoma and multiple myeloma which impact countless lives. At Imugene, we’re dedicated to developing innovative therapies that uniquely harness your body’s own power to fight these cancers.
Our pipeline includes therapies like azer-cel, a CAR T drug that targets CD19 to treat blood cancers. We're also developing oncolytic virotherapies to address a variety of solid cancers.
Together, we can make a difference. Let’s raise awareness, support those affected, and unite towards a future without blood cancer.
#bloodcancerawarenessmonth #cancerfighter #hope #immunotherapy $IMU #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Deciphering the power of CAR T-cell therapy: This groundbreaking treatment is revolutionising cancer care by re-engineering T-cells to fight #cancer cells.
Watch our video to understand how it works and why Imugene’s Allogeneic CAR-T cell therapy, azer-cel, has the potential to change the game for patients.
🎥 Watch here: youtu.be/WcYGsL7gUg8
$IMU #cartcells #immunotherapy #medicaladvancements #cancerresearch #biotechThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We are delighted to be featured in @StockheadAU's #health & #biotech Investor Guide.
In the article, MD and CEO Leslie Chong says achieving an effective CAR-T therapy for solid cancers is the “holy grail” of #oncology. “Only 10% of #cancers are blood cancers while 90% are solid cancers,” she says. “If successful, #oncarlytics could open up 90% of the market.”
👉 Read the full Investor Guide here: stockhead.com.au/investor-guides/investor-guide-health-bi… $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Diamond Equity Research: Price Target of A$0.49
$IMU: Quarterly Report Highlights Significant Progress in Multiple Candidates, Strong Balance Sheet, and Numerous Upcoming Potential Clinical Catalysts
View the full Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… -
Imugene | Cancer Immunotherapies
@TeamImugene
Did you know that healthy T cells from one person can be used to treat another? That's the power of #allogeneic cell therapy.
This ground-breaking treatment involves taking healthy T cells from a donor and transferring them to a patient to replace damaged or diseased cells. It's like giving your body a superhero boost.
From fighting #cancer to treating blood disorders, allogeneic cell therapy is revolutionising healthcare.
Imugene is developing an off-the-shelf allogeneic cell therapy, Azer-Cel, designed to target #cd19 and fight blood cancer. We're excited about its potential to make a difference, and we are united against cancer.
$IMU #allogeneiccelltherapy #celltherapy #azercel #bloodcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene progresses clinical trials supported by strong cash runway | Media coverage by @proactive_au
www.proactiveinvestors.com.au/companies/news/1053036/imug… $IMU #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We're pleased to provide our June 2024 Quarterly Activities Report.
View the full $IMU Report here: app.sharelinktechnologies.com/announcement/asx/b60f5255d0…
#asx #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
We’re pleased to share coverage of Imugene in the 12th episode of 'Going Public' with Mark Bouris titled Developing Cancer Cures through the ASX | Going Public with Leslie Chong and Paul Hopper.
📺Watch the full $IMU episode here: ⬇️
youtu.be/6FykTbCwUbw -
Imugene | Cancer Immunotherapies
@TeamImugene
Great panel discussion today at the Wholesale Investor Venture & Capital conference. Our Managing Director and CEO, Leslie Chong, shared her insights on the exciting life sciences and biotech landscape, highlighting key differences between the Australian and US investment climates.
$IMU #lifesciences #biotech #investment #australia #usa #imugene @WholesaleInvestor #paneldiscussion -
Imugene | Cancer Immunotherapies
@TeamImugene
REMINDER | Our CEO & Managing Director, Leslie Chong, will present tomorrow at the Venture & Capital 2024 investment conference.
Conference details:
Date: Monday, July 29th, 2024
Time: 9:00 AM - 5:00 PM
Access your $IMU complimentary ticket here: capitalhq.app/events/details/vc24syd?discount=RM_SpeakerN… -
Imugene | Cancer Immunotherapies
@TeamImugene
We're thrilled to announce that our CEO & Managing Director, Leslie Chong, will present at the Venture & Capital 2024 investment conference.
Conference details:
Date: Monday, July 29th, 2024
Time: 9:00 AM - 5:00 PM
Venue: Four Seasons Hotel, 199 George Street, The Rocks, Sydney
Access your complimentary ticket here: capitalhq.app/events/details/vc24syd?discount=RM_SpeakerN…
$IMU @WholesaleInvestor #biotech #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
"What we've seen in bile duct cancer has been quite surprising... This is a disease I've treated for 40 years. When someone has stage four, widespread disease, usually their lifespan is in months, and usually, #chemotherapy and #radiation don't work. In our trial, patients had to have failed chemotherapy to enter. To have a patient that is actually now disease-free, all the #cancer is gone, and has been without treatment for over a year and still disease-free. The second patient, we've only treated two before moving ahead with it as a specific indication, that have the second patient where the disease basically has frozen in its tracks and not grown. So the first two patients, it's something that I have not seen before with any other therapy. So quite exciting and very happy to move forward with this.
Managing Director & CEO Leslie Chong and CF33 inventor Dr. Yuman Fong update @JustStocks on our Phase 1 bile tract cancer study and Phase 1 onCARlytics trial.
Watch the full $IMU interview below.
#biotech #cancerresearch #smallcaps #asxnewsThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
1,300 Australians. That's how many were diagnosed with bile tract cancer in 2023.
Bile tract #cancer is a rare and aggressive disease, and current treatment options are limited. At Imugene, we're committed to changing that.
VAXINA holds promise as a new immunotherapy to fight bile tract cancer. We're excited about its potential to make a real difference for patients.
#biletractcancer #immunotherapy #vaxina #clinicaltrials #cancertreatment $IMU #cancerresearch #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Managing Director and CEO Leslie Chong and world-renowned #cancer researcher, physician and surgeon, Dr Yuman Fong sit down with @proactive_au to discuss the MAST (metastatic advanced solid tumours) Phase 1 trial that has been expanded due to early responses in gastrointestinal cancers, particularly #cholangiocarcinoma, using our cancer-killing virus #cf33, known as #vaxinia.
Watch the full $IMU interview here: youtu.be/n_7p6wqEcMYThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
𝗠𝗲𝗲𝘁 𝗗𝗿. 𝗣𝗮𝘂𝗹 𝗪𝗼𝗼𝗱𝗮𝗿𝗱 - 𝗖𝗵𝗶𝗲𝗳 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗢𝗳𝗳𝗶𝗰𝗲𝗿 𝗮𝘁 𝗜𝗺𝘂𝗴𝗲𝗻𝗲
Paul brings a rich background in #paediatric #oncology and stem cell transplantation, having practiced for over a decade and served as a faculty member and Vice Chair of the Clinical Staff at St. Jude Children’s Research Hospital. Transitioning to the #biotech and #pharma industry in 2007, Paul has held significant roles in medical affairs and clinical development at PDL Biopharma, Exelixis, Amgen, Genentech, Bellicum, Immune-Onc, and now Imugene. His work has contributed to the development of a variety of small molecules, #antibodies, #immunotherapies, and CAR-Ts, some of which are now commercially available treatments for patients.
Read more here: www.linkedin.com/feed/update/urn:li:activity:721878090653…
#teamimugene $IMU #leadership #oncology #innovation #clinicaldevelopment #meettheteam -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses first patient for VAXINIA bile tract cancer trial in Melbourne www.proactiveinvestors.com.au/companies/news/1051551/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
CEO Leslie Chong caught up with up @leongettler on his podcast "Talking Business" to discuss her background in cancer, $IMU's immunotherapies and how the Company is well positioned for the future.
Click here to listen to the podcast: shows.acast.com/talkingbusiness/episodes/talking-business… -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU CEO Leslie Chong caught up with @ausbiztv yesterday to discuss the #cf33 (#vaxinia) bile tract cancer study and the current unmet need for the treatment of bile tract cancer as a whole: ausbiz.com.au/media/going-for-the-fda-fast-track-?videoId…
-
Imugene | Cancer Immunotherapies
@TeamImugene
CEO Leslie Chong joined Money News with Scott Haywood in a national radio interview yesterday to discuss Imugene's announcement that the first patient has been dosed in the Company's trial for bile tract cancer (cholangiocarcinoma) using #cf33 (#vaxinia).
Click here to listen: omny.fm/shows/money-news/money-news-with-scott-hayward-10…
@2GB873 @3AW693 @6PR @NewsTalk4BC #imu #immunotherapy #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CF33 technology MAST trial clinical trial was featured earlier this year in a @7NewsAustralia segment.
We look forward to now advancing to the higher doses in the trial to gather further key data and make a genuine difference to patients in need of innovative treatment options, after the first patient was dosed today in our Phase 1 bile tract cancer expansion study.
Imugene | Cancer Immunotherapies
@TeamImugene
📺In case you missed it: In the lead up to today’s World #cholangiocarcinoma Day, our CF33 technology and MAST clinical trial of VAXINIA was featured on Channel 7 News this past weekend.
The segment aired in all capital cities across Australia.
$IMU @SevenNetworkThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce that the first patient has been dosed in our trial for bile tract cancer (cholangiocarcinoma) patients: app.sharelinktechnologies.com/announcement/asx/40c923e4e3…
This is an expansion of the MAST (Metastatic Advanced Solid Tumours) Phase 1 trial after early responses were observed in gastrointestinal cancers, and particularly cholangiocarcinoma, using Imugene’s cancer-killing virus #cf33 (#vaxinia).
The first patient in the trial was treated at St. Vincent’s Hospital (Melbourne), with a total of 10 patients to be enrolled.
$IMU #immunotherapy #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
📸 Here's our MD & CEO, Leslie Chong, proudly standing in front of our signage at Sydney Airport! ✈️
At Imugene, we're always evolving, constantly pushing boundaries, and thinking outside the box. But there's one thing that remains constant: our unwavering commitment to finding new and innovative ways to fight cancer.
$IMU #biotech #cancerresearch #sydneyairport #jcdecaux -
Imugene | Cancer Immunotherapies
@TeamImugene
"While #cd19 has been a powerful target for blood cancers, no such targets currently exist for solid cancers. We aspire to change that with #oncarlytics, which causes cancers to display CD19 on their cell surface so that an approved CD19 therapeutics can target and kill the #cancer." - MD & CEO Leslie Chong
$IMU Media coverage by the @westaustralian.
thewest.com.au/business/bulls-n-bears/imugene-delivers-fi… -
Imugene | Cancer Immunotherapies
@TeamImugene
Latest Equity Research from Roth Capital Partners
Price Target of A$0.42
IMU: Phase 1 OASIS Solid Tumor Trial Starts Combination Therapy Dosing
Read the full $IMU Report here: www.imugene.com/analyst-coverage
#equityresearch #equityrelease #cancerresearch #cancertherapy #asximu #asx #stockstowatch #stocks #asx #biotechnology #biotech #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Our MD & CEO, Leslie Chong sits down with @proactive_au Jonathan Jackson to discuss our recent milestone: dosing the first patient in the intravenous (IV) infusion combination arm of our Phase 1 #oncarlytics trial. This patient, diagnosed with #cholangiocarcinoma, received treatment at City of Hope in California.
Our OASIS trial is the first to combine a CD19-expressing #oncolytic virus with a #cd19-targeting drug. Chong stated that the enrolment of the first IV combination patient advanced the OASIS trial, which integrated our CD19 oncolytic virus with the CD19 bispecific drug, #blinatumomab (Blincyto®), in patients with advanced solid cancers.
Media coverage by Proactive: youtu.be/TpxRvmv0S-M
$IMU #immunotherapy #cancerresearch #clinicaltrial #cd19therapy #biletractcancer #oncolyticvirotherapy #cholangiocarcinomaThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene’s OASIS trial marks a world-first in combining a #cd19-expressing oncolytic virus with a CD19-targeting drug. "
$IMU Media coverage by @proactive_au
www.proactiveinvestors.com.au/companies/news/1050394/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We've dosed the first patient with #cholangiocarcinoma, or bile tract cancer, in the intravenous (IV) infusion combination arm of our Phase 1 #oncarlytics trial at City of Hope in California. This trial marks a world-first by combining a #cd19-expressing oncolytic virus with a CD19-targeting drug, #blinatumomab, to treat advanced solid tumours.
The trial aims to recruit 40-45 patients with advanced solid cancers that have spread and assesses both intratumoural and intravenous administration routes. Initial data from the combination arm is expected in Q4 2024, focusing on converting "targetless" tumours to CD19-expressing targets for effective treatment.
MD & CEO Leslie Chong said: “We are pleased to enroll the first IV combination patient and further advance our #oasis trial, which combines our CD19 oncolytic virus with the already approved and marketed CD19 bispecific in patients with advanced solid cancers. While CD19 has been a powerful target for blood cancers, no such targets currently exist for solid cancers. We aspire to change that with onCARlytics, which causes cancers to display CD19 on their cell surface so that an approved CD19 therapeutics can target and kill the cancer. If successful, onCARlytics could open up 90 percent of the market as CD19 products are only approved in blood cancer and provide a new treatment option for patients with solid tumors.”
Read the full #asx Announcement here: app.sharelinktechnologies.com/announcement/asx/9b0bd74361…
$IMU #immunotherapy #cancerresearch #clinicaltrial #cd19therapy #biletractcancer #oncolyticvirotherapy #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
- 2024 American Society of Clinical Oncology (ASCO) Presentation -
Combination Therapy with the Oncolytic Virus CF33-CD19 and Blinatumomab for the Treatment of Advanced Solid Tumors.
Presented by Dr Paul Woodard, Ph.D. Imugene
$IMU #asco -
Imugene | Cancer Immunotherapies
@TeamImugene
Today, our CEO & MD Leslie Chong met with the esteemed Dr. Yuman Fong at City of Hope to discuss the future of cancer treatment.
Dr. Fong, a leading cancer researcher, physician, and surgeon, has dedicated over 30 years to developing oncolytic viruses. Our lead candidate, CF33, is a chimeric vaccinia (pox) virus developed by Dr. Fong at City of Hope, one of the largest cancer research and treatment organisations in the United States.
Together, Imugene and City of Hope are working tirelessly to turn this innovative treatment into a reality for patients worldwide.
$IMU #cancerresearch #cityofhope #yumanfong #cf33 #oncolyticvirus #cancercure #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
𝗠𝗲𝗲𝘁 𝗗𝗿. 𝗕𝗿𝗮𝗱𝗹𝗲𝘆 𝗚𝗹𝗼𝘃𝗲𝗿 - 𝗖𝗵𝗶𝗲𝗳 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗢𝗳𝗳𝗶𝗰𝗲𝗿 𝗮𝘁 𝗜𝗺𝘂𝗴𝗲𝗻𝗲
Brad brings extensive experience in advancing programs through the clinic and commercialisation, having worked across diagnostics, venture capital, small/large molecules, and cellular therapies. He began his career as a researcher and postdoctoral fellow, transitioning to the industry to make a significant impact in the field.
Brad was drawn to Imugene by our cutting-edge technology, exceptional people, and collaborative culture. With the addition of Azer-cel to our onCARlytics and oncolytic virus assets, Brad is confident in our ability to deliver on our promise to patients fighting cancer. He believes that Imugene’s talented and engaged workforce, along with our collaborative culture, provides the necessary capabilities to advance our pipeline successfully.
As COO, Brad is excited to work with the team in continuing to develop effective strategies and goals, driving towards measurable outcomes and material results. The recent partnership with Kincell Bio is an example of how Imugene can find innovative and cost effective avenues to deliver its clinical pipeline to patients in a reliable way.
In his spare time, Brad enjoys spending time with his wife and four children and is an avid outdoor enthusiast who loves running, biking, and hiking.
@TeamImugene $IMU #leadership #oncology #innovation #clinicaldevelopment #meettheteam -
Imugene | Cancer Immunotherapies
@TeamImugene
Please find below our latest investor presentation from the Bell Potter Conference, which was presented earlier today.
$IMU #bellpotterconference #biotech #smallcaps #smallcapstocks #cancerresearch #biotechnology -
Imugene | Cancer Immunotherapies
@TeamImugene
Join us tomorrow, Thursday, May 30th, as our CEO & Managing Director, Leslie Chong, presents at the @Bell_Potter Emerging Leaders Conference 2024.
Don't miss this opportunity to hear about our latest advancements and future plans.
Register today: extraconnect.co/bell-potter-elc-2024-ext/
$IMU #emergingleaders #bellpotterconference #biotech #smallcaps #smallcapstocks #cancerresearch #biotechnology -
Imugene | Cancer Immunotherapies
@TeamImugene
Diamond Equity Research: Price Target of A$0.49
IMU: Q3 FY2024 Update, Intellectual Property Milestones, and Meaningful Clinical Trial Advancements Anticipated in 2H 2024
View the full $IMU Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#equityresearch #equityrelease #cancerresearch #cancertherapy #stocks #asx #biotechnology #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
𝐌𝐞𝐞𝐭 𝐉𝐨𝐡𝐧 𝐁𝐲𝐨𝐧, 𝐌𝐃, 𝐏𝐡𝐃 - 𝐒𝐕𝐏 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐭 𝐈𝐦𝐮𝐠𝐞𝐧𝐞!
John is our Senior Vice President of Clinical Development at Imugene. John brings a wealth of experience and expertise to our team, having completed his Internal Medicine residency and Hematology-Oncology Fellowship at the University of Washington. His impressive industry career began at Genentech, where he worked on Atezolizumab (anti-PDL1 antibody), and over the past six years, he has made significant contributions to the field of Cell Therapy at various large and small companies, including Juno/Celgene, Lyell, and Fate Therapeutics.
John was drawn to $IMU by our innovative technology platforms, especially azer-cel and OnCARlytics, and the opportunity to collaborate with passionate, experienced professionals. As the SVP of Clinical Development, John oversees all aspects of our Oncolytic Virus and azer-cel programs, from clinical strategy development and trial improvements to data analysis, regulatory interactions, and translational science planning. He also supports our Business Development, Research, and Manufacturing teams with his clinical expertise.
Outside of work, John loves spending time with his family, including his two little girls. He enjoys outdoor activities, cooking, and travelling.
If you want to know more about the amazing staff at Imugene, visit our website at www.imugene.com.
#leadership #oncology #innovation #clinicaldevelopment #meettheteam #meetourpeople #biotech #smallcaps -
Imugene | Cancer Immunotherapies
@TeamImugene
📢 Check out our May newsletter for updates on our clinical progress, new partnerships, and more.
Read the $IMU newsletter here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… -
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene stands out as a frontrunner in immuno-oncology with a robust market capitalisation of $637m and significant cash reserves of $114.1m, reflecting strong investor confidence already."
$IMU Media covered by @StockheadAU.
stockhead.com.au/tech/from-high-tech-cancer-fighters-to-a… -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene's CEO & Managing Director Leslie Chong recently delivered a dynamic 'stand-up and pitch' presentation to investors in Sydney. In her talk, she briefly recounted her journey to leading Imugene's team, which collectively boasts over 150 years of experience. She shared updates on the Phase 1B Study, the sale of our manufacturing facility in North Carolina, and our OnCARlytics Phase One study. This latter study is showing remarkable response rates, and the FDA has granted us fast-track status.
Watch the full $IMU presentation here: youtu.be/Hg_W72EDqv4
#asx #asxnews #cancerresearch #immunotherapy #oncolyticvirus #innovationinoncology #clinicalresearch #cancertreatment #immunooncology #clinicaltrials #cancertherapy #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
JMM & éthica Capital Innovation Interview | May 2024
$IMU #imugene #cancerresearch #cancertherapy #asx #stockstowatch #stocks #asx #biotechnology #biotech #cancer @JMM_AustraliaThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Congratulations to @cgoncology on the impressive results from their Phase 3 BOND-003 trial of cretostimogene. A 75.2% complete response rate in BCG-unresponsive NMIBC is a significant step forward for bladder cancer treatment.
This progress in #oncolytic #immunotherapy aligns with $IMU ’s mission to develop innovative cancer treatments. We're committed to advancing the field and improving patient outcomes.
#oncolytictherapy #bladdercancer #immunotherapy #cancerresearch
CG Oncology, Inc.
@cgoncology
📄 @CGOncology is excited to share updated BOND-003 study results for BCG-unresponsive #nmibc presented by @MarkTysonMD at #aua24. Thank you to the patients & investigators for advancing this research. Join our IR webcast today at 4:30pm ET for details: ir.cgoncology.com/news-releases/news-release-details/cret…
-
Imugene | Cancer Immunotherapies
@TeamImugene
Latest Equity Research from Roth Capital Partners
Price Target of A$0.42
IMU: General Quarterly Business Update, 2H24 To Be Rich In Clinical Data
Read the full $IMU Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#equityresearch #equityrelease #cancerresearch #cancertherapy #asximu #asx #stockstowatch #stocks #asx #biotechnology #biotech #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Today, our CEO and Managing Director, Leslie Chong, had the pleasure of presenting at the JustStocks event in #melbourne during an #investor luncheon. Leslie provided a comprehensive update on our company’s progress and future plans.
$IMU @JustStocks_Au -
Imugene | Cancer Immunotherapies
@TeamImugene
We're pleased to present our Activities Report for the period to 31 March 2024.
View our complete Quarterly Report here: ⬇️
app.sharelinktechnologies.com/announcement/asx/aa4a1bde3c…
$IMU #asx #asxnews #cancerresearch #immunotherapy #clinicalresearch #cancertreatment #immunooncology -
Imugene | Cancer Immunotherapies
@TeamImugene
Cholangiocarcinoma Annual Conference Poster Presentation: "CF33-hlMIS, a Novel Oncolytic Virus for the Treatment of #cholangiocarcinoma and Biliary Tract Malignancies."
Presented by:
Dr Paul Woodard Ph.D. Imugene
#cancerresearch #immunotherapy $IMU #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Dr. Bilal Shah, Associate Member in the Department of Malignant Hematology at the Moffitt Cancer Center, delivered an encore presentation featuring previously presented azer-cel data at the iwCAR-T 2024 meeting on April 19 in Miami, Florida. iwCAR-T is an annual workshop led by scientific leaders in CAR-T, which brings together top clinical and translational research minds to discuss the latest advances.
Find out more: iwcar-t.org/about-iwcar-t/
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Diamond Equity Research: Price Target of A$0.49
IMU: Strategic Sale of North Carolina Facility and Clinical Trial Expansions Advancing
View the $IMU full Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… -
Imugene | Cancer Immunotherapies
@TeamImugene
Latest Equity Research from Senior Analyst John Hester at Bell Potter Securities: Price Target of A$0.15
IMU: Core Assets Progressing Nicely
Read the full Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
$IMU #equityresearch #equityrelease #cancerresearch #cancertherapy #asximu #asx #biotechnology #biotech #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
We're thrilled to share the recording of our recent investor webinar discussing the strategic partnership between Imugene Limited and Kincell Bio.
Watch here: youtu.be/t5eI6-s2Y4s
Join MD & CEO Leslie Chong, COO Dr. Bradley Glover, and Kincell Bio's CEO, Dr. Bruce Thompson as they delve into what this collaboration means for the future of #immunooncology and how it will drive forward our mission to revolutionise #cancer treatment.
$IMU #investorwebinar #strategicpartnership #cancerresearch #biotech #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
We're honoured to have presented our innovative CF33-hNIS (VAXINIA) technology at the prestigious Cholangiocarcinoma Foundation Annual Conference. It was a remarkable opportunity to share our research and insights on a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies.
Thank you to everyone who attended our presentation and engaged with us during our poster session.
$IMU #imugene #oncology #cancerresearch #cholangiocarcinoma @curecc -
Imugene | Cancer Immunotherapies
@TeamImugene
In a recent discussion with @JustStocks_Au, our MD and CEO Leslie Chong talked about significant developments at Imugene, including the expansion of our clinical study for Bile Tract #cancer patients and a strategic new partnership with Kincell Bio.
Leslie will be presenting at the upcoming JustStocks 'Stars In 2024 Series' in Melbourne on April 30th and Sydney on May 1st. We invite all interested parties to join us there to hear more about our innovative approaches to cancer treatment.
For more information and to register for the event, please visit the JustStocks website and look under Investor Events.
Watch the full video here: youtu.be/LNQ_bWGgYJU
#imu #imugene #cancerresearch #biotech #healthcareinnovation #starsin2024 #juststocksThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Latest Equity Research from Roth Capital Partners: Price Target of A$0.42
IMU: Sells CGMP Facility That Manufactures Azer-cel, MAST Trial Making Progress
Full $IMU Research Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#equityresearch #equityrelease #cancerresearch #cancertherapy #asximu #asx #stockstowatch #stocks #asx #biotechnology #biotech #cancer #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
We are excited to share our recent feature on @ausbiztv where Managing Director and CEO, Leslie Chong, discusses our new strategic partnership with Kincell Bio. This collaboration represents a significant advancement in our commitment to revolutionise #cancer treatment through cutting-edge immuno-oncology therapies.
🎥 Watch the full $IMU interview here: youtu.be/MFEc-JVzwf0
#imugene #biotech #cancerresearch #innovation #investinhealth #ausbizThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Join our Managing Director and CEO, Leslie Chong, as she sits down with @proactive_au's Jonathan Jackson to discuss our new partnership with Kincell Bio. Discover how this strategic move involving the sale of our CGMP-compliant cell therapy manufacturing facility in North Carolina will advance both companies forward in the immunocellular therapy market.
🎥 Watch the full $IMU Interview Here: youtu.be/Mt3nnJi3BA8
#proactiveinvestors #healthcare #strategicpartnership #biotech #investing #cancer #cancerresearchThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We will hold an investor webinar on Thursday, 18 April 2024, at 10am AEST to discuss the strategic partnership announced with Kincell Bio.
Presenting as part of the webinar will be our MD and CEO Leslie Chong, COO Dr Bradley Glover and Kincell Bio's CEO Dr Bruce Thompson. It will be hosted by $IMU's U.S. Head of Investor Relations Heather Armstrong.
Shareholders, investors and other interested parties are encouraged to register for the webinar at the following link: us02web.zoom.us/webinar/register/WN_WkUvgUJSQbGJwNey7WujMA
After registering, you will receive a confirmation email with details on how to join the webinar.
A recording will be available at the same link shortly after the conclusion of the session. Investors are encouraged to send questions prior to the webinar to matt@nwrcommunications.com.au
#kincellbio #immunotherapy #partnership #clinicaltrials #cellulartherapy #cancertreatment #biotech #asx #asxnews #webinar -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene and Kincell Bio form manufacturing and process development partnership | $IMU Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1045328/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce a strategic partnership with @KincellBio to support the development and manufacturing of our lead product candidate, Azer-cel.
MD and CEO Leslie Chong commented, “We are delighted to have found a strong partner for the development and manufacturing of our CAR T Azer-cel program.”
This collaboration includes:
- Kincell acquiring our North Carolina CGMP
manufacturing facility for up to $6M USD.
- Kincell providing high-quality development and
manufacturing for Azer-cel clinical trials.
- Imugene achieving significant cost reductions and
extending our cash runway to 2026.
This partnership allows $IMU to focus resources on advancing Azer-cel through clinical development, while Kincell leverages its expertise to optimise Azer-cel's manufacturing process for commercial readiness.
We are excited to work with Kincell to bring this potentially life-saving therapy to patients.
Read the full ASX Announcement here: investorhub.imugene.com/announcements/6291807
#kincellbio #immunotherapy #clinicaltrials #cellulartherapy #cancertreatment #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
"As a team, we’re particularly eager to begin the #cholangiocarcinoma expansion study, given the meaningful difference we’ve seen #vaxinia make for patients with #gastrointestinal #cancers, Managing Director and CEO Leslie Chong said.
🗞️ $IMU Media covered by @westaustralian -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene expands bile tract #cancer study as patient shows complete response during MAST trial phase | Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1045227/imug… $IMU #asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
MD and CEO Leslie Chong sits down with @proactive_au's Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract #cancer (#cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intratumoural arm of the #vaxinia monotherapy dose escalation study, which evaluates the effectiveness of the cancer-killing virus #cf33-hNIS (VAXINIA).
Additionally, this week, $IMU will present VAXINIA at the 2024 Cholangiocarcinoma Foundation Annual Conference. The company continues to gather support for its cutting-edge therapies, which have so far shown no safety concerns across various cancer types, including thymic carcinoma and triple-negative breast cancer.
#proactiveinvestors #imugene #asx #biotech #gastrointestinalcancer #vaxinia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews @cureccThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We've opened enrolments for an expansion study focusing on bile tract cancer, specifically #cholangiocarcinoma, following positive results from our MAST trial.
The trial, which is planned to include 10 patients, aims to build on the encouraging responses observed in #gastrointestinal cancers, particularly cholangiocarcinoma. One patient treated with the CF33-hNIS virus achieved a complete response, while another achieved stable disease.
MD & CEO Leslie Chong said: “As a team we’re particularly eager to begin the cholangiocarcinoma expansion study, given the meaningful difference we’ve seen #vaxinia make for patients with #gastrointestinalcancers, including one patient with cholangiocarcinoma who achieved a complete response and another who achieved stable disease. It’s timely for enrolment to open as we present our VAXINIA technology to the 2024 Cholangiocarcinoma Foundation Annual Conference later this week.”
Read the full $IMU #asx Announcement here: investorhub.imugene.com/announcements/6289678
#masttrial #vaxinia #biletractcancer #oncolyticvirus #clinicaltrial #cancerresearch #immunooncology #fdaapproval #treatment #cancertherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
. @TeamImugene is making strong connections at the @AACR Annual Meeting in San Diego, California. We're currently showcasing our immunotherapy pipeline, our innovative #oncolytic #virotherapy VAXINIA and B cell #immunotherapy HER-Vaxx., through poster presentations.
We've enjoyed engaging with leading #cancer experts and appreciate everyone who's stopped by our posters to learn more.
These discussions are fuelling our commitment to advancing these #immunotherapies for the benefit of patients.
#aacr24 #cancerresearch #immunotherapy $IMU #imugene -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene shines at #aacr with promising #cancer therapy results from VAXINIA and HER-Vaxx | Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1044709/imug… $IMU #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
American Association for #cancer Research (@AACR) Poster Presentation: "Frontline #vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma – Final results from Phase II/HERIZON study"
Presented by:
Joshua Tobias Ph.D. Medical University of Vienna
Poster Number: CT215
Session Date and Time:
Tuesday April 9, 2024, 9:00 AM - 12:30 PM PT
Session Title: Phase II Clinical Trials 1
$IMU #asx Announcement: investorhub.imugene.com/announcements/6279521 #aacr24 -
Imugene | Cancer Immunotherapies
@TeamImugene
American Association for #cancer Research (@AACR) Poster Presentation: "#oncolytic virus CF33-hNIS for the treatment of advanced cancer"
Presented by Dr. Daneng Li from the @cityofhope National Comprehensive Cancer Centre
Abstract Presentation Number: CT182
Session Date and Time:
Tuesday April 9, 2024, 9:00 AM - 12:30 PM PT
Session Title: First-in-Human Phase I Clinical Trials 2
$IMU ASX Announcement: investorhub.imugene.com/announcements/6279521 -
Imugene | Cancer Immunotherapies
@TeamImugene
We are excited to share our participation at the American Association for Cancer Research (#aacr24) Annual Meeting held April 5-10, 2024, in San Diego, CA.
This prestigious conference brings together leading cancer researchers and clinicians from around the world. Imugene is proud to present poster #presentations highlighting our innovative #oncolytic #virotherapy VAXINIA and B cell #immunotherapy HER-Vaxx.
We invite the scientific community and our valued investors to visit our poster presentations and learn more about $IMU's ground-breaking work in immuno-oncology.
#cancerresearch #immunotherapy @AACR -
Imugene | Cancer Immunotherapies
@TeamImugene
Don't miss out on catching up with Imugene's Head of Corporate Development, Dr. Nicholas Ede, as he shares insightful perspectives from the recent #asx Small and Mid-Cap #conference.
Watch the complete $IMU #presentation to gain valuable insights: youtu.be/4RQMOcdaPAI
#oncolyticvirotherapy #cancerresearch #innovation #cancer #biotech #investmentopportunity -
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene Ltd (#asx: $IMU) shares are catching the eye on Thursday morning. In early trade, the #asx300 #healthcare stock is up almost 5% to 11 cents. Investors have been buying the clinical stage immune-oncology company's shares after responding positively to an announcement."
🗞️Guess which ASX 300 healthcare stock is storming higher on #chinese #patent news | Media coverage by @themotleyfool.
www.fool.com.au/2024/04/04/guess-which-asx-300-healthcare… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene granted China patent for Oncolytic Virotherapy CF33 www.proactiveinvestors.com.au/companies/news/1044519/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We've received a Notice of Grant from the Chinese Patent Office for our oncolytic virotherapy #cf33, including #vaxinia and #checkvacc.
This patent, titled "CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF," provides protection for the method of composition and method of use of CF33 until 2037.
CF33, a chimeric vaccinia poxvirus developed from the lab of inventor Professor Yuman Fong, aims to selectively kill #tumour cells and activate the immune system against #cancer cells.
This patent grant in #china, along with earlier grants in #japan and South Korea, marks a significant milestone for $IMU's efforts in the field of #oncolytic #virotherapy.
Read the full #asx Announcement here: investorhub.imugene.com/announcements/6275119 -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene has VAXINIA technology selected for presentation at Cholangiocarcinoma Foundation conference | Media coverage by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1044415/imug… $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CF33-hNIS (VAXINIA) technology has been selected for a short oral presentation during the Basic Science Research Seminar Abstract Session at 12:15 pm on Thursday April 18th at the 2024 Cholangiocarcinoma
Foundation Annual Conference. We will also be presenting a poster during the poster session.
The abstract, titled ‘CF33-hNIS, a novel oncolytic virus for the treatment of #cholangiocarcinoma and biliary tract malignancies,’ concludes that CF33-hNIS monotherapy may be an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, a rare disease with an unmet medical need.
View the full $IMU #asx Announcement here: investorhub.imugene.com/announcements/6272892 @curecc -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO and Managing Director, Leslie Chong, recently sat down with @proactive_au's Jonathan Jackson in partnership with the @ASX Small and Mid Cap Conference.
Watch the full $IMU interview to hear Leslie's insights:
youtu.be/iBDydt9UrY4
#cancertreatment #cancerimmunotherapy #investment #conferenceThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
We're delighted to announce that Dr. Nicholas Ede, Head of Corporate Development, will be presenting at the upcoming @ASX Small and Mid-Cap Conference.
Date: Wednesday, 27 March 2024
Time: 9:20 AM AEDT
Format: Virtual Conference
Join Dr. Ede as he shares insights into Imugene's innovative work in immuno-oncology and its potential to transform #cancer treatment.
For more information and to register, visit: www.asx.com.au/investors/investment-tools-and-resources/e…
$IMU #asx #cancertreatment #cancerimmunotherapy #investment #conference -
Imugene | Cancer Immunotherapies
@TeamImugene
"It is surprising whenever we hear of somebody young getting #cancer because it tends to be the disease of the old age. But recently we have discovered that more and more cancers are being discovered earlier and earlier in life. And we think it actually is related to environmental and genetic changes that have happened over time.' - Yuman Fong
This quote from Professor. Yuman Fong, MD, Chairman of Imugene's Scientific Advisory Board, is especially relevant given Kate Middleton's cancer diagnosis. As a society, we're often taken aback when we hear of young individuals facing cancer diagnoses. This diagnosis serves as a reminder that this disease has no boundaries and can affect anyone, at any age.
The link between environmental factors, genetic predisposition, and cancer incidence is increasingly evident. It underscores the urgency for continued research, advocacy, and support for those affected by cancer.
apnews.com/video/doctors-weigh-in-on-kate-middletons-canc…
$IMU #cancerresearch #cancerawareness -
Imugene | Cancer Immunotherapies
@TeamImugene
We're sending love and support to Kate Middleton as she bravely shares her #cancer diagnosis. Her courage in sharing her story shines a light on the crucial role early detection plays in fighting this disease.
It's important to shed light on the complexities of cancer diagnosis and treatment, and we are grateful for experts such as Professor. Yuman Fong, MD, the Chairman of Imugene's Scientific Advisory Board, for providing insights into this journey. Professor Fong, MD, is the inventor of $IMU ’s cancer-killing virus #vaxinia and #oncarlytics (CF33 oncolytic #virotherapy) that is designed to activate a cancer patient’s immune system to help it fight its #malignant cells.
Kate's journey underscores the importance of awareness and access to quality care for all those battling cancer.
www.huffpost.com/entry/kate-middleton-cancer-what-we-know… -
Imugene | Cancer Immunotherapies
@TeamImugene
Replay Now Available: $IMU Chief Operating Officer, Dr. Brad Glover's presentation at the NWR Virtual #healthcare Conference.
Watch the full replay here: ⬇️
youtu.be/kkxAzZ5pyG0
#cancer #cancerresearch #biotech #biotechnologies @NWRcomms -
Imugene | Cancer Immunotherapies
@TeamImugene
REMINDER | Tomorrow our Chief Operating Officer, Dr Bradley Glover will present at the NWR Virtual Healthcare Conference at 11:00 a.m. AEDT.
Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: us02web.zoom.us/webinar/register/WN_YjjVPKLCTEiFd0IlI72PFA
A recording will be available at the above link shortly after the live session ends, and the replay will also be available on our website and social media platforms.
Questions may be submitted on the day or in advance to matt@nwrcommunications.com.au.
For more information, please visit: nwrcommunications.com/events/healthcare-conference/
We look forward to seeing you there.
$IMU #cancerresearch @NWRComms #biotech #biotechnologies -
Imugene | Cancer Immunotherapies
@TeamImugene
Our latest research, published in the Journal of the American College of Surgeons (@acsJACS ), explores the potential of combining a modified #oncolytic virus (onCARlytics: CF33 CD19) with CAR T-cell therapy to target #pancreaticcancer. Our research at $IMU demonstrates this approach may be a safe and effective way to treat this aggressive disease.
Imugene's research is at the forefront of this exciting new area of #cancer #immunotherapy .
Read more about the study here: journals.lww.com/journalacs/abstract/2024/04000/using_onc… -
Imugene | Cancer Immunotherapies
@TeamImugene
Latest Equity Research from Roth Capital Partners: Price Target of A$0.42
Clinical Progress With onCARlytics And VAXINIA In Solid Tumours - View the full Report here: ⬇️
static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
$IMU #equityresearch #equityrelease #rothcapital #cancerresearch #cancertherapy #biotechnology #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
"International research firm #kpmg recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia #biotechnology collaboration. Australia’s $1.2b #biotech industry currently ranks fifth in the world in terms of research and translation." Imugene $IMU media coverage by @SmallCaps
smallcaps.com.au/australian-biotech-sector-tipped-strong-…
#biotech #cancerresearch #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
March Diamond Equity Research:
Price Target A$0.49
"Financial Report Highlights Continuous Pipeline Progression and Other Strategic Advances."
Read the full $IMU Research Report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#equityresearch #equityrelease #cancerresearch #cancertherapy #asximu #asx #stockstowatch #stocks #asx #biotechnology #biotech #cancer #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Our MD and CEO, Leslie Chong, will present at the upcoming @NWRComms Virtual Healthcare Conference on Thursday, March 21, 2024, at 11:00 a.m. AEDT.
Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: us02web.zoom.us/webinar/register/WN_YjjVPKLCTEiFd0IlI72PFA
A recording will be available at the above link shortly after the live session ends, and the replay will also be available on our website and social media platforms.
Questions may be submitted on the day or in advance to matt@nwrcommunications.com.au.
For more information, please visit: nwrcommunications.com/healthconf
We are looking forward to seeing you there. $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Missed Leslie Chong, Managing Director and CEO of @TeamImugene, at Emergence 2024 in Sydney?
📺 Catch up now by watching the full presentation here: youtu.be/6K2_W0leOio
Subscribe to our YouTube channel for more updates on Imugene's initiatives: 🔽
www.youtube.com/@ImugeneLimited
$IMU #emergence2024 #immunooncology #cancertreatment #immunotherapies #immunooncology #cancerresearch #cancertherapy #clinicalresearch #cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene (#asx: $IMU) to tackle #cancer #tumours with combo treatment - Coverage by @__thewest__
thewest.com.au/business/bulls-n-bears/imugene-to-tackle-c… -
Imugene | Cancer Immunotherapies
@TeamImugene
"CF33 is completely unique, a new beast in the field of cancer landscape. There's nothing like it, it's an #oncolytic virus that expresses #cd19. Now that’s a protein that doesn't exist on solid tumour so what it does is it covers a solid tumour with a CD19 marker and as you imagine if you add a very powerful CD19 Therapeutics like #blincyto® it has an opportunity to obliterate #cancer types that hasn't been touched before so this is a very exciting stage and it's moving quite rapidly." Leslie Chong, Managing Director and CEO, joins @proactive_au's Jonathan Jackson in the Proactive studio.
For more videos, visit our $IMU YouTube channel at www.youtube.com/@ImugeneLimited
Read the full Proactive article here: www.proactiveinvestors.com.au/companies/news/1042793/imug…This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene’s onCARlytics clears Phase 1 milestone in solid tumour therapy trial | Media coverage by @SmallCapsASX. $IMU #asx
smallcaps.com.au/imugene-oncarlytics-phase-1-milestone-so… -
Imugene | Cancer Immunotherapies
@TeamImugene
"It's first in class, there's nothing like it. There's nothing out there that actually covers a solid #tumour with one #disease essentially and then have it treated with something it is revolutionary. We are delighted that we're at the stage so expeditiously. We are enrolling major #cancer centres across the U.S. and hopefully in Australia to bring this product to more patients in need."
MD and CEO Leslie Chong spoke with @JustStocks_Au Andrew Scott soon after announcing our Phase 1 #oncarlytics solid tumour trial that has advanced to combination arm treatment.
Watch more here: www.youtube.com/watch?v=GFqzumo5a6k
$IMU #clinicalresearch #cancertreatment
#cancerresearch #clinicaltrial #immunooncology #cd19oncolyticvirotherapyThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Phase 1 clinical trial of CD19 #oncolytic #virotherapy drug candidate #oncarlytics has cleared its first cohort within the intratumoural monotherapy arm of the study and is ready to commence combination dosing solid tumour patients with CD19 targeting drug blinatumomab (Blincyto® marketed by Amgen).
The #oasis trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by #cd19-targeting therapeutics such as Amgen’s Blincyto®, Gilead’s Yescarta® and Imugene’s own allogeneic CAR T, azer-cel. OASIS potentially represents a paradigm shift in solid tumour treatment.
MD and CEO Leslie Chong said, “It’s once again a credit to our team and collaborators to see yet another study progressing positively and on schedule. Completion of this first monotherapy #intratumoural cohort where #ovarian, #breast and #melanoma patients were dosed paves the way for us to move into an important combination dosing with Blincyto®, where we’ll be eager to see the greater potential of onCARlytics in targeting and eradicating solid tumours."
Read the full $IMU #asx Announcement here: investorhub.imugene.com/announcements/6239483
#immunooncology #cancerresearch #clinicaltrial #cancertherapy #cancer #amgen #gilead -
Imugene | Cancer Immunotherapies
@TeamImugene
Today, on #internationalwomensday, we honour the amazing women who contribute to the mission and vision of Imugene.
This year's theme, #inspireinclusion, speaks to us deeply. We are proud to celebrate the incredible women who make up around half of our team and are breaking down barriers in #stem.
"As a leader and a woman of colour, I'm incredibly proud to see the diversity and talent reflected in our team," says Leslie Chong, our Managing Director. " We’re committed to inspiring the next generation of women in STEM and fostering an inclusive environment where everyone can thrive.”
#imugene #inspireinclusion #womeninscience #womeninstem #diversityandinclusion $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO and MD, Leslie Chong, discussed our four #immunotherapy platforms and the clinical advancements observed across our studies during the Capital HQ #masterclass.
During the #presentation, Leslie elaborated on our innovative technologies driving #cancer treatment, including Allo CAR T Cell Therapy, CF33 Oncolytic Virus, onCARlytics, and B Cell Immunotherapy. She also provided updates on the progress of our clinical trials, highlighting significant instances of complete responses.
Watch the full $IMU presentation and learn more about our progress: youtu.be/C-O-viK-JmM
#capitalhqmasterclass #investors #cancertreatmentThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene is proud to be featured in this @GENbio article highlighting the Australian #biopharma industry.
Australia is a hub for innovation in the #lifesciences sector, with an increasing number of companies developing new treatments for a variety of diseases, and $IMU is proud to be at the forefront of this exciting growth.
We're committed to developing novel immuno-oncology therapies with the potential to significantly improve patients' lives.
📰 www.genengnews.com/topics/drug-discovery/biotech-around-t… -
Imugene | Cancer Immunotherapies
@TeamImugene
Biliary tract cancers are aggressive and often diagnosed late, limiting treatment options. At Imugene, we are developing innovative #oncolyticviruses like VAXINA and onCARlytics to potentially offer new hope for patients.
Learn more about the evolving treatment landscape for biliary tract cancers, highlighting key emerging therapies: www.oncofocus.com/post/infographic-2
$IMU #gallbladdercancer #bileductcancer #clinicaltrials #gallbladderandbileductcancer #gallbladderandbileduct #gallbladder #bileduct #cancerresearch #treatmentoptions #emergingtherapies -
Imugene | Cancer Immunotherapies
@TeamImugene
Half Year Report 2023: investorhub.imugene.com/announcements/6223342
$IMU #asxnews #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
REMINDER | Join $IMU CEO & MD Leslie Chong at Emergence 2024: #investment #conference tomorrow, February 28, at 2:00 pm AEDT.
Venue: Level 2 Hilton Sydney | 488 George St, Sydney
Secure your FREE ticket: app.criisp.io/user/events/details/emg-24-syd?discount=IM_……
@wholesaleinvest #emergence2024 -
Imugene | Cancer Immunotherapies
@TeamImugene
🔊 Don't miss CEO & Managing Director Leslie Chong at the Capital HQ MasterClass 𝗧𝗢𝗗𝗔𝗬. Tune in at 10:42am AEDT to hear Leslie share insights on the future of immuno-oncology at this global conference for #investors and founders.
Access the stream and agenda here: app.criisp.io/events/details/masterclass
$IMU #asx #capitalhqmasterclass -
Imugene | Cancer Immunotherapies
@TeamImugene
Join CEO & MD Leslie Chong at Emergence 2024: The Era of Abundance #investment #conference.
Hear Leslie provide a company update and insights into Imugene's #cancer-fighting #immunotherapies on Wednesday, February 28, at 2:00 pm AEDT.
Event date: 28-29 February 2024
Venue: Level 2 Hilton Sydney | 488 George Street, Sydney NSW 2000 Australia
Secure your FREE ticket: app.criisp.io/user/events/details/emg-24-syd?discount=IM_…
$IMU @wholesaleinvest #emergence2024 -
Imugene | Cancer Immunotherapies
@TeamImugene
As we hit the ground running in 2024, our CEO and Managing Director, Leslie Chong sat down with Andrew Scott from @JustStocks_Au for a quick chat about our key priorities for 2024.
Don't forget to subscribe to our $IMU YouTube channel for more interviews like this one: ⬇️This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO and Managing Director, Leslie Chong, joins @proactive_au to discuss our most recent milestone; the first patient with bile tract cancer being dosed in the intravenous monotherapy arm of the OASIS trial of our virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4).
Read the Proactive Article here: ⬇️
www.proactiveinvestors.com.au/companies/news/1040997/imug…
$IMU #asx Announcement: investorhub.imugene.com/announcements/6202201
$IMU #asxnews #oncarlytics #immunooncology #cancerresearch #clinicaltrial #cancertherapy #bileductcancer #clinicalresearch #cancertreatment #proactiveinvestorsThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
📺In case you missed it: In the lead up to today’s World #cholangiocarcinoma Day, our CF33 technology and MAST clinical trial of VAXINIA was featured on Channel 7 News this past weekend.
The segment aired in all capital cities across Australia.
$IMU @SevenNetworkThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
On Cholangiocarcinoma Day, we stand united in hope.
Cholangiocarcinoma is a rare, aggressive bile duct #cancer that develops in the bile ducts. While it is less common than other cancers, it is equally devastating to those who are affected.
Today, we remember those who have fought and lost their battle against #cholangiocarcinoma, as well as those who continue to fight with courage and determination.
We also acknowledge the tireless efforts of researchers, doctors, and care givers committed to finding a cure. At @TeamImugene, we're dedicated to developing innovative #immunotherapies, including #vaxinia and #oncarlytics with our first patient dosed in the first-in-class OASIS clinical trial, providing new hope for patients with cholangiocarcinoma.
For more information visit our website (www.imugene.com) and to learn more about Cholangiocarcinoma, visit cholangiocarcinomaaustralia.org
#cholangiocarcinomaday #cholangiowarriorsaustralia #research #bileductcancer $IMU @SteveHolmes_ -
Imugene | Cancer Immunotherapies
@TeamImugene
The first patient, with bile tract cancer, has been dosed in the intravenous monotherapy arm of the #oasis trial of our #virotherapy drug candidate #oncarlytics (on-CAR-19, CF33-CD19 HOV4). The trial is a world-first in combining a CD19-expressing oncolytic virus with a #cd19 targeting drug.
Managing Director and CEO Leslie Chong said: “We’re pleased to see onCARlytics continue to advance in the clinic after the first patient on the trial was dosed in late October, and this move into intravenous administration marks another milestone in our mission to bring innovative #cancer treatments to patients in need. With the combination arm of the study still to come, we eagerly await the chance to see more on the potential onCARlytics holds."
Read the full ASX Announcement here: investorhub.imugene.com/announcements/6202201
$IMU #asxnews #cancerresearch #bileductcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene was on the @SevenNetwork last night showcasing the potential of our #cf33 #oncolytic virus to target and fight various #cancers and #tumour types.
A big thank you to the patients involved, Professor Yuman Fong for his scientific leadership, and @amberlaidler7 for covering this story.
To learn more about $IMU's CF33, visit our website at www.imugene.com/oncolytic-virusThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Today, on #worldcancerday, we stand together against a disease that affects millions of people. Our mission is to develop transformative cancer medicines to improve patients' lives.
From our breakthrough CF33 virus to our CAR T-cell therapy azer-cel, we're developing weapons to target solid tumours and blood cancers with precision.
Every step forward, every clinical trial completed, brings us closer to bridging the gap for cancer patients worldwide.
Visit our website (www.imugene.com) to learn more about our work.
For more information on World Cancer Day, click here: www.worldcancerday.org
#closingthegap #imugene #cancerresearch #cancerhope #immunotherapy #fightcancer $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
We achieved several key milestones during the December Quarter. The video below shows some of the highlights.
To view the complete $IMU Quarterly Report, click here: investorhub.imugene.com/announcements/6180508
#asxnews #cancerresearch #immunotherapy #clinicalresearch #cancertreatment #cancer #immunooncology #clinicaltrials #cancertherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO, Leslie Chong, sat down with @SmallCapsASX to discuss our progress in developing #cancer-fighting #immunotherapies, as well as the science behind them.
Watch the $IMU video below to learn more:
www.youtube.com/watch?v=qhduFgCVEK4This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
"This is the first treatment vaccine in any #gastrointestinal #cancer and we have high hopes that it will be very successful... It feels like we're on the cusp of something really big here with this vaccine, we're very excited," Dr Tony Dhillon said.
🗞️First bowel cancer vaccine could be available in two years as #nhs doctors trial the jab | Imugene media covered by @MailOnline.
Read more: www.dailymail.co.uk/health/article-13007931/bowel-cancer-… $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Latest Diamond Equity Research: $IMU Price Target AUD $0.49
VAXINIA’s Releases Early Positive Data, PD1-Vaxx and Azer-cel Advancing Through Clinical Pipeline
View the full report here: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
#equityresearch #equityrelease #cancerresearch #cancertherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
CEO & Managing Director Leslie Chong joins Jonathan Jackson in the @proactive_au studio to discuss the encouraging results from the VAXINIA MAST oncolytic virus Phase 1 trial.
Click on the link ⬇️to watch the $IMU interview:
www.youtube.com/watch?v=69zssnb3qYk
#cancertreatment -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene (#asx: $IMU) presents CF33-hNIS oncolytic virus study details at #asco-GI Cancers Symposium | Media covered by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1038866/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️Imugene (#asx: $IMU) plans Phase 1 #vaxinia MAST trial expansion to target bile duct #cancer | Media covered by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1038861/imug… -
Imugene | Cancer Immunotherapies
@TeamImugene
ASCO Gastrointestinal Cancers Symposium (@ASCO -GI) Poster Presentation
"Oncolytic Virus CF33-hNIS Monotherapy for the Treatment of Gastrointestinal Malignancies"
Presented by Dr. Daneng Li from the @cityofhope National Comprehensive #cancer Centre, which detailed background on #cf33, the MAST study design, objectives and results observed to date.
Read more: www.imugene.com/conference-presentations $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Phase 1 MAST (metastatic advanced solid #tumours) trial evaluating the safety of novel #cancer-killing virus CF33-hNIS (#vaxinia), has continued to progress with the first patients dosed in each arm of the higher dose cohort as part of the Phase 1 study.
Managing Director & CEO Leslie Chong said: “Following the positive news on VAXINIA’s early signals and #fda Fast Track Designation to end 2023, we are pleased to start the new year by announcing the ongoing progress of the MAST trial as we continue to see no safety issues with the drug. We also look forward to expanding the trial to take a closer look at bile duct cancer where we’ve seen early encouraging results.”
Read the full $IMU #asx Announcement here: investorhub.imugene.com/announcements/6166281 #asxnews #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Latest ROTH Capital Partners Equity Research has issued $IMU a ‘Buy’ rating with a price target of AUD $0.46.
"IMU updated its Phase 1 MAST trial evaluating its oncolytic virus CF33-hNIS (VAXINIA) in metastatic advanced solid tumours. With 38 dose escalation phase patients dosed, 31 patients were efficacy evaluable, with about half of the patients having at least disease control (i.e., SD or better), including a CR and two PRs. Particularly positive results in cholangiocarcinoma patients had previously inclined IMU to expand the trial by adding 10-20 such patients. This update follows data released in 4Q23 from 26 efficacy evaluable MAST trial patients."
View the full report here: roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=8a89… -
Imugene | Cancer Immunotherapies
@TeamImugene
🗞️ Imugene receives positive early results, including a 'complete response', in Phase 1 VAXINIA study | Media covered by @proactive_au.
www.proactiveinvestors.com.au/companies/news/1038580/imug… $IMU #asx #asxnews #cancerresearch #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
“Immuno-oncology company, Imugene (#asx: $IMU), jumped 7% this morning after reporting positive early signals from its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating its novel #cancer-killing virus, CF33-hNIS (VAXINIA).”
🗞️Imugene Media covered by @StockheadAU.
Read more: stockhead.com.au/health/asx-health-stocks-imugene-gains-o…
#asxnews -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Phase 1 CF33-hNIS (#vaxinia) study, evaluating the novel #cancer-killing virus, continues to show positive early signals. The study has now dosed 38 heavily pre-treated patients, with CF33-hNIS administered alone or in combination with #pembrolizumab, either intravenously or intratumorally.
Patients with gastrointestinal cancers receiving CF33-hNIS alone demonstrated particularly positive effects, with an 86% disease control rate. The study is expanding to include 10-20 patients with biliary tract cancers.
MD & CEO Leslie Chong said: “This latest data reinforces the early positive responses we’ve seen in #gastrointestinal cancers and in particular for #cholangiocarcinoma (bile duct cancer). It provides an excellent platform to investigate the impact of VAXINIA at higher dose levels as we also expand the trial to additional patients with hard-to-treat biliary tract cancers. It is a proud moment for us to be able to present these results at ASCO-GI, and promote the potential of VAXINIA and CF33 more broadly.”
Read more: investorhub.imugene.com/announcements/6162912 $IMU #asxnews #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Following an exciting year for Imugene in 2023, our MD & CEO Leslie Chong presented last week at the 42nd Annual J.P. Morgan Healthcare Conference in California.
Dive into her presentation and see what's next for Imugene.
➡️youtu.be/IayFQEmilFM
$IMU #cancer #immunotherapy #asxThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
"IMU is focused on advancing four platform technologies, Allo CAR T cell Therapy, CF33 Oncolytic Virus, onCARlytics and B Cell #immunotherapy. The company is backed by an experienced management team with over 150 years of combined experience in drug development and approvals."
🗞️How far have Imugene’s (#asx: $IMU) four novel platforms progressed in the fight against #cancer? | Media covered by @kalkineau.
Read more: kalkinemedia.com/au/news/featured-news/how-far-have-imuge… -
Imugene | Cancer Immunotherapies
@TeamImugene
Congratulations @PrecisionBioSci, on the exciting new licensing deal with @TGTherapeutics for Azer-cel. This is a major step forward in the development of this promising cell therapy, further validating its potential in the treatment of #autoimmune diseases and other indications.
Additionally, this deal validates the value of Azer-cel, as demonstrated by the fact that others see its value and are investing in this novel technology. This speaks volumes about its potential to make a real difference in the lives of patients.
Azer-cel has demonstrated promising results to date including safety and tolerability, efficacy (high overall response rates) and potential for broad applicability. Imugene looks forward to continuing its development for #cancer. $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Join MD & CEO Leslie Chong when she presents at the 42nd Annual J.P. Morgan Healthcare Conference today at 9:30am AEDT.
Webcast Details: jpmorgan.metameetings.net/events/healthcare24/sessions/49… This is an audio-only broadcast, with slides available at the provided link.
$IMU Presentation: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene (#asx: $IMU) well positioned to deliver 2024 milestones \ Media covered by @SmallCapsASX
www.proactiveinvestors.com.au/companies/news/1037172/imug… -
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) and US firm NeoImmuneTech partner to develop next-gen cancer therapy
smallcaps.com.au/imugene-neoimmunetech-partner-develop-ne… @TeamImugene @NeoImmuneTech -
Imugene | Cancer Immunotherapies
@TeamImugene
Our new collaboration will evaluate the ability of @NeoImmuneTech's immune cell amplifier NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing.
To learn more visit our InvestorHub: investorhub.imugene.com/welcome -
Imugene | Cancer Immunotherapies
@TeamImugene
Read the review:
imugene.com/media
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
The conference is being held 7-11 January 2024 at The Westin St. Francis in San Francisco, California, USA.
Our CEO, Leslie Chong will present at 2:30pm Pacific time on Tuesday 9 January 2024 (9:30am AEDT, Wednesday 10 January 2024).
More at investorhub.imugene.com/announcements/5464179 -
Imugene | Cancer Immunotherapies
@TeamImugene
“We are excited to commence this important Phase 2 trial with PD1-Vaxx after being approached by the leading colorectal cancer oncologists from both Australia and the UK.”
- CEO, Leslie Chong
Full interview at www.youtube.com/watch?v=Oh8poBq35ts -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene to open new PD1-Vaxx Phase 2 bowel cancer clinical trial in UK and Australia www.proactiveinvestors.com.au/companies/news/1035303/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“We are excited to commence this important
Phase 2 trial with PD1-Vaxx after being approached by the leading colorectal cancer oncologists from both Australia and the UK.”
- CEO, Leslie Chong $IMU
More at imugene.com #pd1vaxx #immunotherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
Our mission is to develop transformative cancer medicines to improve patients’ lives and to establish value and trust with our stakeholders.
imugene.com | #endcancer | $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
FDA Fast Track designation is awarded to help important new therapies reach patients earlier. It is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill unmet medical needs.
Full interview youtu.be/Rx5IoLtNV_4This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
“The Fast Track process of drug development is designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need, with Fast Track status often leading to earlier drug approval and access by patients.”
- Leslie Chong $IMU -
Imugene | Cancer Immunotherapies reposted
Imugene | Cancer Immunotherapies
@TeamImugene
Learn more about our Oncolytic Virus CF33, invented by Professor Yuman Fong from City of Hope — and CHECKvacc, which is based on the CF33 platform with further enhanced tumour killing ability by adding an anti-PD-L1 antibody gene, which the virus delivers to the cancer cell. $IMU
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
CF33
Oncolytic Virus
We hope to improve the clinical benefits and quality of life for patients with cancers that are difficult to treat using current therapeutic approaches.
Developed by Professor Yuman Fong at the prestigious City of Hope.
Learn more imugene.com/oncolytic-virus -
Imugene | Cancer Immunotherapies
@TeamImugene
Azer-cel best in class Allogeneic CAR T cell therapy?
Leslie Chong X Proactive
Full version at: youtube.com/watch?v=FirE0n-kunY -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU CEO Leslie Chong joined Alan Kohler on Intelligent Investor to discuss our technology portfolio and provide an update on recent activities:
intelligentinvestor.com.au/investment-news/the-world-of-b…
New Analyst Coverage | BIO SHARES:
First Results for Oncolytic Virus CF33 VAXINIA
imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies reposted
RenovoRx
@RenovoRx
RenovoRx is honored to be fighting difficult-to-treat cancers, like pancreatic cancer, with partners like @TeamImugene. We are striving to improve the standard of care for patients diagnosed with #pancreaticcancer. renovorx.com
#pancreaticcancerawareness -
Imugene | Cancer Immunotherapies reposted
RenovoRx
@RenovoRx
RenovoRx Q3 2023 business highlights include the continued advancement of the pivotal Phase III TIGeR-PaC study for the treatment of LAPC and further validation of the TAMP platform through our recent collaboration with @TeamImugene. For more info: ir.renovorx.com/news-events/press-releases/detail/76/reno… $RNXT
-
Imugene | Cancer Immunotherapies
@TeamImugene
Register now:
us02web.zoom.us/webinar/register/WN_EICpoS4OTruIk9bzZSTIvw
After registering, you will receive a confirmation email about joining the webinar.
A recording will be available at the same link shortly after the conclusion of the session, plus on our YouTube channel. $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: Valuation $0.15
"No Time To Waste – Azer-cel Back In The Clinic"
@Bell_Potter
imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses first patient in Phase 1b Allogeneic CAR T Clinical Trial www.proactiveinvestors.com.au/companies/news/1032697/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“It is a great credit to our team that the Phase 1b study has been initiated and the first patient dosed, in under three months since acquiring the technology.”
- CEO, Leslie Chong $IMU #celltherapy #azercell
ASX news at imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to provide a clinical trial update for our Phase 1 MAST trial evaluating the safety and efficacy of VAXINIA -- the trial has now cleared cohort 4 of the intravenous (IV) arm of the monotherapy dose escalation study, plus IV cohort 2 of the combination study. $IMU
Imugene | Cancer Immunotherapies
@TeamImugene
More at www.imugene.com/announcements
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU on ABC noting our share price rally after Monday's ASX news that we received positive early signals showing VAXINIA’s promise as a potent anti-cancer drug. #endcancer
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
ROTH•MKM
$IMU: Positive Initial VAXINIA MAST Trial Data, Expanding Bile Duct Tumor Cohort
12-month target: AUD0.46
www.imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies
@TeamImugene
Now available on demand:
Imugene Investor Webinar
MAST Study Update
youtu.be/k9AUCLiQI2o
#endcancer $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene Investor Webinar: MAST Study Update
Today at 11:00am AEDT
Register at us02web.zoom.us/webinar/register/WN_GAxzRb5hS1SRDzbviBQTLQ
The webinar will discuss the clinical trial update of Phase 1 MAST trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). -
Imugene | Cancer Immunotherapies
@TeamImugene
"Immuno-oncology Innovations Highlighted at ESMO,
Financial Position Strengthened, and Clinical Pipeline Advancing"
Download at imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong X Proactive interview following our ASX news today that we received positive early signals showing VAXINIA’s promise as a potent anti-cancer drug. Full interview at youtu.be/2oPEfkQ1CAU
$IMU Bringing Effective New Treatments And Options To Patients Who Need Them -
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) reports positive early signals from Phase 1 trial of CF33-hNIS cancer killer
smallcaps.com.au/imugene-reports-positive-early-signals-p… @TeamImugene -
Imugene | Cancer Immunotherapies reposted
Bulls N' Bears
@BullsNBearsWA
#asx-listed @TeamImugene has taken a leap forward in its mission to track down and kill #cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus
thewest.com.au/business/public-companies/imugene-enters-f…
$IMU #bullsnbearswa @westaustralian -
Imugene | Cancer Immunotherapies
@TeamImugene
Our MD & CEO Leslie Chong joins the Money News radio program which airs on 2GB (Sydney), 3AW (Melbourne) and 4BC (Brisbane). $IMU
A fantastic interview - listen at:
podcasts.apple.com/au/podcast/leslie-chong-ceo-managing-d… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene advances Phase 1 MAST trial for cancer-killing VAXINIA virus www.proactiveinvestors.com.au/companies/news/1031781/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
ASX News:
Next cohort reached in intravenous arms of monotherapy and combination study for cancer-killing virus CF33-hNIS (VAXINIA)
More at cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU $IMU.ax #cf33 #oncolyticvirus #vaxinia -
Imugene | Cancer Immunotherapies
@TeamImugene
Today we announced a milestone with the start of our Phase 1 clinical trial for #oncarlytics, a CD19 #oncolyticvirotherapy drug candidate. Our CEO, Leslie Chong joined Proactive for a detailed interview. $IMU
Full version available on our YouTube channel:
www.youtube.com/watch?v=INCiZUh84ngThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
“This is a milestone we’ve been eagerly anticipating, given the encouraging signs we have seen from the pre-clinical work performed to date. We believe onCARlytics may provide a new solution for clinicians treating solid tumours ...” - Leslie Chong $IMU
imugene.com/announcements
Imugene | Cancer Immunotherapies
@TeamImugene
• World-first for clinical trial initiation of a CD19 oncolytic virus combination with a CD19 drug;
• Clinical trial being conducted at City of Hope in California and multiple sites across the U.S.
$IMU $IMU.ax #worldfirst #imugene #oncarlytics -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses first patient in “groundbreaking” Phase 1 OASIS clinical trial www.proactiveinvestors.com.au/companies/news/1031016/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce our B cell immunotherapy HER-Vaxx & CF33 oncolytic virotherapy CHECKVacc featured this week at the ESMO Congress, currently being held in Madrid. $IMU
Highlights/conclusions:
imugene.com/announcements
Poster presentations:
imugene.com/conference-presentations -
Imugene | Cancer Immunotherapies
@TeamImugene
@TeamImugene Strategy Meeting $IMU $IMU.ax
imugene.com/leadership-team
imugene.com/management-team
imugene.com/scientific-advisory-board -
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene’s main medicinal trick lies within a let’s-kill-cancer field which is more of a melange of the traditional, less invasive but concurrently madly cutting edge field of treating catalysts which can supercharge the immune system of cancer patients.'
stockhead.com.au/news/imugene-we-need-to-talk-about-blood… -
Imugene | Cancer Immunotherapies
@TeamImugene
Our latest newsletter has just been released and available to download: imugene.com/newsletters $IMU
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene: FDA completes Investigational New Drug Application transfer for azer-cel www.proactiveinvestors.com.au/companies/news/1027973/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Conference Presentation:
www.youtube.com/watch?v=Q9l5YvaiYSw
@Bell_Potter $IMU $IMU.ax #imugene -
Imugene | Cancer Immunotherapies
@TeamImugene
“Attaining the key Japanese patent, on top of gaining protection in the USA this year, is a very important milestone ..." - Leslie Chong $IMU $IMU.ax
Learn more: imugene.com/announcements
Imugene | Cancer Immunotherapies
@TeamImugene
Last week marked 1000 days cancer free for a patient with late-stage NSCLC who was recruited and dosed in December 2020.
This week Professor Michael Boyer presented a trial-in-progress poster in person at the 2023 World Conference on Lung Cancer. $IMU
imugene.com/conference-presentations -
Imugene | Cancer Immunotherapies
@TeamImugene
“Azer-cel has the potential to be the first CD19 directed allogeneic cell therapy and having the FDA support on the manufacturing process can be used for the pivotal trial is an extremely important milestone as it improves robustness and scalability ...” - Leslie Chong $IMU
Imugene | Cancer Immunotherapies
@TeamImugene
-
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) adds further experience to research team as VAXINIA trial clears cohort 1
smallcaps.com.au/imugene-adds-experience-research-team-va… @TeamImugene -
Imugene | Cancer Immunotherapies
@TeamImugene
"There is an excellent correlation with Dr Byon’s experience and our portfolio of assets at Imugene, making him an outstanding fit for the Company. We look forward to him bringing his leadership and new perspectives into the team." - Leslie Chong, CEO $IMU imugene.com/announcements
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
@TeamImugene positioning to be 1st allogeneic CAR T to market. FDA pathway to market sorted. Get on board. #thisistheway
-
Imugene | Cancer Immunotherapies
@TeamImugene
Investor Webinar | Acquisition of License for Azer-Cel $IMU $IMU.ax #celltherapy #oncology #medtech
Visit Imugene's YouTube Channel to Watch:
youtube.com/watch?v=p7PrUf16faA&t=1s -
Imugene | Cancer Immunotherapies
@TeamImugene
Investor Webinar – Acquisition of License for Azer-cel:
Tuesday 22 August 2023 at 11am AEST.
The session will be hosted by Managing Director and CEO Leslie Chong, alongside our new COO, Dr Bradley Glover.
Register for the webinar at the following link: us02web.zoom.us/webinar/register/WN_5Pi9U92DTJCCLrmKacl9BQ -
Imugene | Cancer Immunotherapies
@TeamImugene
Prior to $IMU Dr Glover served as the Executive VP & COO at Celularity, playing a pivotal role in strategic planning, business development, and technical operations. Prior to this he was VP and Head of Corporate Strategy & Operations at renowned cell therapy company Kite Pharma.
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene raises $35 million in strongly supported placement; launches $30 million SPP www.proactiveinvestors.com.au/companies/news/1023899/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Investor Presentation:
AZER-CEL CD19 CAR T LICENSE | August 2023
Visit: imugene.com/investor-presentations
$IMU $IMU.ax #celltherapy #cart #azercel -
Imugene | Cancer Immunotherapies
@TeamImugene
Analyst Coverage
ROTH | IMU Licenses Clinical Stage Allogeneic CD19 CAR T For Liquid Tumors 12m target AUD71c
DIAMOND EQUITY RESEARCH | $IMU Secures Promising Allogeneic CAR-T Cell Therapy Asset Expanding Pipeline and Addressable Market Valuation AUD54c
www.imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies
@TeamImugene
Azer-Cel has the potential to become the first ever approved Allo CAR T Cell Therapy for Cancer — designed to address high and growing unmet needs in the post auto CAR T setting of Diffuse Large B Cell Lymphoma (DLBCL), earlier lines of therapy and other blood cancer indications.
Imugene | Cancer Immunotherapies
@TeamImugene
ASX News: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
About Azer-Cel: imugene.com/allogeneic-car-t-cell-therapy
$IMU $IMU.ax #celltherapy #imugene #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
“We continue to rapidly advance our monotherapy dose while the combination study continues its positive progress. We remain incredibly eager to bring the results of this trial to our shareholders, patients and the wider public.” - Leslie Chong $IMU
ASX: mailchi.mp/ed7ef02d566b/pd1-vaxx-and-checkvacc-asx-announ… -
Imugene | Cancer Immunotherapies
@TeamImugene
Our CF33 Oncolytic Virus technology will be featured at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), to be held in San Diego, USA on 1-5 November 2023. $IMU
Learn more: imugene.com/announcements -
Imugene | Cancer Immunotherapies reposted
RenovoRx
@RenovoRx
.@ContractPharma highlights our collaboration with @TeamImugene to explore the trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP™ therapy platform. www.contractpharma.com/contents/view_breaking-news/2023-0… $RNXT $IMU #pancreaticcancer #livercancer
-
Imugene | Cancer Immunotherapies
@TeamImugene
HER-Vaxx gaining global traction at major oncology meetings:
|> medimix.be/onco/the-pd-8-herizon-study
$IMU $IMU.ax #medtech #hervaxx #immunotherapy
Nick Ede
@Melroseavenick
Very smooth presentation by Dr Joshua Tobias from MedUniVienna at ESMO GI. @TeamImugene HER-Vaxx gaining global traction at major oncology meetings. The PD-8 HERIZON study medimix.be/onco/?p=6156
-
Imugene | Cancer Immunotherapies reposted
Matthew Wright
@mattwright3000
Latest episode of @NWRcomms Vantage Point now available, with @HinsleySimon speaking to Professor Yuman Fong about his work with @TeamImugene on a potentially game changing technology for a range of cancer patients. Check it out at: youtu.be/aWtqLsImyGg
$IMU
@SoCalYuman -
Imugene | Cancer Immunotherapies
@TeamImugene
Professor Yuman Fong & ABC Radio Hobart at the 17th Annual Bioshares Biotech Summit. $IMU $IMU.ax
Full Interview via: imugene.com/media -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene to present cancer therapy platforms at prestigious ESMO Congress www.proactiveinvestors.com.au/companies/news/1021420/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Sneak Peak:
Professor Yuman Fong, Keynote Speaker at this year's Bioshares Biotech Summit in Hobart, Tasmania.
@SoCalYuman $IMU $IMU.ax #immunotherapy -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: ROTH•MKM
"U.S. Oncolytic Virus Patent Allowed, Enrolling 4th CHECKvacc Dose Cohort"
12-month target: AUD0.71
imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies
@TeamImugene
“We believe the synergy between @RenovoRx's trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients.”
- Leslie Chong, MD & CEO $IMU
Learn more: imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
“Receiving this patent allowance for the CF33 family of oncolytic viruses from the US patent office is a crucial step forward & with the US being the largest healthcare market in the world, this is a particularly important patent milestone.” -Leslie Chong cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
-
Imugene | Cancer Immunotherapies
@TeamImugene
Dr Weitzman brings over two decades of global experience in the biopharmaceutical industry to our team, with expertise in the therapeutic areas of solid-tumour and hematologic malignancies. $IMU $IMU.ax
ASX News: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Investor Roadshow Webinar with CF33 Co-Inventor, Professor Yuman Fong.
This Friday, July 21 at 11am AEST.
Register now:
us02web.zoom.us/webinar/register/WN_n78krTj0REuFQvpiguvsuQ $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
“We are pleased with the results we have seen so far with no observed toxicity with early encouraging results in oncolytic virus infection and replication in the TNBC tumours ..." - Leslie Chong, MD & CEO $IMU $IMU.ax
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… #oncolyticvirus -
Imugene | Cancer Immunotherapies
@TeamImugene
Chairman’s Letter to Shareholders | by Paul Hopper
“Our exciting CD19 virus was granted an IND by the FDA, allowing it to start clinical trials this year. This program could be a game changer for solid tumours.”
Read the full letter:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU $IMU.ax #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Below is a special invitation to join our Leadership Team and special guest Professor Yuman Fong from City of Hope, Los Angeles.
Full details below and registration via: docs.google.com/forms/d/e/1FAIpQLSfmhMkWM-AewDNgIpM9aNhsF… -
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) presents new data on HER-Vaxx to world gastric cancer conference
smallcaps.com.au/imugene-presents-new-data-her-vaxx-world… @TeamImugene -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona. $IMU $IMU.ax
Visit: imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
“With the US being the largest healthcare market in the world, this is a particularly important patent extension to protect our PD1-Vaxx technology as we continue its development.” - Leslie Chong, CEO $IMU $IMU.ax
Learn more: imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
Join us next Wednesday, June 28th between 11am - 1pm AEST at the Small Caps Investor Showcase:
www.eventbrite.com.au/e/small-caps-investor-showcase-by-w…
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene to draw on new board member’s US mid-cap biotech experience www.proactiveinvestors.com.au/companies/news/1018438/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
With more than 25 years of experience in the #biotechnology and #pharmaceutical sectors, Ms Drapkin possesses a strong background in finance, capital raising, and strategic #financialplanning.
It’s a pleasure to welcome Kim to the Imugene team.
imugene.com/announcements $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
We created this short video called 'The Why' to show our passion and drive behind Team Imugene.
We work hard, every day, to achieve our mission of developing transformative cancer medicines to improve patients’ lives.
Visit our YouTube channel for more: youtu.be/bIGXtIAkJUs -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model Another insightful contribution from lead author Dr Shyam Chaurasiya etal @SoCalYuman @cityofhope @TeamImugene aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-22…
-
Imugene | Cancer Immunotherapies
@TeamImugene
“As we continue to move through the cohorts at pace, we’re aiming to have this high-quality science peer reviewed & recognised within publications or conferences befitting of its results and potential benefit to patients in need.” - Leslie Chong $IMU
ASX cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Analyst Coverage:
ROTH•MKM
12-month target:
AUD0.71
"Doses First Combination NSCLC Patient in PD1-Vaxx + Tecentriq Phase 1/1b"
imugene.com/analyst-coverage
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
New Interview | Leslie Chong X Proactive
Imugene Doses First Combination Patient in PD1-Vaxx Trial
#bcell #immunotherapy #biotechnology
$IMU $IMU.ax
Full version via: youtu.be/osCzrS7eSUs -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses first patient in PD1-Vaxx combination trial www.proactiveinvestors.com.au/companies/news/1016614/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
DIAMOND EQUITY RESEARCH
IND Clearance Enables OnCARlytics to enter Human Clinical Trials
Valuation: A$0.46
imugene.com/analyst-coverage
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
“It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug. PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with NSCLC ..." - Leslie Chong, CEO $IMU $IMU.ax
More: imugene.com/announcements -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
stockhead.com.au/health/asx-biotechs-are-looking-up-and-t… @TeamImugene has 5 FDA IND's for its immunotherapies. #hervaxx #pd1vaxx #checkvacc #vaxinia #oncarlytics
-
Imugene | Cancer Immunotherapies
@TeamImugene
2GB SYDNEY | Radio Interview:
www.2gb.com/imugene-cancer-drug-trial-green-lit-by-us-fda/ -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
@Bell_Potter
Visit:
imugene.com/analyst-coverage
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
On-Demand:
Visit our YouTube channel to watch our 'FDA IND Clearance for onCARlytics' Webinar with Leslie Chong and Saul Priceman, PhD from City of Hope.
youtu.be/bkcmDym8Qic -
Imugene | Cancer Immunotherapies
@TeamImugene
Introducing 'The Why' a short video illustrating the purpose and passion of 'Team Imugene' as we strive, daily, towards our mission to develop transformative cancer medicines to improve patients’ lives.
Watch now:
youtu.be/bIGXtIAkJUs
#endcancer #immunotherapy $IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Combination CAR T Oncolytic Virus Immunotherapy Kills Tumors. With todays FDA IND clearance it's time to get inspired again. @TeamImugene youtu.be/54YlPVujvio via @YouTube
-
Imugene | Cancer Immunotherapies
@TeamImugene
“The start of our onCARlytics study which is first-in-class is a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers which to date have been untreatable with CD19-targeting biological drugs." Leslie Chong
imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
Meet Dr Jakob Dupont, MD
$IMU $IMU.ax #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce onCARlytics technology in combination with Eureka Therapeutics' ARTEMIS® cell receptor platform has presented preclinical data at ASGCT demonstrating enhanced anti-tumour activity in vivo against hepatocellular carcinoma tumours. imugene.com/announcements
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to provide shareholders with our newsletter for May 2023. mailchi.mp/43e3fa112b02/imugene-shareholder-newsletter-ju…
-
Imugene | Cancer Immunotherapies
@TeamImugene
Professor Yuman Fong will give the keynote address at this year's Bioshares Biotech Summit, July 24-25 in Hobart, Tasmania.
Our Chief Business Officer, Monil Shah, will also be presenting.
Learn more: bioshares.com.au/event/17th-bioshares-biotech-summit
$IMU #oncology #immunotherapy #endcancer $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Our mission is to develop transformative cancer medicines to improve patients’ lives and to establish value and trust with our stakeholders. We are supported by a leading team of cancer experts with extensive experience in developing new cancer therapies.
Meet Prof. Yuman Fong: -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Cancer vaccines: 10 biotech companies that have changed the game @TeamImugene in excellent and innovative company labiotech.eu www.labiotech.eu/best-biotech/cancer-vaccine-companies/
-
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) presents abstract on ‘impressive’ pre-clinical liver cancer treatment response
smallcaps.com.au/imugene-presents-abstract-pre-clinical-l… @TeamImugene -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene's onCARlytics and Artemis® T cells combination presented as part of abstract at American Society of Gene and Cell Therapy’s Annual Meeting www.proactiveinvestors.com.au/companies/news/1013937/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Our #oncarlytics technology, in combination with Eureka Therapeutics’ Artemis® T cell platform, has been presented as part of an abstract at the American Society of Gene and Cell Therapy’s Annual Meeting (ASGCT).
Visit cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… to learn more.
#tcell $IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene nets A$12.6 million research and development tax refund www.proactiveinvestors.com.au/companies/news/1013253/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce our Quarterly Cash Flow report (Appendix 4C) for the quarter ended 31 March 2023. $IMU $IMU.ax
mailchi.mp/a5e0545a27b9/pd1-vaxx-and-checkvacc-asx-announ… -
Imugene | Cancer Immunotherapies reposted
Small Caps 🇨🇳 (中文)
@SmallCaps_cn
Imugene以1260万澳元的回扣提升银行余额,用于发展免疫肿瘤疗法
smallcaps.com.au/imugene-lifts-bank-balance-rebate-progre… #asx $IMU @TeamImugene -
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) lifts bank balance with $12.6m rebate to progress immune-oncology therapies
smallcaps.com.au/imugene-lifts-bank-balance-rebate-progre… @TeamImugene -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce receiving an R&D tax refund for the 2022 financial year, totalling $12.6m.
The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities.
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) reveals positive imaging data for oncolytic virotherapy candidate CHECKvacc
smallcaps.com.au/imugene-positive-imaging-data-oncolytic-… #aacr23 @TeamImugene @AACR -
Imugene | Cancer Immunotherapies
@TeamImugene
AACR 2023 Poster Presentation:
"hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer"
Presented by Dr Jamie Rand, @cityofhope
imugene.com/conference-presentations
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
“While it was pleasing to see the primary objective of safety and tolerability of #checkvacc confirmed, the imaging data presented showed several other positive outcomes resulting from our first-in-human trial ...”
-Leslie Chong $IMU $IMU.ax
Learn more: imugene.com/announcements -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Big shoutout to our onCARlytics collaborators for an amazing release. @TeamImugene and @WeAreArovella leaders in immuno-oncology.
Arovella Therapeutics ASX: ALA
@WeAreArovella
Arovella releases cancer treatment data $ALA www.afr.com/markets/equity-markets/asx-to-rise-us-earning…
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
BIOSHARES
Imugene: Nine Clinical Programs to Advance in 2023
Visit:
imugene.com/analyst-coverage
$IMU $IMU.ax #clinicaltrials #imugene #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
New Investor Presentation | April 2023
Non-Deal Roadshow | USA
View: imugene.com/investor-presentations
$IMU $IMU.ax #immunotherapy #clinicaltrials #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong X Proactive Investors
Interview Topic:
First patients dosed in monotherapy IT & IV cohort 3 of VAXINIA MAST trial
youtu.be/3BUWRtgCJi0
⤴
#curecancer -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial www.proactiveinvestors.com.au/companies/news/1011316/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) advances phase one study of ‘cancer-killing’ virus
smallcaps.com.au/imugene-advances-phase-one-study-cancer-… @TeamImugene -
Imugene | Cancer Immunotherapies
@TeamImugene
“Still being less than 12 months since the very first patients were dosed, we’re now well advanced on amassing the critical data we require to publish on the outcomes of this study, and we remain very positive on the potential benefits ...” - Leslie Chong
imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
"An ASX-listed company, which is developing a range of #immunotherapy technologies that allow the body to track down and fight off cancer cells. The company’s most recent breakthrough is a treatment known as oncolytic virus therapy."
More: thenewdaily.com.au/finance/the-innovators/2023/03/28/aust… $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
NWR Communications
Virtual Healthcare Conference 2023
Imugene Limited
Developing Cancer Immunotherapies
Presented by Leslie Chong, CEO & MD
☞ youtube.com/watch?v=XhR6rThKkmI -
Imugene | Cancer Immunotherapies
@TeamImugene
We captured footage from our non-deal roadshow in Australia this month, which we are proud to share below.
Featuring Leslie Chong, Professor Yuman Fong and Dr Jakob Dupont. $IMU $IMU.ax
www.youtube.com/watch?v=fOtaeqfdf9w -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU Investor Presentation
Non-Deal Roadshow
Australia
March 2023
Download:
imugene.com/investor-presentations -
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU: Yesterday in Sydney
Paul Hopper, Leslie Chong, Professor Yuman Fong and Jakob Dupont spoke about our onCARlytics platform to a room of supportive shareholders.
Learn more: imugene.com/oncarlytics-cf33-cd19 -
Imugene | Cancer Immunotherapies
@TeamImugene
Updated Analyst Coverage:
DIAMOND Equity Research | H1 FY2023 Financial Result Update and Progress with Clinical Trials
Valuation: 46c AUD
Learn more: imugene.com/analyst-coverage
$IMU $IMU.ax #immunotherapy #biotechnology -
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Imugene (#asx: $IMU) forges development path of immunotherapies and cancer-killing virus
www.youtube.com/watch?v=iQTEbRt7d1w @TeamImugene -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene thrilled as first patients dosed in VAXINIA MAST combination study www.proactiveinvestors.com.au/companies/news/1007919/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Small Caps
@SmallCapsASX
Don't despair, there are hidden gems on the ASX
www.youtube.com/watch?v=gETI7Ex8Vpo -
Imugene | Cancer Immunotherapies
@TeamImugene
“Having continued through the #monotherapy dose escalation unimpeded thus far, we’re eager to see #vaxinia used in combination with the well-known Pembrolizumab drug and see the potential benefit this can bring to patients." - Leslie Chong, CEO $IMU
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Tony Locantro
@LocantroTony
This activity isn't the "norm" and we eventually come out of periods of chronically low share prices in the micro-caps. $IMU @TeamImugene $CHM @Chimeric $RAD @TeamRadioPharm $MMA @MaronanMetals $RDM
#uranium #gold #silver
Small Caps
@SmallCapsASX
Don't despair, there are hidden gems on the ASX
www.youtube.com/watch?v=gETI7Ex8Vpo -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce the appointment of Chief Financial Officer (CFO) Mike Tonroe as Company Secretary, effective 2 March 2023.
Mr Tonroe was previously Company Secretary of ASX and NASDAQ-listed Genetic Technologies Limited and Opthea Limited. imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
Register now to join the next session of ASX CEO Connect, where our CEO Leslie Chong will be a featured speaker. $IMU. $IMU.ax
www2.asx.com.au/investors/investment-tools-and-resources/… -
Imugene | Cancer Immunotherapies
@TeamImugene
We invite you to visit our investor section to read our latest analyst coverage from ROTH Capital Partners.
Their 12-month price target is AUD 0.71.
• imugene.com/analyst-coverage
#cf33 #oncarlytics #oncolyticvirus $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to release our Half-Year Report & Accounts for the period ended 31 December 2022.
Read & Subscribe:
mailchi.mp/311714b89997/pd1-vaxx-and-checkvacc-asx-announ…
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to invite you to a Shareholder Reception featuring special guests Professor Yuman Fong and Dr Jakob Dupont.
Sydney | Monday, March 13th
4:30-6pm
Melbourne | Wednesday, March 15th
4:30-6pm
For more information, and to RSVP, visit:
mailchi.mp/50101f672261/pd1-vaxx-and-checkvacc-asx-announ…
$IMU -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Do you know that @TeamImugene is an ethical company developing safe and relatively inexpensive cancer therapies to stimulate your own immune system in the fight against cancer? Help our team of world renowned scientists rid the world of the scourge of cancer. ASX:IMU $IMU
Cancer Research Institute
@CancerResearch
Immunotherapy capitalizes on the innate power of the immune system to eliminate cancer, giving patients hope for a cure. Discover how immunotherapy is impacting every day while transforming tomorrow: www.cancerresearch.org/what-is-immunotherapy #immunotherapy #cancerresearch #immunotherapyfaq
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
So great to be working with an organisation rated so highly. @TeamImugene @SoCalYuman @SaulPriceman
City of Hope
@cityofhope
City of Hope received the highest ranking possible for a U.S. cancer center by the National Cancer Institute @theNCI and was awarded more than $23M to support research, cancer training and education programs, and community outreach over the next five years www.cityofhope.org/city-hope-earns-highest-ranking-nation…
-
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene (ASX:IMU) shares jump on US patent for PD1-Vaxx immunotherapy
@TeamImugene #immunotherapy #asx $IMU
kalkinemedia.com/au/news/featured-news/imugene-asximu-sha… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene locks in further US patent protection for PD1-VAXX www.proactiveinvestors.com.au/companies/news/1005751/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“It’s vital to our business that we continue locking in intellectual property protection across the portfolio of assets, and I am proud to continue to strengthen our IP ..." - Leslie Chong, CEO & MD $IMU
#pd1vaxx #immunotherapy #clinicaltrial $IMU.ax
www.imugene.com/news/2023/2/10/imugene-pd1-vaxx-immunothe… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
1stOncology
@1stOncology
#imugene reported that #vaxinia trial advances to Combination Cohort 1 & #monotherapy Cohort 3 $IMU www.1stoncology.com/blog/vaxinia-trial-advances-to-combin…
-
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene made several presentations at well-respected healthcare conferences this quarter, as well as material progress on its VAXINIA trial, dosing the first patient in the second intravenous cohort assessing the safety of novel cancer-killing virus ..."
www.proactiveinvestors.com.au/companies/news/1005131/heal… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
With our rapid progress in treating patients in our VAXINIA trial, now in combination with pembro, it's time to reshare this. @TeamImugene The First Human Trial Of Virus That Kills Cancer | Imugene Vaxinia Expla... youtu.be/dAejZ0qQw5o via @YouTube
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene advances VAXINIA trial to combination patient cohort 1 and monotherapy cohort 3 www.proactiveinvestors.com.au/companies/news/1004995/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are very pleased to share our latest newsletter, now available to download via: imugene.com/newsletters
$IMU $IMU #immunotherapy #endcancer #asx200 -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce Phase 1 MAST study evaluating the safety of our novel cancer-killing virus CF33-hNIS (#vaxinia) has cleared cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial. $IMU $IMU.ax #asx
Learn more: imugene.com/announcements
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong, CEO & MD has commented that “early data arising from our patients dosed at low levels with our CF33 oncolytic virus have indicated immune activation is occurring in the tumour microenvironment, turning the tumour from ‘immunologically cold to hot’." $IMU $IMU.ax
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie emphasises "this is a perfect time to introduce an immune checkpoint inhibitor such as pembrolizumab.”
$IMU $IMU.ax #vaxinia #cf33 #oncolyticvirus -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Nice that @TeamImugene HER-Vaxx is the first summarised from ASCO. Most definitely practice-changing research.
ASCO
@ASCO
Now that #gi23 is complete, catch up on all the practice-changing research presented at the Symposium with in-depth coverage from #ascodailynews: dailynews.ascopubs.org/meetings/gastrointestinal-cancers-…
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
Diamond Equity Research
"Initial Clinical Trial Data Encouraging with Strong Financial Position"
Valuation: 46c AUD
• Oncolytic Virus - An Emerging Frontier in Cancer Immunotherapy, onCARlytics - ‘Mark and Kill’ Approach & more.
imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies
@TeamImugene
ASX news:
Quarterly Activities and Cash Flow Report Quarter ended 31 December 2022 $IMU
imugene.com/announcements -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to share two more articles from America discussing encouraging results of how HER-Vaxx + chemotherapy improves survival in HER2 advanced gastric/GEJ cancer:
dailynews.ascopubs.org/do/encouraging-results-seen-her-va…
&
www.cancertherapyadvisor.com/home/news/conference-coverag…
$IMU #hervaxx #immunotherapy #clinicaltrial $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Healthcare publisher OncLive have featured our HER-Vaxx technology below.
Learn more:
HER-Vaxx Fact Sheet
static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
$IMU $IMU.ax
OncLive.com
@OncLive
Patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma treated with HER-Vaxx + standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone. #oncology www.onclive.com/view/early-exploration-with-her-vaxx-exte…
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Superstar ⭐️Great to be working with innovators like @SaulPriceman @SoCalYuman @CityofHopeSurg @TeamImugene
UroToday.com
@urotoday
Engineered cell therapies for metastatic castrate-resistant #prostatecancer. @SaulPriceman @cityofhope joins @CaPsurvivorship @DanaFarber to discuss clinic-ready CAR T cell therapies for #mcrpc > www.urotoday.com/video-lectures/advanced-prostate-cancer/… @PCFnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Watch Leslie Chong's interview with Proactive's Andrew Scott following her presentation at the JP Morgan Healthcare Conference in San Francisco. $IMU
Visit our YouTube channel:
youtube.com/watch?v=PwON_tI61Ws -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene off to strong start to 2023 with JP Morgan Healthcare Conference www.proactiveinvestors.com.au/companies/news/1003980/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
The 20th iteration of this event highlights the latest developments and breakthroughs in the field of gastrointestinal #oncology, attended by more than 4,000 scientific figures, clinical researchers, academics, oncologists and medical practitioners.
$IMU: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Imugene | Cancer Immunotherapies
@TeamImugene
2023 ASCO
GASTROINTESTINAL CANCERS SYMPOSIUM imugene.com/conference-presentations
$IMU $IMU.ax
Imugene | Cancer Immunotherapies
@TeamImugene
Dr Tanuj Chawla, MD presenting at the ASCO Gastrointestinal Cancers Symposium currently being held in San Francisco.
Conference Presentations: www.imugene.com/conference-presentations -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene HER-Vaxx and CF33 platforms feature at ASCO Gastrointestinal Cancers Symposium www.proactiveinvestors.com.au/companies/news/1003880/imug… @TeamImugene $IUGNF #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We have compiled Leslie Chong's presentation from the 2023 JP Morgan Healthcare Conference (audio + slides) to provide our shareholder's with further insight from this prestigious event in San Francisco.
Visit our YouTube channel:
www.youtube.com/watch?v=vuneDZVb51g -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to receive and share this image today from Leslie Chong's presentation at the 2023 JP Morgan Healthcare Conference in San Francisco — the largest and most informative healthcare investment symposium in the #biotechnology industry. $IMU
#jpmorgan #jpmhc23 #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Business reporter Jared Lynch writes about our approval to begin human trials for our VAXINIA treatment:
'Human trials for Imugene’s cancer-destroying drug'
www.theaustralian.com.au/business/imugene-drug-aimed-at-c… $IMU -
Imugene | Cancer Immunotherapies reposted
stock setter
@MarcJacksonLA
$IUGNF Imugene gets ethics green light to start Australian Phase 1 trial of oncolytic virotherapy candidate VAXINIA www.proactiveinvestors.com/companies/news/1002646/imugene… @TeamImugene $IMU $IUGNF #imu #imu #iugnf
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene gets ethics green light to start Australian Phase 1 trial of oncolytic virotherapy candidate VAXINIA www.proactiveinvestors.com.au/companies/news/1002646/imug… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
"Accomplishing this goal speaks to the perseverance and dedication of Imugene’s clinical and research team as we continue to build on our clinical and commercial potential ..." - Leslie Chong, CEO $IMU $IMU.ax
Read our ASX announcement: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#clinicaltrials
Imugene | Cancer Immunotherapies
@TeamImugene
"In addition to the positive preclinical results, we’re incredibly eager to unlock the potential of #vaxinia and the #oncolytic #virotherapy platform for Australians inflicted with cancer." - Leslie Chong, CEO $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO Leslie Chong has presented at the 41st Annual JP Morgan Healthcare Conference in San Francisco.
You may now access her presentation via:
imugene.com/investor-presentations
#endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to share Mr. Paul Hopper's 'Letter to Shareholders', which was announced this morning on the ASX:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #immunotherapy #biotechnology #clinicaltrials -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene to present HER-Vaxx and CF33 platforms at ASCO Gastrointestinal Cancers Symposium in January www.proactiveinvestors.com.au/companies/news/1001463/imug… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce HER-Vaxx and CF33 technologies will feature at the upcoming @ASCO Gastrointestinal Cancers Symposium - an international event highlighting the latest developments and breakthroughs in the field of gastrointestinal oncology. $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Roth Capital Partners have issued another equity research company note for Imugene. $IMU $IMU.ax
Learn more by visiting: imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies
@TeamImugene
We have been invited to present at the 41st Annual J.P. Morgan Healthcare Conference, being held 9-12 January 2023.
Leslie Chong will present at 9:30am Pacific time on Wednesday 11 January 2023 (4:30am AEDT, Thursday 12 January 2023).
Details: jpmorgan.metameetings.net/events/healthcare23/sessions/44… $IMU -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Health Beat: Cancer-killing virus on the march @Teamimugene $IMU #thisistheway www.wfmz.com/health/health-beat/health-beat-cancer-killin… via @69News
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene presents new and first CHECKvacc data at 2022 San Antonio Breast Cancer Symposium www.proactiveinvestors.com.au/companies/news/1000724/imug… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged we are seeing positive signals ..."
- Leslie Chong, CEO $IMU $IMU.ax #biotech
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene presents positive new data at key congress www.proactiveinvestors.com.au/companies/news/1000295/imug… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Our Executive Director of Clinical Science, Sharon Yavrom has presented at the 7th Oncolytic Virotherapy Summit 2022 in Boston, USA. oncolytic-virotherapy-summit.com
View the conference presentation: imugene.com/conference-presentations
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch Leslie Chong's interview following our #asx news of our positive new HER-Vaxx HERIZON data presented at ESMO Asia 2022. $IMU $IMU.ax
Full interview via our YouTube channel:
www.youtube.com/watch?v=v3ADKC-ntao&list=PLtuhdj8lir8yxVO… -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to share our latest analyst coverage titled:
'IMU: Favorable Phase 2 HER-Vaxx DoR Data
Presented at the ESMO Asia Congress'
Visit: imugene.com/analyst-coverage
$IMU $IMU.ax #immunotherapy #medtech #asx200 -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses first patient in VAXINIA IV cohort 2 trials www.proactiveinvestors.com.au/companies/news/1000154/imug… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Key conclusions of the overall survival benefit of HER-Vaxx included HER-Vaxx-&-chemotherapy showing a statistically significant 42% overall survival benefit compared to chemotherapy alone; 13.9 vs 8.3 months.
Learn more cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #endcancer #asxnews $IMU.ax
Imugene | Cancer Immunotherapies
@TeamImugene
Speaking to the Congress on Sunday 4 December 2022, principal investigator Marina Maglakelidze outlined the study design, information regarding demographics and characteristics of the 36 patients in the trial, and data covering safety and adverse events. $IMU $IMU.ax
@ESMO_Open
Imugene | Cancer Immunotherapies
@TeamImugene
Principal investigator Marina Maglakelidze $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce our Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patient dosed as part of intravenous (IV) cohort 2 of the trial. $IMU
ASX news cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Imugene | Cancer Immunotherapies
@TeamImugene
“As recently noted by Professor Yuman Fong in his visit to Australia, the Imugene team continues to progress development of these assets at an excellent pace, and this announcement is yet another example of that.”
- Leslie Chong, CEO $IMU $IMU.ax #vaxinia #medtech #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: DIAMOND EQUITY RESEARCH
OnCARlytics Pre-Clinical Highlights and Continued Progress on Multiple Fronts
Valuation: 46c AUD
Visit: imugene.com/analyst-coverage
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
#innovation from @TeamImugene HER-Vaxx R&D team. #combinations #immunotherapy Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer www.mdpi.com/1954966 #mdpicancers via @Cancers_MDPI
-
Imugene | Cancer Immunotherapies
@TeamImugene
This week concluded our 2022 investor roadshows in Sydney and Melbourne. We had the pleasure of our Scientific Advisory Board member's Professor Yuman Fong and Dr Saul Priceman (from @cityofhope) joining us in meeting our valued #investor community.
imugene.com/investor-presentations
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Yesterday, our CTO Nick Ede presented our HER-Vaxx story @TIDESInforma, which is the industry’s leading event in Europe aiming to accelerate therapeutics to market by expediting R&D and building new partnerships.
HER-Vaxx Fact Sheet: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
$IMU #immunotherapy
Nick Ede
@Melroseavenick
Just happened in Vienna at #tideseurope. Great to present our HER-Vaxx story. @TeamImugene $IMU #innovation #immunotherapy
-
Imugene | Cancer Immunotherapies
@TeamImugene
ASX news:
AGM Presentation 2022
imugene.com/investor-presentations
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
ASX news: Investor Presentation
imugene.com/investor-presentations
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Our new onCARlytics fact sheet is now available to download in PDF: static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t…
$IMU $IMU.ax | ASX: IMU #asx200
#immunotherapy #medtech #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce onCARlytics (CF33-CD19) oncolytic virus in combination with Estrella’s CD19-Redirected ARTEMIS® T cells was presented at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC). $IMU @sitcancer #endcancer
ASX news cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Celularity Inc. (NASDAQ:CELU)
@celularity
Today we presented data from preclinical studies of our placental-derived CYCART-19 T cells in combination with @TeamImugene’s onCARlytics (CF33-CD19) oncolytic virus at SITC. Read the full press release on our website: celularity.com/imugenes-oncarlytics-combination-with-celu…
#sitc #celularity #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
Our Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of our cancer-killing virus CF33-hNIS (VAXINIA) has progressed to the next stage.
Read our ASX announcement to learn more:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU $IMU.ax #endcancer #vaxinia #oncolyticvirus -
Imugene | Cancer Immunotherapies
@TeamImugene
Our oncolytic virus, onCARlytics (CF33-CD19) in combination with CD19 bispecific antibody blinatumomab was presented at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), held in Boston, USA on 8-12 November 2022.
Learn more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Imugene | Cancer Immunotherapies
@TeamImugene
“Blinatumomab, sold under the brand name Blincyto, is a bispecific T cell engager antibody that targets CD19 and is used to treat a particularly acute form of #leukemia ..." - Leslie Chong, CEO $IMU $IMU.ax
#oncolyticvirus #immunotherapy @sitcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce #oncarlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the Annual Meeting of the Society for Immunotherapy of Cancer (#sitc). $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Imugene | Cancer Immunotherapies
@TeamImugene
"The results presented at SITC further build our confidence as to the potential benefit to patients from these technologies and provide an excellent platform for further clinical development." - Leslie Chong, CEO $IMU @sitcancer $IMU.ax #oncarlytics #cf33
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to share our latest investor presentation from the 2022 Bell Potter Healthcare Conference, available to download below.
☞ imugene.com/investor-presentations
$IMU | Developing Cancer Immunotherapies -
Imugene | Cancer Immunotherapies
@TeamImugene
Arovella Therapeutics has partnered with us to combine ALA-101 with our onCARlytics platform, which opens up the possibility of using ALA-101 to tackle solid tumours.
Today, they announced key information regarding a European patent:
#inkt #oncarlytics #celltherapy $IMU.ax $IMU
Arovella Therapeutics ASX: ALA
@WeAreArovella
"Receiving the notice that this European patent application will proceed to grant is an excellent milestone for our technology ..." - Michael Baker, CEO
Read our ASX news: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#inkt #celltherapy #biotechnology $ALA $ALA.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Prof. Yuman Fong speaks with KPLC News about how VAXINIA stimulates the immune system to track down cancers:
"...we will be able to partner with other agents that also do that and together, grow therapies for cancers that, until now, have no treatment.”
www.kplctv.com/2022/11/01/health-headlines-scientists-dev… -
Imugene | Cancer Immunotherapies reposted
stock setter
@MarcJacksonLA
$IUGNF Imugene reaches new dosing milestone in Phase 1 VAXINIA trial www.proactiveinvestors.com/companies/news/996783/imugene-… @TeamImugene $IMU $IUGNF #imu #imu #iugnf
-
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene (ASX:IMU) doses first patient in VAXINIA intratumoral cohort-2
@TeamImugene #vaxinia #asx $IMU
kalkinemedia.com/au/sponsored/imugene-asximu-doses-first-… -
Imugene | Cancer Immunotherapies
@TeamImugene
We invite you to attend our upcoming Shareholder Receptions in Melbourne and Sydney, where you will have the opportunity to hear from our management team and the co-inventor's of onCARlytics; Professor Yuman Fong & Dr Saul Priceman from City of Hope. RSVP: mailchi.mp/ba1ccca5dcae/pd1-vaxx-and-checkvacc-asx-announ…
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene reaches new dosing milestone in Phase 1 VAXINIA trial www.proactiveinvestors.com.au/companies/news/996783/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Join @TeamImugene at Bell Potter's 2022 Healthcare Conference, a three-day virtual event showcasing the best of Australasia’s small and mid-cap #healthcare companies.
• November 8–10
• 8:30am–6:00pm AEDT
Contact your Bell Potter adviser or representative for access. $IMU #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
“The VAXINIA trial continues to progress on schedule and we’re very excited to see the results it can deliver for these patients dealing with significant tumour growth.” - Leslie Chong, CEO $IMU
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#endcancer #vaxinia #cf33 -
Imugene | Cancer Immunotherapies
@TeamImugene
In the latest episode of 'Trending Today' (Fox Business) we share our groundbreaking solutions for developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. $IMU #endcancer
Watch now: youtu.be/jNVxSzvmLVw -
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene (ASX:IMU) and ABL ink deal to fast-track VAXINIA manufacturing
@TeamImugene #vaxinia #asx $IMU
kalkinemedia.com/au/sponsored/imugene-asximu-and-abl-ink-… -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong discusses our ABL partnership with Andrew Scott from @proactive_au providing further insight into advancing our oncolytic virus candidate towards later-phase clinical trials.
Watch via YouTube: www.youtube.com/watch?v=l86IUAQF9cE&t=43s
$IMU #vaxinia #oncolyticvirus $IMU.ax #asxnews -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene talks ABL partnership for VAXINIA and $80 million institutional capital raise www.proactiveinvestors.com.au/companies/news/995772/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene teams with ABL to bring VAXINIA into next clinical chapter www.proactiveinvestors.com.au/companies/news/995744/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“Reliability of drug supply is a major hurdle for the clinical development of many modern biological oncology drug candidates. De-risking this critical component of clinical development by working with ABL is a significant milestone." - Leslie Chong $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and synergizes in combination with a dual HER2 B-cell vaccine @TeamImugene @OhioState www.tandfonline.com/doi/full/10.1080/2162402X.2022.212769…
-
Imugene | Cancer Immunotherapies
@TeamImugene
"While many gene therapy companies focus on restoring lost functions to normal cells, the Australia-based immuno-oncology company Imugene is employing the method to help kill cancer cells. In 2019, the company acquired an oncolytic virus called CF33 ..."
www.genengnews.com/topics/drug-discovery/gene-therapy-hit… -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce an abstract regarding the overall survival results from our HERIZON study has been accepted for a mini oral presentation at the ESMO Asia Congress 2022 in Singapore, December 2-4.
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#bcell #immunotherapy #esmo22 $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Our onCARlytics #cf33 oncolytic virus technology will be featured in three abstracts at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), to be held in Boston, USA on 8-12 November 2022.
More via: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #immunotherapy #biotech -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene bolsters drug development team with senior appointments of industry experts www.proactiveinvestors.com.au/companies/news/994329/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Paul Wright has been appointed Vice President CMC (Chemistry, Manufacturing & Controls) and brings over 25 years experience to our team as a bioprocess development leader, including over 20 years at Pfizer, with a proven ability to manage large teams. $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Dr Selvaggi is a pulmonologist, trained in thoracic malignancies management with a focus on lung cancers and mesothelioma. More then a decade of experience has seen him in clinical development roles with GSK, Novartis Oncology & Bristol Myers Squibb. $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
DIAMOND EQUITY RESEARCH | Therapeutic Cancer Vaccines and Oncolytic Virus Powered Immunotherapies Targeting Solid Tumors
Price Target $A0.48
Download: www.imugene.com/analyst-coverage
$IMU #immunotherapy #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
A great article on #immunotherapy — reported as the new frontier of cancer treatment: jwpm.com.au/industrial-marketing-blog/immunotherapy-the-n…
-
Imugene | Cancer Immunotherapies
@TeamImugene
CEO Magazine is an iconic brand, which inspires excellence in business. 'The Immunity Card: Leslie Chong' discusses how our CEO found her niche & looks at our pipeline and the idea of using the body’s natural immunity to target and obliterate cancer.
theceomagazine.com/executive-interviews/healthcare-pharma… $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
"Our onCARlytics platform opens up the possibility to treat solid tumours with existing CD19 targeting drugs and we are excited to see how Arovella's iNKT cell platform and other drugs in our trial perform on the back of our platform." - Leslie Chong $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Rod Myer from THE NEW DAILY writes about a "new breed of entrepreneur" in Australia and is optimistic about future "developments in the fields of medical and information technology, green tech and biotech."
More thenewdaily.com.au/finance/finance-news/2022/09/20/medica…
$IMU #biotech #medtech #technology $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
“I’m very proud of our team and partners on the VAXINIA study who continue to push through the various requirements that come with running a clinical trial ...” - Leslie Chong, CEO $IMU
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#clinicaltrial #breastcancer #cancertreatment $IMU.ax -
Imugene | Cancer Immunotherapies reposted
stock setter
@MarcJacksonLA
$IUGNF Imugene receives gene regulation approval for VAXINIA Phase 1 trial expansion to Australia www.proactiveinvestors.com/companies/news/992994/imugene-… @TeamImugene $IMU $IUGNF #imu #imu #iugnf
-
Imugene | Cancer Immunotherapies
@TeamImugene
“We’re pleased to see this regulatory hurdle cleared on schedule which will allow the smooth progression of our VAXINIA Phase 1 trial as planned.”
- Leslie Chong, CEO $IMU
Read today's ASX news: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
"This capital raising ensures a long runway for the exisiting programmes while also providing flexibility to add complementary assets should attractive opportunities present ..."
- Paul Hopper, Founder & Executive Chairman
More: imugene.com/announcements
$IMU #immunotherapy #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Combination therapy targeting both HER2 and PDL1, based on what we have observed in @Teamimugene preclinical and clinical studies.
#nextherizon #neoherizon #esmo2022 $IMU
View our poster presentation: imugene.com/conference-presentations -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong's interview with Proactive provides extra detail about our ASX news of dosing our first patient in the phase 2 trial of nextHERIZON (HER-Vaxx), plus news three abstracts have been accepted at SITC for onCARlytics at the conference in November.
www.youtube.com/watch?v=JCPgaH9MjOcThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
Enjoy our latest interview with the CEO & MD of @TeamImugene, Leslie Chong.
We discussed #imugene's stacked #immunotherapy pipeline and discussed what's ahead for this exciting #biotech company. $IMU
youtu.be/SjOFJkdxNEg -
Imugene | Cancer Immunotherapies
@TeamImugene
The first patient was dosed at Adelaide's Queen Elizabeth Hospital under the direction of Principal Investigator, Professor Tim Price.
With the promising results we've seen from HER-Vaxx we are eager to take the next step in its development.
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
“Dr Dupont is a key opinion leader across immune-oncology, cell therapy & early oncology drug development, bringing a wealth of industry, research & academic experience to enhance the strength of our already world class Board of Directors." - Leslie Chong
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
“Our #vaxinia trial has made headway since commencement in May. We expect this to continue as site activation and patient recruitment builds momentum and we look forward to updating our stakeholders as this positive progress continues ...”
- Leslie Chong
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to release our Annual Report, Corporate Governance Statement, Appendix 4G and Environmental Social and Governance (ESG) Report.
Download & Subscribe: mailchi.mp/05c62afd289a/pd1-vaxx-and-checkvacc-asx-announ…
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
New Investor Presentation:
IMUGENE
Developing Cancer Immunotherapies
August 2022
Download: www.imugene.com/investor-presentations
$IMU #immunotherapy #medtech #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to invite you to join Leslie Chong this Wednesday at 12pm AEST for a special event discussing the future of oncology.
Register via: reachmarkets.com.au/the-insider-mtc/
$IMU #immunotherapy #oncology #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Via @StockheadAU
“Based on the valuations of similar companies developing drugs in these fields of therapy, we believe Imugene has a fair value of about $3 billion or [USD] 50c per share.”
- Robert LeBoyer, Noble Capital
Learn more:
stockhead.com.au/health/heres-what-biotech-imugene-needs-…
$IMU #biotech -
Imugene | Cancer Immunotherapies
@TeamImugene
"A very interesting look at an early stage biotech, where it is with trials and data, plus some words of advice on how to look at investing in biotechs in general ..."
Listen to Leslie Chong's episode: www.buzzsprout.com/1852332/episodes/10982820
$IMU #immunotherapy #oncology #endcancer $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Our new Executive Director of Clinical Science at @TeamImugene Dr Sharon Yavrom is speaking on #cf33 OV platform in December. #groundbreaking #standingroomonly #thisistheway
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
ROTH Capital Partners | Recent Clinical Highlights from Last Week Underscore Continued Progress
Price target: 71c AUD
imugene.com/analyst-coverage -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Advancing together and moving forward: Combination gene and cellular immunotherapies. Crossing a river to climb a mountain to treat solid tumors with CAR T #oncarlytics @TeamImugene @SaulPriceman www.cell.com/molecular-therapy-family/oncolytics/fulltext…
-
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong catches up with Proactive following our ASX news this morning: $IMU and @cityofhope dose first patient in cohort 3 of phase 1 trial to test cancer-killing oncolytic virus against #breastcancer.
Full Video: youtu.be/JNBybMazgGc
#checkvacc #clinicaltrialsThis media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
"CHECKvacc has the potential to improve clinical response and survival in this indication where there are currently no meaningful treatments, and we are eager to deliver on that.” - Leslie Chong, CEO $IMU
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#checkvacc #oncolyticvirus #virotherapy
Imugene | Cancer Immunotherapies
@TeamImugene
CF33-hNIS-antiPDL1 is an immune checkpoint inhibitor armed chimeric vaccinia poxvirus from the lab of CF33 inventor Professor Yuman Fong, Chair of Sangiacomo Family Chair in Surgical Oncology at City of Hope, and a noted expert in the oncolytic virus field. $IMU @SoCalYuman #asx
Imugene | Cancer Immunotherapies
@TeamImugene
Oncolytic viruses (OVs) are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival. $IMU #oncolyticviruses #immunesystem #cancerresearch
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene and City of Hope dose first patient in cohort 3 of phase 1 trial to test cancer-killing oncolytic virus against breast cancer www.proactiveinvestors.com.au/companies/news/989666/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene showcases new PD1-Vaxx data at World Conference on Lung Cancer www.proactiveinvestors.com.au/companies/news/989413/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Professor Michael Boyer M.D., MBBS, FRACP, PhD, Chris O’Brien Lifehouse Hospital presenting @TeamImugene PD1-Vaxx @IASLC #wclc22
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Standing room only at @TeamImugene presentation @IASLC #wclc22 #pd1vaxx
-
Imugene | Cancer Immunotherapies
@TeamImugene
Our Phase I IMPRINTER trial has been presented as a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in Vienna, Austria.
Read our ASX News:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
View the Poster Presentation:
imugene.com/conference-presentations
$IMU #lungcancer #biotech -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
@TeamImugene looking forward to presenting this weekend! $IMU #pd1vaxx
IASLC
@IASLC
#wclc22 kicked off with a press briefing in Vienna! @karenkellymd, @MEipeldauer, & Drs. Prosch & Pirker highlighted the opportunities for learning & collaboration at the conference and discussed some of the novel data that will be presented.
-
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene (ASX:IMU) ticks off key clinical milestones in June 2022 quarter
@TeamImugene #healthcare #asx $IMU
kalkinemedia.com/au/sponsored/imugene-asximu-ticks-off-ke… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
'Dear Dr. Kaumaya, Congratulations! Your article..."Immunogenicity and antitumor efficacy of...PD1-Vaxx and combination.. with...B-Vaxx" is among the most highly cited in OncoImmunology in the last five years'. Love your work Prof! @TeamImugene www.tandfonline.com/doi/full/10.1080/2162402X.2020.1818437
-
Imugene | Cancer Immunotherapies reposted
Gastric Cancer Foundation
@GastricCancerFD
@TeamImugene reported that its experimental vaccine HER-Vaxx plus the SOC chemotherapy regimen showed a 41.5% survival benefit over chemo alone in a clinical trial. #gastriccancer www.imugene.com/news/2022/6/27/imugene-presents-final-her…
-
Imugene | Cancer Immunotherapies
@TeamImugene
Mike Tonroe will commence in the newly created CFO role in September 2022, bringing extensive experience within the #biopharmaceutical industry + international finance leadership working in the US, Canada, UK, Hong Kong and Australia.
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #biotech -
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
#icymi - We revisited a recent interview with @TeamImugene CEO & MD, Leslie Chong.
Enjoy these highlights as we discussed their #hervaxx #immunotherapy treatment on the back of their recent Phase 2 trial results. $IMU
youtu.be/YkLYwI2lqJ4 -
Imugene | Cancer Immunotherapies
@TeamImugene
"It is very exciting times for Imugene, and analysts are fairly positive on the stock. US firm ROTH Capital Partners has a price target on the stock of 71 cents; while fellow US firm Noble Life Science Partners has 50 US cents ..."
Read more: www.nabtrade.com.au/investor/insights/latest-news/news/20… $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
New data from non-small cell lung cancer patients in our Phase I IMPRINTER trial has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) from 6-9 August 2022 in Vienna, Austria.
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #lungcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
After yet another productive period here @TeamImugene, which has included many key milestones, we are very pleased to share the latest edition of our shareholder newsletter with you.
Visit: www.imugene.com/newsletters
#endcancer #immunotherapy #medtech $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch Leslie Chong's V-Con Smallcap Showcase Presentation - click below or visit: vimeo.com/725904350
$IMU
Stockhead
@StockheadAU
Small Caps Showcase – Find out which Companies are set to perform & best bargains amidst turbulent market conditions @hazergroupltd @medlabclinical @Pilot_EnergyLtd @GreatBoulder @energy_invictus @KaziaTx @ADXEnergy_ @TeamImugene @wisraustralia @IONIC_RE stockhead.com.au/stockhead-tv/v-con-small-caps-showcase-c…
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
@TeamImugene Professor Pravin Kaumaya confirmed speaker on our B cell vaccine programs.
-
Imugene | Cancer Immunotherapies
@TeamImugene
Dr Yavrom is a clinical scientist with nearly 20 years of industry experience in both established and emerging #pharmaceutical companies - she has been the clinical study lead for several #clinicaltrials and has experience with multiple tumour types. $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Bulls N' Bears
@BullsNBearsWA
Did you catch @TeamImugene MD Leslie Chong's #bullsnbearsreport interview on radio @3AW693 Melbourne about Imugene’s successful clinical trial of its immunotherapy for stomach cancer that showed material increases in overall survival rates?
$IMU #imugene www.3aw.com.au/imugene-serious-inroads-a-highly-successfu… -
Imugene | Cancer Immunotherapies reposted
BioWorld
@BioWorld
@TeamImugene reports positive final overall survival data in phase II HER-Vaxx gastric cancer trial www.bioworld.com/articles/520246-imugene-reports-positive… #biotech #pharma
-
Imugene | Cancer Immunotherapies
@TeamImugene
Targeted Oncology have featured our HER-Vaxx news showing efficacy in GEJ cancer, visit: www.targetedonc.com/view/chemotherapy-plus-her-vaxx-shows…
$IMU -
Imugene | Cancer Immunotherapies reposted
ausbiz
@ausbiztv
Leslie Chong CEO of @TeamImugene $IMU will be speaking with #ausbiz on the HER-Vaxx results from the randomized Phase 2 trails.
11am AEST on ausbiz.com.au -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Go @TeamImugene !! Love it!!
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage:
ROTH Capital Partners
"Highly Positive Final Phase 2 HER-Vaxx Survival Data Justifies More Trials"
• Price Target: 71c
Download the PDF:
roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=9214…
$IMU #immunotherapy #medtech $IMU.ax -
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
Enjoy our latest interview with the @TeamImugene CEO, Leslie Chong.
We discuss $IMU's recent milestone as they released their #hervaxx Phase 2 clinical trial results.
#biotech #imugene #immunotherapy $IUGNF
youtu.be/xu7SedTPe78 -
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene’s HER-Vaxx is a b-cell peptide cancer immunotherapy, which is injected like a vaccine, and designed to treat tumours that over-express a certain receptor known as HER-2/neu. This also occurs in types of breast, ovarian, lung & pancreatic cancers."
www.afr.com/companies/healthcare-and-fitness/imugene-soar… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene releases final data from Phase 2 HER-Vaxx study www.proactiveinvestors.com.au/companies/news/985850/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Finance News Network
@Finnewsnetwork
Stocks of the Hour: Imugene, Centrepoint Alliance & Tamboran Resources
www.finnewsnetwork.com.au/archives/finance_news_network38… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Beautiful data from our Vienna labs. HER-Vaxx active in Her-2+ lung metastases. @Teamimugene Active immunization with a Her-2/neu-targeting Multi-peptide B cell va... www.sciencedirect.com/science/article/pii/S1936523322000407
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene records positive final safety and efficacy data from Phase 2 trial targeting gastric cancer www.proactiveinvestors.com.au/companies/news/985827/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong will be joined by Principal Investigator Dr Tanuj Chawla and consulting statistician Brent Blumenstein to discuss the final HER-Vaxx overall survival results in our randomized Phase 2 trial in advanced #gastriccancer. $IMU
Register via Zoom: us02web.zoom.us/webinar/register/WN_Lik-eBynRCCJ3iIUK-JFvg -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to present positive final overall survival data from our Phase 2 study of HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer following analysis of safety and efficacy data.
Learn more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #gastriccancer $IMU.axPost not available here, view on X
Imugene | Cancer Immunotherapies
@TeamImugene
More:
• HERIZON-extension Cohort Review Committee (CRC) confirmed a dose of HER-Vaxx 100μg for future studies commencing soon.
• New clinical batch manufactured and delivered in 2022 to supply all planned HER-Vaxx clinical trials.
$IMU $IMU.ax #gastriccancer #clinicaltrial
Imugene | Cancer Immunotherapies
@TeamImugene
“Reliability of drug supply is a major hurdle for clinical development of many modern biological oncology drug candidates. De-risking this critical component of clinical development is a significant achievement for Imugene.” - Leslie Chong, $IMU CEO
$IMU.ax #endcancer #hervaxx -
Imugene | Cancer Immunotherapies
@TeamImugene
"As per our previous newsletters, each month we look at an investment in more detail and this month its Imugene Limited (IMU) ..."
Merchant Biotech Fund:
mailchi.mp/7d037d4d3357/merchant-biotech-fund-newsletter-… -
Imugene | Cancer Immunotherapies
@TeamImugene
Listen to CAPETALK Radio (567AM) in South Africa cover news of our VAXINIA First Patient Dosed.
Listen & Read: www.primediaplus.com/404/
@CapeTalk #jointheconversation $IMU #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Yahoo Finance have written an article titled "Cancer-fighting virus tested in human" which features Yuman Fong and CF33-hNIS (Vaxinia). $IMU
Read here: au.finance.yahoo.com/news/cancer-fighting-virus-tested-hu…
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong explains the virus is known as CF33 because it's the 33rd virus that Dr Fong created, and the most potent against cancer cells ..." $IMU
Cancer-fighting virus tested in human:
au.finance.yahoo.com/news/cancer-fighting-virus-tested-hu… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
We share this vision of vaccinating against cancer at @TeamImugene New generation of cancer-preventing vaccines could wipe out tumors before they form www.science.org/content/article/new-generation-cancer-pre…
-
Imugene | Cancer Immunotherapies reposted
California Biotech
@CABiotech
.@TeamImugene and @CityofHope announced that the first patient had begun treatment in a revolutionary clinical trial of their cancer-killing Oncolytic virus. www.biospace.com/first-patient-dosed-with-imugene-s-cance…
-
Imugene | Cancer Immunotherapies
@TeamImugene
"The start of the CF-hNIS trial in solid tumors is another milestone for the company's three technology platforms, with ASCO data from PD1-Vaxx and HER-Vaxx supporting our expectations for those trials."
Price target 50c USD.
New Analyst Coverage:
imugene.com/analyst-coverage
$IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Medical News Today provide in-depth coverage of #vaxinia:
“We are keen to revolutionize cancer therapy, and no longer are we satisfied with incremental improvements in survival, we want to cure patients ..."
- Leslie Chong, CEO & MD
www.medicalnewstoday.com/articles/cancer-killing-virus-in… $IMU #cancertherapy
Imugene | Cancer Immunotherapies
@TeamImugene
"By making cancer into one disease and having a targeted agent to obliterate it, that’s the holy grail of cancer therapeutics!” - Leslie Chong, CEO $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
Dr Ben Miles provides an excellent explanation on VAXINIA - detailing the history of viruses and cancer, how viruses kill cancer, how #vaxinia works, and how far away we are from curing cancer.
YouTube: www.youtube.com/watch?v=dAejZ0qQw5o
Our Technology: imugene.com/oncolytic-virus
#cf33 $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Learn more about our Oncolytic Virus CF33, invented by Professor Yuman Fong from City of Hope — and CHECKvacc, which is based on the CF33 platform with further enhanced tumour killing ability by adding an anti-PD-L1 antibody gene, which the virus delivers to the cancer cell. $IMU
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Dr. Woo is an internationally recognised surgeon-scientist with clinical expertise in robotic surgery and #gastriccancer. She holds several key positions at City of Hope and is a Visiting Professor at Xiangya Medical School, China.
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce an abstract detailing the Phase 1 CHECKVacc trial in adults with triple negative breast cancer has been published at the American Society of Clinical Oncology’s @ASCO 2022 Annual Meeting.
More: www.imugene.com/announcements
$IMU $IMU.ax #asco #breastcancer
Imugene | Cancer Immunotherapies
@TeamImugene
Learn more about CHECKvacc:
This media couldn't be displayed. See it on the original post. -
Imugene | Cancer Immunotherapies
@TeamImugene
Professor Yuman Fong has received an honorary doctorate from the Elmezzi Graduate School of Molecular Medicine at Northwell Health.
Congratulations from us all @TeamImugene #yumanfong $IMU @SoCalYuman
Yuman Fong
@SoCalYuman
Congratulations to the new graduates of The Elmezzi Graduate School of Molecular Medicine. You are the next generation of translational scientists. Looking forward to your successes impacting human disease, @sarasiskind @sakkolMD @MiyaraMD John Eun, Tomas Huerta, Muhammad Shoaib.
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to announce results from our Phase 1 #pd1vaxx IMPRINTER trial in adults with non-small cell #lungcancer has been published today in an abstract at the American Society of Clinical Oncology’s 2022 Annual Meeting.
More: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #asco2022 @ASCO -
Imugene | Cancer Immunotherapies reposted
GeneOnline
@GeneOnlineNews
@TeamImugene and @kalivir_immuno are harnessing oncolytic viruses to target cancer.
#cancer #oncology #virus
www.geneonline.com/these-companies-are-harnessing-oncolyt… -
Imugene | Cancer Immunotherapies
@TeamImugene
"The treatment can also help prime peoples' immune systems against cancer, according to Imugene Limited, a clinical cancer research company."
Source: @Newsweek
$IMU $IMU.ax #endcancer #followthescience #asx
www.newsweek.com/vaxinia-oncolytic-virus-therapy-cancer-h… -
Imugene | Cancer Immunotherapies
@TeamImugene
National coverage from The Australian Business Review:
@australian @TeamImugene $IMU $IMU.ax #asx
www.theaustralian.com.au/business/imugene-rises-as-chairm… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene chair says company "as strong as ever" amid turbulent global market www.proactiveinvestors.com.au/companies/news/982899/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
"The virus itself has been engineered specifically to kill #cancer cells. And, in previous animal trials, #scientists have seen very promising results. These kinds of viruses have been a “smoking gun” in the fight against cancer for over a century."
$IMU
www.bgr.com/science/first-human-patient-injected-with-rev… -
Imugene | Cancer Immunotherapies
@TeamImugene
"Dear Fellow Shareholders, we are writing to you regarding the share price performance of Imugene over the last few months and to point out that Imugene is as strong as it has ever been in its history."
- Paul Hopper and Leslie Chong
More: app.sharelinktechnologies.com/announcement/asx/76decf9cb0…
$IMU #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
If you missed this past Channel 7 News Exclusive on #cf33 with Professor Yuman Fong and Leslie Chong (2019), we have reposted it again for your convenience as it provides great detail about the technology and its potential to cure cancer.
$IMU #yumanfong #imugene $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Learn more about #oncolyticviruses from the below video by @cityofhope:
$IMU #cf33 #yumanfong
Imugene | Cancer Immunotherapies
@TeamImugene
Using a Virus to fight cancer: Oncolytic Viruses Explained
Video by @cityofhope
#oncolyticvirus #oncolyticviruses #virus #endcancer $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: ROTH Capital Partners
"First Phase 1 Advanced Solid Tumor Patient Dosed with CF33-hNIS VAXINIA"
• 12-Month Price Target: AUD 0.71
Download the PDF: imugene.com/analyst-coverage
$IMU $IMU.ax #cf33 #immunotherapy #vaxinia -
Imugene | Cancer Immunotherapies
@TeamImugene
Professor Yuman Fong from City of Hope talks with the ASX Investor in a must-watch interview following news yesterday of our first patient being dosed in a Phase 1 #clinicaltrial of our novel cancer-killing virus CF33-hNIS VAXINIA.
#vaxinia $IMU #cf33
www.youtube.com/watch?v=qlQ2Gmtt_Mc&list=PLtuhdj8lir8zJGD… -
Imugene | Cancer Immunotherapies reposted
City of Hope
@cityofhope
City of Hope and @TeamImugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors.
Read more: r.socialstudio.radian6.com/6dd2ac35-a3a4-41b5-82f9-c0475e…. #clinicaltrial -
Imugene | Cancer Immunotherapies
@TeamImugene
Professor Yuman Fong and Leslie Chong talk with Proactive about our #cf33 news this morning where City of Hope has achieved a 'first-in-the-world' milestone for testing an #oncolytic virus in people with metastatic solid tumors.
YouTube: youtu.be/5WaQypScXsM
#immunotherapy -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene and City of Hope dose first patient in phase 1 trial to test cancer-killing oncolytic virus against solid tumours www.proactiveinvestors.com.au/companies/news/982544/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“Interestingly, the same characteristics that eventually make cancer cells resistant to chemotherapy or radiation treatment actually enhance the success of oncolytic viruses, such as CF33-hNIS.”
- Yuman Fong
Learn more cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #immunotherapy #oncolyticvirus -
Post not available here, view on X
Imugene | Cancer Immunotherapies
@TeamImugene
“The dosing of the first patient in our #vaxinia study is a significant milestone for $IMU and clinicians faced with the challenge of treatment for #metastatic advanced #solidtumours. Prof. Yuman Fong and the City of Hope team have provided outstanding research."
- Leslie Chong
Imugene | Cancer Immunotherapies
@TeamImugene
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumors.
@cityofhope @TeamImugene @SoCalYuman $IMU
$IMU.ax #immunotherapy #cf33 #vaxinia #asx -
Imugene | Cancer Immunotherapies reposted
Matthew Wright
@mattwright3000
Presenting as one of ‘The Drug Developers’, @TeamImugene MD and CEO Leslie Chong tells the Bioshares Biotech Summit of the numerous shots on goal $IMU has in its portfolio.
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Investor Presentation
Bioshares Biotech Summitt 2022
By Leslie Chong, CEO
Download via: imugene.com/investor-presentations
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong speaks to Proactive about the Australian component of a phase 2 clinical trial for our cancer #immunotherapy candidate HER-Vaxx following approval from the Human Research Ethics Committee.
$IMU #hervaxx #clinicaltrials
Full Interview:
www.youtube.com/watch?v=Z8g7YiYoFIU -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene thrilled with ethics approval for phase 2 HER-Vaxx trial www.proactiveinvestors.com.au/companies/news/981798/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene receives ethics approval to begin phase 2 clinical trial of cancer immunotherapy HER-Vaxx www.proactiveinvestors.com.au/companies/news/981782/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
"The start of our Australian study is a significant milestone for $IMU & clinicians treating Australians faced with the challenge of HER-2+ #gastriccancer & we look forward to further evaluating #hervaxx in combination with pembrolizumab..." - Leslie Chong
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Toward comprehensive imaging of oncolytic viroimmunotherapy If you can track it, you can kill it @Teamimugene VAXINIA and CHECKVacc www.cell.com/molecular-therapy-family/oncolytics/fulltext…
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1 Tracking where CHECKVacc is killing cancer @Teamimugene www.cell.com/molecular-therapy-family/oncolytics/fulltext…
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer More remarkable preclinical results for VAXINIA @Teamimugene $IMU www.cell.com/molecular-therapy-family/oncolytics/fulltext…
-
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene (ASX:IMU) makes great strides in its product pipeline in March 2022 quarter
@TeamImugene #healthcare #asx $IMU
kalkinemedia.com/au/sponsored/imugene-asximu-makes-great-… -
Imugene | Cancer Immunotherapies reposted
Investurnerr
@InvesTurnerr
$IMU, $IMU.AX
“@TeamImugene is a clinical stage immuno-oncology company developing new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.”
stockhead.com.au/health/fighting-back-3-asx-cancer-stocks… -
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene shares welcome dosing of first cohort 2 patient in novel oncolytic virotherapy CHECKvacc’s Phase I trial
@TeamImugene #oncolyticvirotherapy #checkvacc #asx $IMU
kalkinemedia.com/au/sponsored/imugene-shares-welcome-dosi… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses first cohort two patient in phase one CHECKvacc trial www.proactiveinvestors.com.au/companies/news/979605/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
City of Hope has dosed the first cohort 2 patient in the Phase I #clinicaltrial of our oncolytic virotherapy candidate, CHECKvacc, an immune checkpoint inhibitor armed chimeric vaccinia poxvirus from the lab of #cf33 inventor Professor Yuman Fong. ASX cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… $IMU
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Great work @SoCalYuman
City of Hope
@cityofhope
👏 City of Hope congratulates Yuman Fong, M.D. (@SoCalYuman) for receiving the 2022 Flance-Karl Award from the Council of the American Surgical Association and the ASA Foundation Board.
“I am thankful to my colleagues for the environment in which I can mentor young surgeons" -
Imugene | Cancer Immunotherapies
@TeamImugene
Now available on YouTube:
Revolutionary company changing the lives of cancer patients | w/ Leslie Chong - Imugene CEO
Watch here: www.youtube.com/watch?v=30k6TmoUovk&list=PLtuhdj8lir8yxVO… -
Imugene | Cancer Immunotherapies
@TeamImugene
Listen to the Equity Mates Investing Podcast:
Changing the lives of cancer patients - Dr Leslie Chong of #imugene | ASX CEO Connect Series
play.acast.com/s/8c560a52-84ff-4b06-b819-f4e9bd6e85ef/623… via @acast $IMU $IMU.ax #immunotherapy #biotech -
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
Into April we head, after global markets staged a big recovery led by #lithium & #commodity stocks 📈
Today we discuss 3 top #asx stocks to watch for April 2022:
#lakeresources, @TeamImugene & #latinresources
$LKE $LRS $IMU
youtu.be/jS0-XarUrXQ -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene talks dose escalation for CHECKvacc's City of Hope trial www.proactiveinvestors.com.au/companies/news/977893/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: ROTH Capital Partners
• 12-Month Price Target: AUD 0.71
"CHECKvacc Enters Second Dose Cohort, Cleared to Start U.S. VAXINIA Phase 1"
Read here: roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=4c8c…
$IMU $IMU.ax #checkvacc #oncolyticvirus #asx -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene confirms dose escalation in phase 1 trial of new cancer drug CHECKvacc www.proactiveinvestors.com.au/companies/news/977677/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene proceeds to second dose cohort in CHECKvacc’s Phase I trial
@TeamImugene #checkvacc #healthcare $IMU
kalkinemedia.com/au/sponsored/imugene-proceeds-to-second-… -
Imugene | Cancer Immunotherapies
@TeamImugene
Oncolytic viruses (OVs) are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival. $IMU $IMU.ax
ASX: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
clinicaltrials.gov Study ID: NCT05081492 -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene receives ethical clearance to start US Phase 1 clinical trial www.proactiveinvestors.com.au/companies/news/977540/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“Following the outstanding work of Professor Yuman Fong and the @cityofhope team, in addition to the positive pre-clinical results, we’re incredibly eager to unlock the potential of VAXINIA & the oncolytic #virotherapy platform more broadly.” Leslie Chong
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases Groundbreaking results from @Teamimugene Vienna Prof Wiedermann lab www.sciencedirect.com/science/article/pii/S1936523322000407
-
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong's interview from the ASX CEO Connect conference is now available to watch on YouTube: www.youtube.com/watch?v=hH7vcEkr3eg $IMU $IMU.ax
Imugene | Cancer Immunotherapies
@TeamImugene
ASX CEO Connect $IMU stats:
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage from ROTH Capital Partners:
" $IMU FY1H22: Progress Across the Board, Very Well-Funded, Reiterate AUD0.71 Price Target "
Download the PDF: roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=ed7d… -
Imugene | Cancer Immunotherapies
@TeamImugene
Register to attend this LIVE flagship conference, Emergence 2022, from March 9-11 at the Fullerton Hotel, Martin Place 1, Sydney.
Leslie Chong will participate at the on-stage panel session discussing '#personalisedhealthcare'.
Visit: emergence22.com/sydney
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
The Market Online AU
@marketonlineau
#trendingnow (#asx: $IMU)
@TeamImugene generates income of $5.34m in H1 FY22.
Find out more: themarketherald.com.au/imugene-asximu-generates-income-of… -
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene continues to advance its clinical pipeline in 1H FY22
@TeamImugene #clinicalpipeline #hervaxximmunotherapy #asx $IMU
kalkinemedia.com/au/sponsored/imugene-continues-to-advanc… -
Imugene | Cancer Immunotherapies
@TeamImugene
ASX News:
Half Yearly Report and Accounts $IMU $IMU.ax
Download: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
ASX CEO Connect | Tomorrow after a market briefing from nabtrade, Leslie Chong will be presenting our latest update on #imugene.
Register to join the live webinar and have the opportunity to submit questions:
www2.asx.com.au/investors/investment-tools-and-resources/…
$IMU $IMU.ax
Imugene | Cancer Immunotherapies
@TeamImugene
Connect with Leslie Chong: events.asx.com.au/en/ceo-connect-march-2022-4a4b2eVgQ0/ov…
1 March 2022 $IMU -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Another fascinating paper from @TeamImugene CF33 OV team from @cityofhope @CityofHopeSurg @SoCalYuman Being able to track where CF33 goes critical.
Molecular Therapy Family of Journals
@MolTherapy
From @moltherapy Oncolytics (#mto) from @cityofhope: PET imaging and treatment of #pancreaticcancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel #oncolyticvirus, CF33-hNIS-antiPDL1 www.cell.com/molecular-therapy-family/oncolytics/fulltext…
-
Imugene | Cancer Immunotherapies
@TeamImugene
Today's 'Science Series' focusing on our B Cell Immunotherapy, PD1-Vaxx, is now on YouTube.
Watch here: youtube.com/watch?v=tSkREkYJVgs
#immunotherapy #bcell #pd1vaxx $IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
New Investor Presentation:
Science Series - PD1-Vaxx
Download: imugene.com/investor-presentations $IMU -
Imugene | Cancer Immunotherapies reposted
ASX 🏛 The heart of Australia's financial markets
@ASX
We are delighted to announce @TeamImugene will be joining us for @ASX CEO Connect extended results session on March 1. Register here: r.socialstudio.radian6.com/9a84ac40-5019-444e-8f6a-c302dc…
#asxceoconnect #midcaps #largecaps #asx #investing -
Imugene | Cancer Immunotherapies
@TeamImugene
Our next 'Science Series' will focus on our B cell immunotherapy, PD1-Vaxx, featuring our Senior Director of Clinical Science Dr Nimali Withana and Professor Pravin Kaumaya.
Wednesday, February 23
10:00am AEDT
Register now: mailchi.mp/6f1de706b102/imugene-science-series-with-pd1-v…
$IMU #endcancer #biotech #asx -
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene (ASX:IMU) targeting treatment of solid tumours via onCARlytics
@TeamImugene #oncarlytics #asx $IMU
kalkinemedia.com/au/sponsored/imugene-asximu-targeting-tr… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Great talk by @SaulPriceman on his teams CAR T projects including CD19 directed onCARlytic. Very educational video for anyone interested in CAR T for solid tumors. @TeamImugene @cityofhope @SoCalYuman
ASGCT
@ASGCTherapy
Speaking now at @ESGCT's e-seminar: ASGCT Member Saul Priceman is discussing advancing #immunotherapy platforms for the treatment of solid tumors. Join us now on YouTube! www.youtube.com/watch?v=0Ke_vd6Ylw4
-
Imugene | Cancer Immunotherapies
@TeamImugene
Connect with Leslie Chong: events.asx.com.au/en/ceo-connect-march-2022-4a4b2eVgQ0/ov…
1 March 2022 $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Here's an insightful interview with Paul Hopper discussing his biotech experiences and providing insights into the 2022 Australian biotech sector.
More: thewest.com.au/business/public-companies/where-markets-me… $IMU -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene leads ASX higher as consumer sentiment suffers inflation fears www.proactiveinvestors.com.au/companies/news/973566/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Stockhead
@StockheadAU
V-Con: @timothyboreham Hot Stock Picks for 2022 with host @Oriel_Morrison
@FirefinchLtd $FFX @rarex_asx $REE @TeamImugene $IMU @TeamRadioPharm $RAD
stockhead.com.au/stockhead-tv/v-con-tim-borehams-hot-stoc… -
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
After a bumpy, volatile January to kickstart 2022 - we are into February and #earningsseason 📈
Today we discuss 4 top #asx stocks to watch for February 2022:
@TeamImugene, @WeebitNano, @bhp & @Square -
$IMU $WBT $BHP #sq2 #asxstocks
youtu.be/i7IF9x9mQpE -
Imugene | Cancer Immunotherapies reposted
Andrew Scott
@AndrewScottTV
$RAD $CHM $PGO $WSR $ALY @TeamRadioPharm @Chimeric @PacgoldASX @Westar_Res @AlchemistsLtd @LocantroTony
Tony Locantro talks 2022 buying opportunities and 'under-appreciated' stocks
www.proactiveinvestors.com.au/companies/news/973041/tony-… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Beautiful results. Imagine if we could the same for solid tumours? Hold my beer... #oncarlytics @Teamimugene Leukaemia-fighting CAR T-cells kept patients in remission for 10 years — and counting www.abc.net.au/news/science/2022-02-03/leukaemia-car-t-ce… via @ABCaustralia
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: ROTH Capital Partners
IMU: Clinical Supply Deal with Roche -
European and Japanese Patents Granted
12-month price target - AUD0.71
Download: roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=c33a…
$IMU #immunotherapies #biotechnology #asx -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene welcomes new Chief Medical Officer and talks significant new patents www.proactiveinvestors.com.au/companies/news/972724/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer www.proactiveinvestors.com.au/companies/news/972722/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Welcome to @TeamImugene, Dr Steven Cha is a qualified Haematologist with over 16 years of experience in leading #oncology drug development within the #biotechnology and pharmaceutical industries and has been appointed as our new Chief Medical Officer. $IMU cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
-
Imugene | Cancer Immunotherapies
@TeamImugene
“Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese patent office is a crucial step forward and is the first of many expected patent grants from multiple countries ..." - Leslie Chong, CEO
News: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
"It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug. PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with non-small cell #lungcancer..." -Leslie Chong CEO $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Imugene | Cancer Immunotherapies
@TeamImugene
“I am excited to be partnering with my former program and company Genentech/Roche for this combination, I am even more excited for the patients” - Leslie Chong $IMU $IMU.ax
-
Imugene | Cancer Immunotherapies
@TeamImugene
“Attaining the key European patent is an important milestone and is another major pharmaceutical market to grant patent protection for HER-Vaxx until 2036.”
- Leslie Chong, CEO
Read the full ASX announcement: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#hervaxx #gastriccancer #immunotherapy $IMU -
Imugene | Cancer Immunotherapies reposted
Kalkine Media Australia
@kalkineau
Imugene Limited tapping breast cancer market via oncolytic virus CHECKvacc
@TeamImugene #breastcancer #checkvacc #asx $IMU
kalkinemedia.com/au/sponsored/imugene-limited-tapping-bre… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Couldn’t agree more. #morecureslesstoxic #followthescience @TeamImugene
Yuman Fong
@SoCalYuman
Beyond first generation modulation of check points. Our knowledge of the immunosuppressive micro environment is growing exponentially… and with it comes increasingly effective immunotherapies. Anticipating many more cures… even at stage 4. #morecureslesstoxic
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Media from Pharma in Focus:
"Roche leader switches camps, Aussie Biotech announces two new international hires"
Read more: pharmainfocus.com.au -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage | Nobel Capital Markets
Price Target: $0.50 USD
Three Innovative Platforms That Could Change Cancer Treatment: www.channelchek.com/company/iugnf/research-report/anay1corzu
$IMU #followthescience #endcancer -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Just marvellous R&D from Prof Dr Ursula Wiedermann etal and translated to clinic by @TeamImugene A new era of immuno-oncology is beginning #2022 $IMU. .
ESMO Open
@ESMO_Open
Check out the newest @ESMO_Open review: Vaccination against Her-2/neu, with focus on peptide-based vaccines #cancervaccine @cczielinski @myESMO #oncoalert
-
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
We caught up with the @TeamImugene #ceo Leslie Chong over the New Year break and discussed the $IMU
2022 story.
Enjoy this discussion about #imuene's #immunotherapy pipeline as $IMU.ax continues to emerge as a leading #asx #biotech.
youtu.be/1MfNjN_Mm7Y -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene gets A$6.5 million cash boost to support commercial and clinical milestones www.proactiveinvestors.com.au/companies/news/970590/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We have received a Notice of Grant from the South Korean Intellectual Property Office for Patent Application number 10-2017-7032987 which protects our HER-Vaxx immunotherapy to 2036, currently in development for HER-2 positive #gastriccancer.
Learn more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Imugene | Cancer Immunotherapies
@TeamImugene
Our CEO, Leslie Chong has commented:
“Attaining the key South Korean patent, on top of gaining protection in Japan and China in 2021, is a very important milestone. This will protect HER-Vaxx in the world’s largest HER-2 positive #gastriccancer markets until 2036.” $IMU #her2 -
Imugene | Cancer Immunotherapies
@TeamImugene
"I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial and we are now progressing to the Phase 1b combination studies in treatment naïve patients..." - Leslie Chong, CEO $IMU #followthescience
Learn more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Today we announced the appointment of industry leaders Ursula McCurry and Dr Nimali Withana to our senior management team. They are both former Roche/Genentech employees and experts in oncology clinical development.
Read our ASX news: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#imugene #endcancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene featured as one of the best performing stocks on the Australian market in 2021: www.abc.net.au/news/2021-12-31/market-outlook-2022-end-of… $IMU
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Combination immunotherapy is the way forward, Prof Kaumaya. @OhioState @TeamImugene #followthescience 2020 Innovator of the Year Finalist: Pravin Kaumaya youtu.be/GcrcEWJr9Ms via @YouTube
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Great to be featured in #asgctyearinreview @TeamImugene @SoCalYuman @cityofhope @CityofHopeSurg
ASGCT
@ASGCTherapy
#asgctyearinreview: @cityofhope researchers in @moltherapy Methods & Clinical Development (#mtm): A Comprehensive Preclinical Study in Support of Clinical Trial using the Oncolytic Chimeric Poxvirus CF33-hNIS-anti-PD-L1 for the Treatment of #breastcancer www.cell.com/molecular-therapy-family/methods/fulltext/S2…
-
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
Today we discuss 3 of our top #asx stocks from 2021. It was a phenomenal year with breakout successes from @BrainChip_inc, @lake_resources & @TeamImugene.
We explored some of the highlights and discuss where $BRN, $IMU & $LKE may head in 2022.
youtu.be/rm5nMdKFP1Q -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
@TeamImugene the network is growing! #beingwatched 2021 Pipeline Updates: Promising Ongoing Trials in Breast Cancer From TROP2 ADCs to Oncolytic Viruses www.cancernetwork.com/view/2021-pipeline-updates-promisin… via @CancerNetwrk
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
@TeamImugene CheckVacc trial going well. Bring on 2022 for our patients. @cityofhope @COH_SurgOnc @CityofHopeSurg @SoCalYuman
CURE Today
@cure_today
City of Hope has opened its first-in-human clinical trial for an investigational therapy in patients with advanced breast cancer. #bcsm @cityofhope
www.curetoday.com/view/oncolytic-virus-clinical-trial-ope… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Cui suggests that future cancer vaccines may be more effective if they can jumpstart both antibody-producing B cells and helper T cells to bolster a broader immune system response. @TeamImugene PD1-Vaxx HER-Vaxx www.cell.com/cell/pdf/S0092-8674(21)01322-2.pdf
-
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Thanks @ASGCTherapy for the support of this exciting research from @cityofhope and @TeamImugene
ASGCT
@ASGCTherapy
From @cityofhope researchers in @moltherapy Methods & Clinical Development (#mtm): A Comprehensive Preclinical Study in Support of Clinical Trial using the Oncolytic Chimeric Poxvirus CF33-hNIS-anti-PD-L1 for the Treatment of #breastcancer www.cell.com/molecular-therapy-family/methods/fulltext/S2…
-
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
The #asx Index Rebalance's are about to be official with leading names like @TeamImugene, @NovonixBattery & @LiontownRes included into the #asx200.
Today we explore why #indexrebalance's are important and what this means for $IMU, $NVX & $LTR 📈
youtu.be/NBlmmx4gOsY -
Imugene | Cancer Immunotherapies reposted
ASX Investor
@ASXInvest
It was a pleasure discussing all things #biotech with leading #asx Executive Chairman, Paul Hopper.
Enjoy this comprehensive interview as we explored the @TeamImugene, @Chimeric, @WeAreArovella and @TeamRadioPharm stories.
$IMU $CHM $ALA $RAD #imugene
youtu.be/gLWZPuHYi7U -
Imugene | Cancer Immunotherapies
@TeamImugene
We are so proud of our Founder and Chairman for receiving this acknowledgement from @biotech_daily - well deserved Paul - we are all looking forward to a very successful 2022. $IMU
David Langsam
@biotech_daily
Biotech Daily: 2021 – The Year In Review
Chair of the Year Paul Hopper
@Chimeric @TeamImugene @TeamRadioPharm @WeAreArovella
Team of the Year
$NEU Neuren
CEO of the Year Kate Quirk
@alcidion
@asxlongtail @sinatramarc @timothyboreham @ir_department @Beck_WEComms -
Imugene | Cancer Immunotherapies reposted
Australian Tech Girl 🇦🇺🦘
@NessGood1
Imugene 14th Dec 2021 - Gangbuster 2022 Prediction - growing by leaps and bounds while advancing novel technology pla... youtu.be/1j54SkEY2yY via @YouTube
-
Imugene | Cancer Immunotherapies
@TeamImugene
We have received a Notice of Allowance from the People's Republic of China Patent Office, which protects our HER-Vaxx #immunotherapy, currently in development for HER-2 positive #gastriccancer $IMU #followthescience $IMU.ax
ASX News: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies reposted
ausbiz
@ausbiztv
Leslie Chong CEO at @TeamImugene will join us live at 1.30 on the FDA approval of 2 clinical trials of its oncology drug candidates.
Fun Fact: $IMU is up 420% YTD -
Imugene | Cancer Immunotherapies reposted
Andrew Scott
@AndrewScottTV
$IMU @TeamImugene
Imugene's Leslie Chong thrilled with two significant FDA IND approvals
www.proactiveinvestors.com.au/companies/news/968935/imuge… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene secures FDA approval for two clinical trials of promising oncology drug candidates www.proactiveinvestors.com.au/companies/news/968933/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
"To achieve two IND’s for our programs (OV and B Cell) concurrently is an outstanding result for the team.”
- Leslie Chong, CEO $IMU #endcancer #hervaxx
Read today's full #asx announcement:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
“Imugene receiving this IND approval for VAXINIA from the FDA is a crucial step forward. The start of our VAXINIA OV study is a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers." -Leslie Chong CEO $IMU
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Following on from our news yesterday of our clinical trail update for our oncolytic #virotherapy, #checkvacc, the below publication provides further details on what we did to get FDA approval to run the trial. The below tweet is from our Chief Technology Officer:
$IMU #asx200
Nick Ede
@Melroseavenick
Great to be an author on this CF33 paper! @TeamImugene @SoCalYuman @CityofHopeSurg @cityofhope A Comprehensive Preclinical Study in Support of Clinical Trial using the Oncolytic Chimeric Poxvirus CF33-hNIS-anti-PD-L1 for the Treatment of Breast Cancer www.cell.com/molecular-therapy-family/methods/fulltext/S2…
-
Imugene | Cancer Immunotherapies
@TeamImugene
"Celularity, Imugene Collaboration to Focus on CAR T in Solid Tumors"
Source: @GeneTherapyLive
#cf33 #celltherapy $IMU
Read below:
www.genetherapylive.com/view/celularity-imugene-collabora… -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene doses second patient in CHECKvacc study www.proactiveinvestors.com.au/companies/news/968352/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
“As this is our first Oncolytic Virotherapy in the clinic, it’s great to have no safety issues thus far with our first patient and we are very pleased to see our second patient joining ..." - Leslie Chong, CEO
Read our ASX news:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#oncolyticvirus $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
"The City of Hope-developed therapy, CF33-hNIS-antiPDL1, is genetically engineered from a naturally occurring virus (chimeric oncolytic orthopoxvirus). The patents covering CF33-hNIS-antiPDL1 have been licensed to Imugene Limited (ASX: $IMU) ..."
Learn more: #immunotherapy #cf33
City of Hope
@cityofhope
City of Hope has opened a first-in-human clinical trial evaluating the use of a cancer-killing oncolytic virus to treat patients with metastatic triple-negative #breastcancer. www.cityofhope.org/breakthroughs/city-of-hope-opens-oncol…
-
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene and Archer Materials benefit from S&P Dow Jones Indices rebalance www.proactiveinvestors.com.au/companies/news/968219/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
We are proud to announce, effective prior to the open of trading on December 20th, that Imugene Limited will enter into the S&P/ASX 200 Index.
#followthescience $IMU
Read the S&P Dow Jones announcement:
www.spglobal.com/spdji/en/documents/indexnews/announcemen… -
Imugene | Cancer Immunotherapies
@TeamImugene
We are pleased to share with you our latest newsletter - now available via our website: imugene.com/newsletters
$IMU $IMU.ax #immunotherapy #followthescience -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong joins @ausbiztv to discuss this week's ASX news of our clinical trial deal with Merck KGaA and Pfizer Inc: www.youtube.com/watch?v=snJfxQJm7Fo
-
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: ROTH Capital Partners
" $IMU.AX: Supply Deal with Merck KGaA & PFE
for BAVENCIO/Chemo/HER-Vaxx Ph2 Trial. We raise our PT to AUD0.71 from AUD0.62 "
Now available to download from our website:
www.imugene.com/analyst-coverage
$IMU #immunotherapy #cancer -
Imugene | Cancer Immunotherapies
@TeamImugene
Following the @ASX news of our clinical trial supply agreement with Merck KGaA and Pfizer, our CEO Leslie Chong catches up with Andrew Scott at Proactive Investors to provide more detail.
Watch now on our YouTube channel:
youtu.be/25sRnv5CAg0
$IMU $IMU.ax #clinicaltrails -
Imugene | Cancer Immunotherapies
@TeamImugene
We have announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR: MRK) and Pfizer Inc. (NYSE: PFE) to evaluate the safety and efficacy of HER-Vaxx.
ASX News:
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
Learn more about HER-Vaxx:
www.imugene.com/b-cell-immunotherapies
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch Paul Hopper's keynote address at the Emerging Small Caps 2021 Summit:
► [ youtube.com/watch?v=FX_W9GRNdDM ]
$IMU $IMU.ax #cancerresearch #followthescience -
Imugene | Cancer Immunotherapies
@TeamImugene
Watch our inaugural ‘Science Series’ featuring our oncolytic viraltherapy, CHECKvacc, covered in great detail with the inventor Professor Yuman Fong and the principal investigator, Dr. Yuan Yuan, who is leading the triple negative breast cancer study $IMU
www.youtube.com/watch?v=UtMVyITUU9E -
Imugene | Cancer Immunotherapies
@TeamImugene
Don't miss our Science Series on CHECKvacc - today at 10am AEST.
CHECKvacc is our oncolytic viraltherapy invented by Professor Yuman Fong from City of Hope in Los Angeles.
Register now via:
us02web.zoom.us/webinar/register/WN_rUIrW6qMS3uPjEPqNXYCyQ
View our previous coverage on 7News:
www.youtube.com/watch?v=IueaaWfoEJY -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong's latest interview: Biotech Unlocked - Showcasing Australia's Next Investment Horizon
Watch now via our YouTube channel:
youtube.com/watch?v=9sQJ0D2Ku2Y
$IMU $IMU.ax -
Imugene | Cancer Immunotherapies reposted
Proactive Australia
@proactive_au
$IMU Imugene attracts Buy rating and upgraded price target of A$0.62 from ROTH Capital Partners www.proactiveinvestors.com.au/companies/news/965373/imuge… @TeamImugene $IMU $IUGNF #imu #imu #iugnf #asx #asxnews
-
Imugene | Cancer Immunotherapies
@TeamImugene
Wow, thank you so much everyone, we just hit 500 subscribers on YouTube! #500subs $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
Join us on Thursday, November 11, 10am AEST for our 'Science Series'. This session will feature our oncolytic #viraltherapy CHECKvacc with Professor Yuman Fong and Dr. Yuan Yuan.
Register now: us02web.zoom.us/webinar/register/WN_rUIrW6qMS3uPjEPqNXYCyQ $IMU @SoCalYuman @YuanYuanMDPhD #breastcancer $IMU.ax #science -
Imugene | Cancer Immunotherapies
@TeamImugene
Leslie Chong speaks to Proactive Investors to provide further detail about our special collaboration with Eureka Therapeutics to developed a ‘mark and kill’ approach to treating solid tumours.
$IMU $IMU.ax @EurekaThera #fightcancer #cancers
Learn more: youtu.be/St6U7f1lpAg -
Imugene | Cancer Immunotherapies
@TeamImugene
New Analyst Coverage: ROTH Capital Partners
"imu.ax: Solid Tumor Partnership with Eureka
Therapeutics, Raising PT to AUD 0.62"
Now available to download from our website:
imugene.com/analyst-coverage
$IMU.AX $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
"Imugene soars after partnership to 'kill' cancer"
- By Jared Lynch
@jaredm_lynch @australian
www.theaustralian.com.au/business/trading-day/asx-200-set…
$IMU $IMU.ax #immunotherapy #cancerresearch -
Imugene | Cancer Immunotherapies
@TeamImugene
Today's investor presentation following the ASX news of our special collaboration with Eureka Therapeutics is now available to watch on our YouTube channel: youtu.be/GFpyVqMCy38
$IMU $IMU.ax #tcells #cd19 #biotechnology ASX: IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Investor Presentation Imugene & Eureka Therapeutics:
$IMU $IMU.ax #endcancer
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Imugene | Cancer Immunotherapies
@TeamImugene
Our strategic collaboration with Eureka will evaluate their anti-CD19 ARTEMIS® T-cell therapy in combination with our CD19-expressing oncolytic virus, onCARlytics, in solid tumours.
Learn more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
$IMU $IMU.ax #tcells #oncolyticvirus #endcancer
Imugene | Cancer Immunotherapies
@TeamImugene
“By combining oncolytic virus and CAR T-cell therapies, we have developed a ‘mark and kill’ approach to treating solid tumours with T-cell therapies,” - Saul Priceman, Ph.D., Assistant Professor, Department of Hematology and Hematopoietic Cell Transplantation at @cityofhope $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
Register now:
BIOTECH UNLOCKED | Showcasing Australia's Next Investment Horizon. In partnership with the @ASX
Experts explain why biotechs are worthy investments, and explain how to value innovation and execution.
November 4, 2021
09:00-12:00 AEDT
↧
www.ausbiz.com.au/events/2021-11-04-In+partnership+with+t… -
Imugene | Cancer Immunotherapies reposted
Nick Ede
@Melroseavenick
Very impressive that @TeamImugene CF33 oncolytic virus founder Prof Dr Yuman Fong makes the top list of cited surgeons of all time! With CheckVacc now in the clinic, plenty more citations to come!
Mustafa Raoof
@MustafaRaoofMD
Not surprising super @SoCalYuman on this list!
-
Imugene | Cancer Immunotherapies
@TeamImugene
Our mission to develop transformative cancer medicines to improve patients’ lives became one step closer with yesterday's milestone ASX news.
Learn more:
www.proactiveinvestors.com.au/companies/news/963833/imuge…
$IMU #breastcancerawarenessmonth #breastcancer @cityofhope @SoCalYuman @YuanYuanMDPhD $IMU.ax #asx -
Imugene | Cancer Immunotherapies
@TeamImugene
Using a Virus to fight cancer: Oncolytic Viruses Explained
Video by @cityofhope
#oncolyticvirus #oncolyticviruses #virus #endcancer $IMU -
Imugene | Cancer Immunotherapies
@TeamImugene
Investor Presentation: CF33 ONCOLYTIC VIRUS ACQUISITION static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t… $IMU #oncolyticvirus #biotech #endcancer (ASX: IMU)
-
Imugene | Cancer Immunotherapies
@TeamImugene
RESULTS OF GENERAL MEETING – Oncolytic Virus Acquisition Complete $IMU CEO Leslie Chong said “we are delighted to be able to complete the acquisition of Vaxinia Pty Ltd and City of Hope licence of such a promising next generation oncolytic virus www.imugene.com/announcements #endcancer
-
Imugene | Cancer Immunotherapies
@TeamImugene
NEW Analyst Coverage: BioShares | Imugene's Expanding Oncology Pipeline: Trial 1: HER-Vaxx, Trial 2: PD1-Vaxx, Trial 3: Vaxinia & Trial 4: CheckVacc www.imugene.com/analyst-coverage $IMU #clinicaltrials #asx #cancerresearch (ASX: IMU)
-
Imugene | Cancer Immunotherapies
@TeamImugene
We have received a research and development (R&D) tax refund of AUD 4.13 million as part of the Australian government’s R&D tax incentive. This incentive recognises the important immuno-oncology research activities undertaken by us during the 2019 FY www.imugene.com/announcements $IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene Reports Impressive B-cell vaccines Data at ESMO Congress 2019 kalkinemedia.com/au $IMU #bcell #immunotherapy #esmo19
-
Imugene | Cancer Immunotherapies
@TeamImugene
10-Point Checklist For Choosing A #biotech Stock $IMU #oncoalert #cancer kalkinemedia.com/au ASX: IMU
-
Imugene | Cancer Immunotherapies
@TeamImugene
You can now view our ESMO 2019 Presentations here: www.imugene.com/publications $IMU #endcancer #esmo19 #oncoalert (ASX: IMU)
-
Imugene | Cancer Immunotherapies
@TeamImugene
Imugene HER2 and PD1 vaccines combine synergistically to inhibit cancer cell growth - promising preclinical data presented at ESMO 2019 $IMU #endcancer #oncoalert #esmo19 www.imugene.com/announcements
-
Imugene | Cancer Immunotherapies
@TeamImugene
Comprehensive Phase 1b HER-Vaxx Cancer Vaccine Results Presented at the European Society of Medical Oncology (ESMO) Congress - read the announcement: www.imugene.com/announcements $IMU #esmo19 #oncoalert #endcancer
-
Imugene | Cancer Immunotherapies
@TeamImugene
$IMU Exploring the #immunotherapy Market Opportunity, the Market Opportunity Across our #vaccines, the Opportunity in the #oncolyticvirus Market and our Stock Performance kalkinemedia.com/au
-
Imugene | Cancer Immunotherapies
@TeamImugene
Watch Prof. Yuman Fong give a presentation to investors in Sydney after announcing we would acquire a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope #endcancer #oncology #cancer (ASX: IMU) www.youtube.com/watch?v=b6nmOQ6PsBM


























































































































































































































































































































































































































































